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ABSTRACT 
Monoclonal antibody (Mab) internalization by cancer cells has been recently gaining 
increasing recognition as one of the important factors affecting the action of Mabs or 
immunoconjugates (ICs) on tumour sites. This project addresses the underexplored 
subject of internalization, by comparing existing internalization assays in terms of 
accuracy and consistency, as well as by developing more rapid and concise methods for 
the detection of internalized antibody. A number of in vitro techniques for investigating 
internalization are evaluated, using a model which consists of a well characterized anti-
carcinoembryonic antigen (anti-CEA) Mab and a number of CEA expressing human 
cancer cell lines. Employing two alternative radiolabelling assays, evidence for 
internalization of an anti-CEA Mab by a CEA-positive colorectal cancer cell line 
(LS174T) was obtained throughout the time intervals examined (5 min to 150 min.). A 
widely employed internalization assay involving the use of a low pH buffer for the 
dissociation of surface antigen-antibody bonds, has been thoroughly analyzed and shown 
not to fulfill its alleged role, thereby introducing inaccuracies in the experimental 
method. Electronmicroscopy employing horseradish-peroxidase labelled anti-CEA Mab, 
permitted the direct visualization of anti-CEA Mab related staining in intracellular 
compartments of a high CEA-expressor human colorectal cell line (SKCOl). SDS/PAGE 
analysis of samples derived from cytosolic and membrane components of solubilized cells 
from lung and colonic cancer cell lines, provided evidence for non-degraded internalized 
anti-CEA Mab throughout seven half hour intervals, starting at 5 minutes. Internalized 
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anti-CEA was detected in all CEA expressing cell lines (LS174T, SKCOl, BENN) but 
not in the case of a very low CEA expressor line (COLO 320). When the last method 
was compared to a newly developed internalization assay involving flow cytometry, 
results were very similar for all the above cell lines. Given that these two methods 
consistently provided comparable results, use of flow cytometry for the detection of 
internalized antibody is suggested as a fast and uncomplicated alternative to the 
internalization assays used at present. Finally, the question of the endocytic route 
followed by CEA-anti-CEA complexes is addressed through blocking clathrin-mediated 
endocytosis in the cell lines examined. Preliminary results indicate that such complexes 
may be internalized only partially by clathrin-coated vesicles, with an alternative uptake-
endocytic mechanism also at work. 
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I. 1. 
CHAPTER I 
INTRODUCTION 
CANCER : Def'mition and History 
The disease, or body of diseases, grouped under the term cancer is today the 
second most frequent cause of death in the developed world. This fear-inspiring disease 
has probably plagued the human race since the very origins of its existence since there 
is evidence that cancer may pre-date Homo sapiens possibly by millennia. Signs of 
benign tumours such as of an osteoma and a haemangioma were, for example, found in 
the remains of a dinosaur that lived during the Cretaceous period, whereas the remains 
of animals sharing the planet with primitive hominids bear traces of possible benign 
tumours (Tomatis, 1990). 
The term cancer is derived from the Greek word "karkinos" meaning "crab". 
This term originated in the description of certain malignant tumours which appeared to 
have a central core and "limbs" (swollen veins looking like crab claws), through which 
the disease was believed to spread through the rest of the body. In accordance with the 
somewhat vague term used to describe cancer, a number of misconceptions concerning 
its "incurable" or "contagious" nature governed general attitudes towards the therapy and 
medical care of individuals inflicted with the disease. Cancer was considered 
incurable by Hippocrates and attempts at surgical intervention were generally 
discouraged, since it was believed that they would render the lesions worse. However 
cancer of the breast seemed to be a particularly likely candidate for surgery and it is 
reported that in the second century AD Galen successfully operated on a case of breast 
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cancer followed by similar attempts by Paul of Egina (seventh century) and Lafranco 
(fourteenth century) (Tomatis, 1990 and references within). 
During the seventeenth century well respected clinicians such as Zacutus 
Lusitanus and Daniel Sennert reinforced the notion that cancer was contagious (Cassileth, 
1983), a myth leading to refusal of admission of cancer patients to many hospitals. It was 
only in 1740 that the first special hospital for cancer patients was created in Reims, 
France, due to the efforts of canon Jean Godinot (D' Argent, 1965). The next such 
initiative was undertaken by surgeon John Howard resulting in the opening of a cancer 
ward at the Middlesex hospital in London, in 1792 (Hayward, 1965). 
Research on cancer was probably first undertaken more than a century later, with 
the frrst laboratory being that established in Buffalo, New York, in 1899, under the 
direction of Dr Roswell Park. Interest in research matured as the accumulation of cases 
relating cancer development to probable causative agents became increasingly extensive. 
Increased risk for breast cancer development was noted as early as 1713 when it was 
reported by Ramazzini that elevated occurrence of breast cancer among nuns might be 
related to an absence of reproductive life. In the late eighteenth century defmite 
"carcinogenic agents" began to be recognized starting with tobacco snuff (Hill, 1762) and 
chimney soot which was found to be related to the development of scrotal cancer seen 
in individuals who had been chimney sweeps (Pott, 1775). A -number of other 
carcinogenic substances were recognized during the nineteenth century, mostly related 
to the work place, such as aromatic amines which were found to cause bladder cancer 
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in workers in dye factories (Rehn, 1977). The increasing awareness both of the existence 
of causative agents for cancer and the possibilities for cure for at least certain types of 
the disease led to the frrst "international" cancer congress held in Heidelberg and 
Frankfurt in 1906. 
Surgical intervention as a means for cancer therapy advanced substantially during 
the last part of the nineteenth and the beginning of the twentieth century. Particularly, 
progress was made in the surgery of abdominal cancer by the Austrian surgeon Christian 
Billroth in the 1870's, in the surgery of cancer of the uterus by Wertheim and in the 
surgery of breast cancer by William Hallsted in 1902. 
Roentgen's discovery of X-rays in 1895 was immediately put to use in the 
radiation treatment of breast cancer in 1896, whereas cancer chemotherapy was only 
introduced after the Second World War following declassification of war-time 
experimental fmdings and particularly those involving nitrogen mustards (Boyland et al., 
1949; Cassileth, 1983). However, it was not until oestrogens were frrst used in the 
therapy of prostate cancer in the 1940's that chemotherapy was established as the third 
modality for cancer treatment (Huggins et al., 1941; Hayward, 1965; Huggins, 1967). 
Today, surgery, radiotherapy and chemotherapy are often used in combination for 
the immediate treatment and eradication of the disease. Although surgery, (usually in 
combination with radiotherapy), remains the initial approach for combatting most major 
forms of primary cancer, a wide variety of chemotherapeutic protocols are also being 
used alone. For example, chemotherapy may be the only type of cancer treatment for 
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many of the tumours that appear early in life, for the eradication of residual disease and 
in certain types of tumours which respond favourably to particular drugs. Furthermore 
chemotherapy is expected to play an increasingly important role particularly in the 
treatment of metastatic disease as more potent cytotoxic agents and more specific ways 
to deliver them are developed. 
As the list of cancer causing agents rapidly increases it also becomes increasingly 
obvious that one of the focal points in the struggle against cancer should be in the area 
of prevention. Containment of chemical waste in this era of industrialization, banning of 
commercially promoted well-known carcinogens such as tobacco and education on 
protection from both chemical and environmental cancer causing agents should greatly 
reduce the incidence of cancer especially in the developing countries where it is unlikely 
that appropriate treatment will be available in the near future. 
I. 2. How serious is the Cancer Problem? 
The burden of cancer in the world has been estimated both in terms of incidence 
(new cases of the disease in a unit of time) by Parkin et al (Parkin et al., 1988) and in 
terms of mortality (number of deaths in a unit of time) by Hakulinen et al (Hakulinen et 
al., 1986), for the year 1980. 
Incidence data indicated that approximately 6.35 million new cases of cancer 
occurred in 1980, of which 3.25 million were in men and 3.1 million were in women 
(figures exclude cancer of the skin other than melanoma which are generally not fatal). 
s 
The pattern of incidence and types of cancer varied widely among different populations, 
however the number of cases was rather evenly divided between developed and 
developing countries (49.3% vs 50.7%). Considering that the population ratio between 
developed vs developing countries is in the range of 1:3 cancer incidence is clearly much 
higher in developed countries. 
Estimates of number of deaths were based on a statistical model introduced by 
Preston (Preston, 1976), which gave a summary of mortality from 17 broad groups of 
cases in over 200 populations in various stages of development. These mortality data 
showed the world cancer toll to approximate 4.2 million deaths in 1980. At the time, on 
a world scale cancer ranked third as a cause of death with infectious diseases and 
diseases of the circulatory system well in the lead (Table 1) (Hakulinen et al., 1986). 
However these global figures reflect the shorter average life span as well as a much 
higher proportion of deaths due to infectious diseases for most populations in the 
developing world. 
In the United States alone cancer mortality accounted for 476,927 deaths in 1987 
(22.5% of the total number of deaths) and was only second to heart disease which 
accounted for 35.8% of total deaths according to the report on Vital Statistics of the 
United States, 1987 (Boring et al., 1991). For 1994 newly diagnosed cancers in the 
United States are estimated at 1,208,000 and cancer deaths for all sites are estimated at 
538,000 (Boring et al., 1994). This steady rise in cancer incidence and mortality 
corresponds to a population increase, particularly in the aging bracket. Furthermore it 
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was estimated that 75% to 80% of all cancers in the United States may be due to 
environmental factors (Doll et al., 1981). The environmental influence on cancer 
development is supported by data on international variation in cancer incidence (Muir et 
al., 1987). In Table 2 international variation ranges from 155-fold for melanoma to 5-
fold for leukaemia. This variation is not believed to be influenced by factors such as 
diagnostic and reporting practices among countries, or indeed by genetic factors to any 
great extent (Fraumeni et al., 1993). Furthermore it is believed that with increased 
proportions of an aging population and reductions in deaths from coronary artery and 
cerebral vascular disease, cancer will become the leading cause of death in the United 
States by the year 2000. Given this dismal prospect, the National Cancer Institute set, 
in November 1983, the national objective of reducing cancer mortality rates by 50% by 
the year 2000, through the intensification of preventive, screening and novel treatment 
programs (Greenwald et al., 1986). In practical terms this goal would translate to a 
reduction in cancer death rates from 168 per 100,000 in the year 1980 to 84 per 100,000 
in the year 2000. 
Unfortunately, to date, this objective does not seem likely to be realized. Cancer 
death rates in the United States amounted to 170.4 per 100,000 in 1987 (a total of 
476,927 deaths), whereas the estimated cancer death rate for the year 1994 is 172 deaths 
per 100,000 (a total of-·538,000 deaths) (Boring et al., 1994). Furthermore the cancer 
incidence for all cancer sites seems to follow a steady increase. For example, a close to 
15% increase was noted between 1973 and 1987, according to the Cancer Statistics 
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Review 1973-1987 in the 1990 edition of the National Cancer Institute's (NCI), annual 
resource book of cancer data (Newman, 1990), with melanoma of the skin showing an 
83% increase, followed by non-Hodgkin's lymphoma with 51% and prostate cancer with 
46%. Cancer mortality has also increased by 34.1% for lung and bronchial cancer, 
29.8% for melanoma, 23.6% for multiple myeloma and 21.7% for non-Hodgkin's 
lymphoma. Such dismal statistics obscure success stories such as reductions in mortality 
of 60% for testicular cancer, 49.5% for Hodgkin's disease and 39.6% for cervical 
cancer. 
A similar trend in incidence and mortality rates seems to be prevailing in Canada. 
Estimated incidence for all cancers in the year 1992 was 115,000 new cases (Canadian 
Cancer Statistics, 1992). The average cancer incidence rate for both sexes was 303.5 per 
100,000 whereas a total of 58,300 deaths due to cancer were estimated for the same year 
(an average mortality rate of 144 per 100,000 for both sexes). Estimates for 1993 showed 
a small increase in both incidence and mortality, with estimated incidence reaching 
116,200 new cases (average cancer incidence rates for major cancer sites being 340 for 
males and 264 for females) (Canadian Cancer Statistics, 1993). Cancer death estimates 
for 1993 were 59,700, with average mortality rates of 174 per 100,000 for males and 
113 per 100,000 for females. Similarly for 1994 estimates of cancer incidence have 
increased to a total of 121,300 new cases, whereas cancer deaths for this year are 
estimated to reach 61,000. 
Three types of cancer account for 55% of the new cases in each sex: lung, 
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prostate and colorectal cancers in males, and breast, lung and colorectal cancer in 
females. A third of the cancer deaths in males are due to lung cancer while lung cancer 
is now the primary cause of cancer deaths for females with breast cancer a very close 
second (Canadian Cancer Statistics, 1994). Furthermore, cancer was the leading cause 
of loss of years of life as measured by potential years of life lost (PYLL) in 1989, with 
lung cancer, breast cancer and colorectal cancer accounting for about half of the potential 
life lost. In addition to this enormous drain in potentially productive human life, cancer 
imposes an immense imancial drain in terms of health care considering the long 
hospitalizations and costly therapy necessary for the cancer patient. For example, the 
total direct and indirect costs corresponding to all cancers, coronary heart disease, motor 
vehicle injuries and stroke were estimated in the United States to amount to 23.15, 
13. 72, 14.44 and 6.46 billions of dollars respectively in 1975 (Thomas, 1991). Recent 
updates from the National Cancer Institute (NCI) in the United States report that the 
direct medical costs of cancer are $35 billion a year and rising (American Cancer 
Society, 1993). Considering the additional morbidity (cost of lost productivity) and 
mortality costs, the overall costs for cancer were a staggering $104 billion for 1990. 
Currently screening costs (including mammograms, Pap smears and colorectal exams) 
add another $3 to $4 billion to overall cancer costs. It is worth mentioning that, despite 
the enormous therapeutic and financial benefit of early screening, U.S. legislation 
mandating medicare coverage for cervical and breast cancer screening was only passed 
by Congress in 1989 and 1990 respectively. 
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Considerations such as the above along with the apparent fading of the United 
States' effort to control this devastating disease paint a very bleak picture of its future 
influence on the developed world. The problem is compounded with an increasingly 
hostile environment in terms of exposure to an ever expanding variety of chemical, 
biological and physical carcinogenic factors. It is therefore imperative that efforts be 
intensified both in terms of cancer prevention and in terms of novel cancer research with 
an emphasis on the application of this research in the clinical environment. 
Table 1 
Global and regional patterns of annual deaths by cause, 19801 
Region All Infection and 
causes parasitic 
(# of diseases 
deaths (%) 
x1000) 
World 50911 33.1 
Africa 8562 48.7 
Latin 3197 31.0 
America 
North 2081 3.6 
America 
East Asia 8842 23.0 
South Asia 20315 43.8 
Europe2 7713 8.6 
Oceania 201 17.7 
Developed 10652 7.6 
Developing 40259 39.9 
1 Source: (Hakulinen et al., 1986) 
2 Including the USSR 
Neoplasms Diseases 
(%) of the 
circulatory 
system(%) 
8.4 26.2 
3.1 12.3 
9.0 24.7 
21.5 54.5 
10.6 33.7 
4.3 15.6 
18.1 53.8 
16.0 42.2 
19.2 53.6 
5.5 19.0 
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Other 
and 
unknown 
(%) 
32.4 
35.9 
37.3 
20.4 
32.8 
36.3 
19.6 
24.1 
19.7 
35.7 
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Table 2 
International variation in Cancer Incidence (1978-1982)* 
Ratio High (H) Rate Incidence Low (L) Rate Incidence 
(H/L) Area Area 
Melanoma 155 Queensland 30.9 Osaka 0.2 
(Australia) (Japan) 
Nasopharynx 100 Hong Kong 30.0 South Western 0.3 
(U.K.) 
Prostate 70 Atlanta 91.2 Tianjin 1.3 
(U.S., black) (China) 
Liver 49 Shanghai 34.4 Nova Scotia 0.7 
(China) (Canada) 
Penis 42 Recife 8.3 Israel 0.2 
(Brazil) (Born Eur. & US) 
Oral cavity 34 Bas-Rhin 13.5 Poona 0.4 
(France) (India) 
Cervix uteri 28 Recife 83.2 (Brazil) Israel 3.0 
(non-Jewish) 
Esophagus 27 Calvados 29.9 Urban Cluj 1.1 
(France) (Romania) 
Stomach 22 Nagasaki 82.0 Kuwait 3.7 
(Japan) 
Multiple 22 Alameda 8.8 Phillipines 0.4 
Myeloma (U.S., black) 
Lung 19 New Orleans 110.0 Madras 5.8 
(U.S., black) 
Colon 19 Connecticut 34.1 Madras 1.8 
(U.S., white) (India) 
Breast 7 Hawaii 93.9 Israel 14.1 
(Hawaiian) (non-Jewish) 
Leukemia 5 Ontario 11.6 Nagpur 2.2 
(Canada) (India) 
* Selected data from (Fraumeni et al., 1993) 
I. 
I. 
3. 
3.1 
Biology of Cancer 
Tumour cell Proliferation 
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Unlimited and uncontrollable proliferation of tumour cells is probably the most 
outstanding feature of the large panel of diseases grouped under the term cancer. Since 
stringent controls over cellular proliferation are imposed very early on in embryonic 
development it has become evident that any cell which does not obey the normal 
proliferation constraints may give rise to a tumour. Virchow was thus able to realize 
through microscopic examination of tumours that neoplasms originate from normal cells 
through uncontrollable growth (Tannock, 1989). Analysis of data on the growth of 780 
human tumours in patients not receiving treatment, revealed that tumours follow an 
exponential growth curve so that a tumour takes a constant time to double its volume 
(T0 ) (typical volume doubling times for common solid tumours are in the range of 2 to 
3 months). However, analysis of data from multiple adjuvant studies in breast cancer, 
revealed that in all instances the cancer growth curves followed Gompertzian growth 
kinetics (Norton, 1988). In Gompertzian kinetics, the growth fraction of the tumour is 
not constant but decreases exponentially with time. This type of growth has a serious 
impact both on predictions of tumour behaviour according to its size, as well as on 
patterns of regrowth of residual tumour cells following treatment. Since the routine 
current detection techniques (physical and radiologic examination) can detect tumours of 
about 1 em in diameter, the smallest detectable tumour would contain approximately 1 (f 
cells - which, assuming metastatic potential, will have ample time to seed metastases, and 
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will have undergone approximately 30 doublings if it is clonally derived from a single 
transformed cell. A potentially lethal tumour mass of 1 kg would then require only 10 
further doubling cycles. Establishing a general model for preclinical tumour growth based 
on present clinical data, mathematical models and variability of tumour growth potential 
according to its stage of development, has proven quite difficult (Shackney et al., 1978; 
Folkman, 1975). Probably the major complicating factor involves the variable stages in 
tumour development, which generally include an initial need for establishing a blood 
supply network, evading the host's immune system, the subsequent increasing need for 
vascularization and increasing cell death due to necrosis for solid tumours. 
Tumour cells are remarkably similar to their normal countetparts in terms of basic 
biochemistries and even in terms of basic cell kinetics. Usually tumour cells do cycle 
through four temporally distinct phases (Clement et al., 1991) namely M (mitosis), G1 
(the interval between the end of mitosis and the initiation of DNA replication), S (the 
interval during which DNA synthesis takes place and G2 (the interval between the end 
of S phase and the beginning of the next mitosis). Furthermore quiescent 
(nonproliferating) cells, have for the most part an unduplicated (2n) DNA content and 
are said to be in G0• Cells usually enter G0 when there is a lack of nutrients or growth 
factors in the environment, or due to negative signals such as in the case of cell contact. 
Cell survival is favoured by the ability to enter G0 , since cells arrested in this phase 
generally survive longer than cells arrested in G1• Cells in both phases have the same 
DNA content but cells in G0 usually require twice the amount of time to enter S phase 
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as compared to cells in G1• Also transition from G0 to G1 to Sis sequential with each step 
requiring different growth factors. The major difference between normal and tumour cells 
in terms of cell kinetics is that most tumour cells usually lose the ability to enter G0 
(Baserga, 1985; Pardee et al., 1978; Marx, 1986), which can be detrimental both to the 
cell and the organism. In addition even those tumour cells (such as some tumorigenic 
fibroblasts) which may retain the ability to enter G0 , when deprived of serum in culture, 
enter this phase more reluctantly and leave it more readily than normal fibroblasts. 
The overall rate of tumour cell proliferation may be approximated by estimating 
the proportion of cells undergoing DNA synthesis (S phase). Such data have been 
generated through the use of thymidine labelling techniques and autoradiography or 
through flow cytometry (McDivitt et al., 1985; Barlogie et al., 1983), for most types of 
human malignancies and generally indicate that tumours do not have a higher proportion 
of S phase cells than some normal tissues. Many solid tumours in humans contain at most 
10% cells in S phase although this percentage is usually higher in rapidly growing 
tumours. Furthermore estimates of growth fractions derived by comparing the proportion 
of S-phase cells to that predicted from the phase distribution of cycling cells are usually 
in the order of 20% to 30% . Thus a large proportion of tumour cells seem to be out of 
cycle and this could be due to factors such as differentiation or death due to lack of 
nutrients as a result of limited vascular accessing especially in larger tumours (Tannock, 
1968). The rate of tumour cell loss has been estimated by Steel (Steel, 1967) by 
comparing potential doubling time (doubling time without cell loss), with measured 
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volume doubling times, and it was found to be 80% or more of the rate of cell 
production. Therefore although two characteristics of tumour cells, namely loss of ability 
to differentiate (anaplasia) and immortality, are considered to act together in order to 
deter tumour cells from entering an irreversible quiescent state, it seems that tumour 
growth for most human malignancies is based on a moderate excess in cell production 
over cell loss. 
I. 3.2 Cell Transformation 
Ideally, cellular changes due to carcinogenesis should be studied in the intact 
animal model. However this approach is impractical due to the near impossible task of 
identifying, isolating and purifying early cancer cells. For this reason cell transformation 
has been classically studied in vitro usually employing normal fibroblasts in culture which 
are exposed to cancer inducing agents (Hamburger, 1991). The agents that have been 
used to induce carcinogenesis in this model mostly involve common carcinogens such as 
chemical agents (for example, benzpyrene on a murine prostate cell line (Chen et al., 
1969), or 4-nitro-quinoline-1-oxide on human fibroblasts (Kakunaga, 1984)), irradiation 
(such as x-rays on rodent and human (Borek, 1980) fibroblasts) and transforming viruses 
on a number of different cell lines (Burger et al., 1972b; Bissell, 1976). 
Changes caused by cell transformation can be grouped into three major categories, 
namely, changes in growth properties, changes in cell surface and changes in the pattern 
of oncogene activation (Barbacid, 1987a; Land et al., 1983b; Kahn et al., 1986; 
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Macdonald et al., 1991). Although such alterations are by no means universal for cancer 
cells they are the ones most frequently associated with transformation (Hamburger, 1991 
and references within). 
i. Changes in growth properties. Transformed cells exhibit loss of contact 
inhibition (Abercrombie, 1970) which leads to a much higher saturation density compared 
to normal cells; they are able to divide and propagate indeimitely given the necessary 
nutrients (i.e. they are immortal); they have much lower requirements for nutrients and 
growth factors (Cuttita et al., 1985); and imally they do not depend on anchorage for 
growth (MacPherson et al., 1964) (i.e. they do not need to attach to a substratum). 
ii. Changes to the cell surface. Although the general structure of the plasma 
membrane is not altered, transformed cells are agglutinated at a much lower lectin 
concentration than that required for normal cell agglutination (Burger et al., 1972a); 
microf"Ilaments and microtubules are frequently found to be more poorly organized in 
transformed cells; transformed cells seem to have the ability for enhanced transport of 
nutrients; transformed cells have either drastically reduced levels of fibronectin or 
completely lack this protein; imally, transformed cells show an increase in secretion of 
plasminogen activator which causes an increase in concentration of proteases. 
iii. Changes in oncogene activation. Transformation is often associated with 
overexpression of certain oncogenes such as the ras gene (Barbacid, 1987b) as well as 
the existence of mutations and cooperativity between some oncogenes (Land et al., 
1983a). 
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I. 3.3 Invasion, Metastasis and Angiogenesis 
Solid (non-haematologic) tumours are likely to metastasize in approximately 60% 
of cancer patients. These patients have microscopic and most of them, multiple 
metastases at the time of primary tumour treatment (Liotta, 1986a; Fidler et al., 1982; 
Schirrmacher, 1985) and it is this metastatic disease which lmally compromises the 
patient. Furthermore there exists great variability in metastatic potential among tumours, 
depending on their histologic type, aggressiveness and initial location. 
Carcinomatous invasion, refers to the penetration of tumour cells through the 
basement membrane and into the underlying stroma. Once tumour cells have attached to 
the matrix, (a process which is possibly mediated by glycoproteins such as Jaminin and 
fibronectin, receptors for which exist on tumour cells), there follows disruption of the 
basement membrane which is believed to be related to specific changes associated with 
the malignant phenotype (Liotta et al. , 197 4). One such change is the increased 
production by cancer cells of lytic enzymes such as plasminogen activator, which cleaves 
plasminogen in plasma to its active form. Decreased int~cellular adhesiveness of cancer 
cells (probably due to decreased fibronectin production) and increased motility (mostly 
due to loss of contact inhibition), are also believed to greatly contribute to the invasive 
ability of malignant cells. Several chemotactic factors, growth factors and motility factors 
appear to influence the direction of tumour cell locomotion (Garrod, 1990). Autocrine 
motility factors (Liotta et al., 1986b) are a recently described group of proteins which 
are believed to be secreted by tumour cells and to act both in an autocrine and paracrine 
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tumour specific fashion to stimulate both chemotactic (directional) and chemokinetic 
(random) motility. 
Tumour necrosis, which usually arises from a combination of factors such as 
release of lytic enzymes, release of tumour necrosis factors and vascular insufficiency 
in rapidly growing tumours, seems to be the process most closely associated with release 
of tumour cells into the blood stream following invasion. Although it has been estimated 
that millions of cells may be released daily into the circulation by primary tumours 
(Liotta, 1986a), it has also been shown experimentally that the majority of cancer cells 
introduced into the venous circulation of mice are rapidly trapped in the capillary bed of 
the lungs with less than 1% remaining after 24 hours. Seeding of metastases therefore 
appears to be a very inefficient process (with less than 0.01% of circulating tumour cells 
initiating metastatic colonies (Schirrmacher, 1985) mostly because the circulation acts as 
a very hostile environment for tumour cells (Garrod, 1990). The sites that are most likely 
candidates for the establishment of metastases are the lungs, liver, lymph nodes and 
brain. The preferential metastatic potential of these sites may be due to haemodynamic 
factors, since cancer cells are most likely to be trapped in the capillaries of the organs 
that they encounter trrst such as the lungs for cells that enter the circulation before 
draining into the vena cava or the liver for cells entering the hepatic portal system. 
Alternatively, or in combination with haemodynamic factors, there may exist the 
possibility of differential requirements for survival of cancer cells which might be offered 
by particular local environments (the "seed and soil" hypothesis). 
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The study of induction of metastatic potential at the genomic level has recently 
attracted much scientific interest. Research both on oncogenes (Nicolson, 1987; Egan et 
al., 1987) and "antimetastasis" (Steeg et al., 1988; Leone et al., 1991) genes is beginning 
to reveal the possibility of controlling metastasis by identifying and possibly inactivating 
genes which seem to confer metastatic potential when transfected to non-metastasizing 
lines (Leone et al., 1991; Gunthert et al., 1991; Reber et al., 1990; Hofmann et al., 
1991; Arch et al., 1992). 
Another possible control point for containing metastatic spread could involve the 
control of the emergence of a new vascular network designed to provide the necessary 
nutrients for the growth of newly emerging tumours (Mahadevan et al., 1990). 
Angiogenesis is essential for the preservation and growth of solid tumours beyond 
2mm in diameter (about 106 cells) (Folkman et al., 1987; Folkman, 1985; Folkman et 
al., 1976). A number of proteins, collectively termed angiogenesis factors (AGFs) have 
been isolated mostly from tumour cells (tumour angiogenesis factor (T AF) (Folkman, 
1974), fibroblast growth factors (FGFs) (Gospodarowicz et al., 1987), transforming 
growth factor a (TGFa) (Schreiber et al., 1986), but also from macrophages and mast 
cells (tumour necrosis factor (TNFa) or cachectin (Leibovich et al., 1987) and heparin). 
Since 1971 there has been an active field of antiangiogenesis research which has focused 
both on the discovery of antiangiogenic compounds and the development of specific 
inhibitors of angiogenic factors or related responses. 
In short, although the biology of cancer cells does not appear to differ greatly 
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from that of their notmal countetparts in tetms of cell cycle kinetics and growth 
potential, there exist a number of almost universal aberrations in the cancer cell, several 
of which can be exploited for diagnostic or therapeutic putpases. 
I. 
I. 
4. 
4.1 
Cancer Diagnosis 
Conventional Diagnostic Methods 
Although screening for certain types of cancer, such as cervical (MacGregor, 
1976), breast (Shapiro et al., 1982; Baker, 1982; Tabar et al., 1985), colorectal 
(Hardcastle et al., 1986; Eddy et al., 1987; Fleisher et al., 1989) and lung (Bomot et al., 
1973), has had a very positive impact in tetms of early diagnosis, it is very unlikely that 
screening and preventive programs will play a major role worldwide in arresting a wide 
variety of cancer types early enough to prevent metastasis, at least in the near future. The 
key to effective eradication of this disease therefore, seems to lie with improving current 
diagnostic methods and developing novel techniques. To date, despite technically 
revolutionary new approaches to cancer diagnosis, it is disheartening to note that 
diagnostic imaging (which includes the most non-invasive approaches such as 
ultrasonography, computer tomography, conventional radiography and magnetic 
resonance imaging) has not shifted the detection threshold for solid tumours to a level 
lower than 1-2 cm3 of tumour mass at best. Mammography, which is the most widely 
used screening technique for the detection of early breast cancer, has improved to the 
point of detecting cancers of 2 em or smaller at the noninvasive stage. Trials have 
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demonstrated that screening reduces breast cancer mortality by approximately 25 % 
(Harris et al., 1993). Unfortunately, as discussed above, a 2 em tumour will have had 
ample time for seeding metastases. 
In addition the technological advances in terms of diagnostic tools have by no 
means diminished the effect of the human factor. There now exists a wide choice among 
diagnostic procedures each of which may be particularly well-suited to tumour detection 
at certain sites but completely inappropriate for others. Furthermore higher sensitivity 
in detection techniques can produce quite complex imaging data which can prove difficult 
to interpret. 
I. 4.1.a Ultrasonography (Ainge et al., 1991) 
Ultrasonography, which uses high frequency sound waves to generate body 
images, is a quick and safe procedure which is most effective when used for detecting 
homogeneous tissue structures such as the liver, pancreas, kidneys, gynaecologic tumours 
etc. In general, sonography is best suited for detection of lesions greater than 4-5 em, 
preferably within a solid organ. For smaller lesions, or where acoustic barriers exist such 
as gas or bone, other diagnostic methods are preferable. 
I. 4.1.b Computed Tomography (Cubberley et al., 1991) 
Computed tomographic scanning (CT) which was introduced clinically in 1975, 
has a spatial resolution comparable to that of ultrasound and better than that of nuclear 
medicine. CT employs ionizing radiation at levels similar to those used by conventional 
radiography and provides excellent resolution with the added advantage of the 
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tomographic transverse perspective. It is the most accurate noninvasive method for 
detection of primary and secondary hepatic malignancies, cancer of the pancreas, renal 
carcinoma, adrenal malignancies and lymphomas. However, since CT is relatively 
expensive, time consuming and uncomfortable for the patient, it is usually considered 
only where other simpler techniques are deemed insufficient. 
I. 4.1.c Nuclear Medicine (Johnston, 1991) 
Nuclear medicine involves the intravenous injection of small doses of 
radioisotopes or radioactively tagged compounds. Choice of the appropriate isotope or 
compound may lead to its preferential localization or uptake by a particular tissue type, 
and II diseased II may then be compared with its normal counterpart. Detectors sensing 
ionizations caused by radioactivity may use gaseous, liquid or solid phases with the most 
efficient being solid such as sodium iodide crystals. The most popular nuclear medical 
device translating this radioactivity into images is the scintillation camera. Isotope 
imaging has proven very useful for the detection of thyroid and parathyroid tumours, 
brain tumours, questionable lung tumours, primary bone cancer, lesions in Hodgkin's, 
non-Hodgkin's and Burkitt's lymphoma and in the search for metastatic cancers by liver 
and bone imaging. However, in no cases were lesions of less than 1 em detected, with 
detection sensitivity increasing with lesion sizes between 1 and 5 em and decreasing after 
5 em. 
I. 4.1.d Nuclear Magnetic Resonance Imaging (NMR) (de Lange, 1991) 
Nuclear Magnetic Resonance (NMR) imaging (developed in 1973) is the most 
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recent imaging technique. It is based on protons (mostly hydrogen atoms) emitting a 
signal of the same frequency as the one they absorb after being bombarded by pulses of 
electromagnetic energy of the appropriate wavelength. This signal can then be used to 
construct a computer-generated image of the location of that particular hydrogen. NMR 
images display excellent tissue contrast, while the technique itself is noninvasive and 
carries no biological hazards. It is particularly promising in the areas of oncologic 
examination of the head, neck, spinal chord, brain and soft tissues. However its 
specificity is still rather low and it is a lengthier and more expensive process than CT 
scanning which usually still provides higher anatomical detail at most sites outside the 
CNS. Nevertheless NMR imaging is a diagnostic area of major future potential. 
I. 4.1.e Oncological Angiography (Lang, 1991) 
Oncological angiography involves the attempt to characterize many neoplasms by 
their distinctive vascular patterns. Although other, less invasive, diagnostic modalities 
have diminished its use during the last decade, angiography still exhibits a high 
sensitivity for the detection of certain tumour types such as parathyroid adenomas and 
may provide a necessary additional road map prior to resection of lesions. In addition 
arteriography is recently gaining importance in therapeutic oncology. 
Despite the technological leaps involved in diagnostic procedures, they do not 
remotely approximate the capabilities of endoscopic procedures and analyses of biopsies 
for early detection and accurate description of tumour characteristics. For example, using 
current endoscopic procedures such as laparoscopy (a rather inexpensive technique 
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devised some 80 years ago), lesions of 0.5-2 mm in diameter can be seen from a 10 mm 
object distance (Berci, 1991). This detection capability cannot of course be compared 
with either ultrasound or CT, but it has to be borne in mind that endoscopic procedures 
and biopsies are probably the last diagnostic resort, due to their being highly invasive and 
with some degree of danger for the patient. 
It becomes clear from the above that it would be ideal to perfect the previously 
mentioned, high-tech, non-invasive techniques so that they can detect tumour lesions of 
such small sizes that dissemination and metastasis are not likely to have begun. It is 
likely that the most appropriate method to achieve this goal would come with the ability 
to "focus in" on the lesion, rather than attempt to scan the suspect neighbourhood. There 
has been tremendous effort during the last couple of decades in attempting to specifically 
recognize tumour tissue and differentiate it from its nonnal surroundings. In the effort 
to render non-invasive diagnosis more efficient, molecules specifically associated with 
particular tumours have been searched for, in the hope of "targeting" any particular 
tumour. Although, to this day, tumour specific markers have only been found for B and 
T cell leukemias, a number of cancer-associated molecules have been discovered, most 
of which are actively used both in diagnosis and therapy of some cancer types. 
I. 4.2 Cancer Markers 
"Cancer markers" are cellular macromolecules many of which are in general 
produced nonnally at some early time during development (usually embryonic), but are 
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present either at very low or undetectable amounts in the adult. The onset of the 
carcinogenic process may trigger at one point an increase in production of these markers. 
These "oncodevelopmental" markers, when re-expressed, are usually related to their 
tissue of origin. Cancer markers include secreted proteins, cell surface molecules, 
hormones, enzymes and isozymes, cluster designation (CD) markers and karyotypic 
abnormalities, cytoskeletal markers and more recently oncogenes and suppressor genes. 
Specific discussion of each marker is beyond the scope of this work. Suffice it to 
say that the history of tumour markers might be divided into three eras (Sell, 1991). The 
frrst era began in 1846 when it was discovered that urine samples of patients with 
multiple myeloma (then known as "mollities ossium") contained a heavy precipitate (the 
Bence-Jones protein (Bence-Jones, 1847)), which 100 years later was recognized as 
immunoglobulin light chains produced in excess by approximately half of patients with 
plasmacytomas. Then followed the association of various hormones and enzymes with 
specific cancers, however significant elevations of such substances are usually not related 
to any one particular cancer type and may be affected by a variety of biological events, 
so that they cannot be used as unequivocal diagnostic tools. 
The second era of tumour markers is delmed by the discovery of two very useful 
"tumour antigens", namely alphafetoprotein (AFP; G.I. Abelev, 1963 (Abelev, 1971)) 
and carcinoembryonic antigen (CEA; Gold & Freedman, 1965 (Gold et al., 1965b; Gold 
et al., 1965a)). Elevated AFP aids in the diagnosis of approximately half the patients 
with hepatocellular carcinoma, while elevations in CEA are mostly used for the detection 
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of colorectal malignancies or metastatic cancers and for measuring disease progression. 
However the most revolutionary discovery of the second era has been in obtaining 
antibodies of predetermined specificity, after the experiments of Kohler and Milstein in 
1975 (Kohler et al., 1975). A variety of murine monoclonal antibodies (Mabs) to human 
tumours were widely applied against melanoma, colorectal carcinoma, carcinoma of the 
lung and most other tumours. Although much enthusiasm was initially generated and a 
relatively large number of diagnostic studies with radiolabelled antibodies, as well as 
therapeutic studies (usually with monoclonal antibodies alone) were performed, a number 
of factors unfortunately contributed to the "tapering off'' of most researchers' interests, 
at least on the therapeutic side. One such consideration was the murine origin of those 
monoclonal antibodies, which generated a human anti-mouse (HAMA) response in most 
patients, more often expressed as minor side effects such as fever, chills, pruritus, chest 
tightness, dyspnea, rash, arthralgia, myalgia and hypotension. The major problem created 
by the HAMA response was that it limited the possibility of prolonged therapy. 
However the most serious problem by far was the inability to discover more 
specific tumour markers so as to ensure exclusive tumour localization. Despite such 
drawbacks novel approaches to "tumour targeting" with monoclonal antibodiies, such as 
the use of chimaeric or human antibodies, open up new avenues for their use in the 
clinical environment. 
The third era of tumour markers involves the quickly accumulating information 
on oncogenes and oncogenic viruses. Expression of several oncogenes has been 
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associated with cancerous disease states, often of an inheritable nature, thus adding the 
power of genetic counselling and early diagnosis to the therapist's annamentarium. 
Furthermore the possibilities for use of molecular biology techniques in recognizing 
abnormalities (such as gene deletions and mutations) at the level of the genome and 
possibly rectifying certain of them, open up immense possibilities in the diagnosis and 
treatment of cancer. 
I. 4.3 Immunodiagnosis 
Imaging studies with radiolabelled antibodies began as early as 1948 when David 
Pressman conducted studies demonstrating the localization of radiolabelled antibodies in 
normal tissues (Pressman et al., 1948) and later in experimental tumours (Pressman et 
al., 1953; Pressman et al., 1957; Bale et al., 1957). Presently radioimmunodetection 
(RAID) combined with the use of single photon emission computed tomography (SPEC'!) 
has revealed lesions as small as 0.5 to 1 em (Goldenberg et al., 1992; Goldenberg et al., 
1990; Goldenberg et al., 1989; Britton et al., 1989; Bares et al., 1987; Granowska et al., 
1986), whereas the smallest detectable lesion using planar imaging was not less than 2 
em. Although RAID is theoretically subject to the usual targeting problems, such as lack 
of tumour-specific markers, antigen and cell heterogeneity within a tumour and 
circulating tumour antigen, it seems to circumvent most of these (Goldenberg et al., 
1992; Goldenberg, 1988; Nowell, 1990; Goldenberg et al., 1980). Specifically, it seems 
that RAID does not require entirely cancer-specific antigens, since targeting has been 
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achieved with only 15% of the tumour cells expressing the target antigen (Doerr et al., 
1990) and even very high titers of circulating antigen do not neutralize the injected 
antibody. Furthermore many of the carrier antibodies presently in use are pan-carcinoma 
antibodies, making possible the imaging of a large panel of tumours, while there seems 
to be no need for "tailoring" the antigen-antibody system to individual patients. Antibody 
dosage, size, affmity and immunogenicity are all points that are under continuous 
investigation (Goldenberg et al., 1992). Results to date indicate that desirable antibody 
doses range from 0.25 mg (Goldenberg et al., 1978; Goldenberg et al., 1980) to above 
40 mg (Divgi et al., 1991), and that monovalent or bivalent antibody fragments are more 
desirable for imaging purposes (Wahl et al., 1983; Larson et al., 1983; Chatal et al., 
1984; Siccardi et al., 1986). Antibody affmity is a moot point in targeting, but it is 
becoming increasingly obvious that higher affmity antibodies are not necessarily the most 
efficient (Sharkey et al., 1990; Weinstein et al., 1987; Fujimori et al., 1989). The issue 
of HAMA response is as important in RAID as in any other application of targeting and 
the creation of chimaeric, humanized or human carrier antibodies (LoBuglio et al., 1989; 
Pinsky et al., 1991) would be the avenue to explore for reducing or eliminating this 
problem. 
Presently, the radiolabels most commonly in use include 1311, 1231, 111In and 99mTc, 
with 1231(6 hr half-life) and 99my'c (13.2 hr half-life) being detected most efficiently. 99mTc 
allows for the highest permitted administered dose and results in the best imaging 
properties among the four RAID isotopes mentioned above (Britton et al., 1989). 
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However its short half-life precludes its use for detection of targets showing slower 
uptake (Goldenberg et al., 1990; Goldenberg et al., 1989; Pinsky et al., 1991). 
Although the degree of sensitivity in the detection of lesions differs with the 
antibody-radioisotope system used and the type of lesion examined, an increasing number 
of clinical trials indicate that use of RAID is very helpful both in contrrming cancer sites 
revealed by current diagnostic techniques and, most importantly, in disclosing occult 
tumours. A European multicentre clinical study using 1311 or 1111n-labelled anti-CEA 
F(ab')2 (Siccardi et al., 1989) revealed that in 20% of the patients RAID disclosed occult 
lesions and resulted in altering patient management in 13 % of the cases. Another 
multicentre study using ~c-labelled anti-CEA Fab' (Pinsky et al., 1991) found a 42% 
clinical benefit in colorectal cancer patients. Most RAID studies have focused on 
colorectal cancer patients partly due to successful detection of nodal metastases in normal 
size lymph nodes (Nowell, 1990) (which remain undetectable by conventional 
techniques), as well as higher accuracy in detecting liver metastases (Goldenberg, 1991). 
Given that at the time of presentation of nodal metastases half the colorectal cancer 
patients have udetected micrometastases and will die of the disease (Thompson et al., 
1987), and about 20% of those patients have liver metastases (Welch et al., 1978), the 
additional sensitivity provided by RAID is of essence. Most RAID studies on colorectal 
cancer patients have used anti-CEA antibodies (Goldenberg et al., 1980; Goldenberg et 
al., 1989; Goldenberg et al., 1983; Larson, 1990; Goldenberg, 1991) linked to any of 
the four radioisotopes mentioned. In addition, human and chimaeric antibodies have been 
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employed (Steis et al., 1990; Bischof Delaloye et al., 1991). RAID has also been used 
in the diagnosis of a large panel of other cancer types with most studies concentrating 
on ovarian carcinoma and breast cancer (Krag, 1993; Britton et al., 1989; Larson, 1990), 
and prospective trials have shown RAID to be generally superior to other imaging 
methods. 
I. 
I. 
5. 
5.1 
Cancer Therapy 
Conventional Techniques (Cancer Medicine, 1993) 
The three major modalities which have routinely been used either separately or 
most often in combination, are surgery, radiotherapy and chemotherapy. 
I. 5.1.a Surgical Oncology 
Surgery will normally only be undertaken if staging indicates that the tumour is 
localized. Furthermore, surgical excision attempting to achieve cure, is reserved for 
localized tumours of a histological type which is likely to be conimed to the primary site. 
Unfortunately, there is an extremely high relapse rate for common solid tumours treated 
surgically, suggesting that at the time of resection of the primary there probably exist 
occult microscopic metastases. Due to this fact surgery is usually applied in combination 
with radiotherapy and/ or chemotherapy. 
I. 5.1.b Radiation Oncology 
Radiotherapy is based on the premise that ionizing radiation will result either on 
_a "direct hit" or in the production of free electrons which will react with water to form 
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highly reactive free radicals. These radicals will act by causing strand breaks in DNA 
and the radiation sensitivity of a tissue or tumour will depend both on the amount of 
damage sustained by the cells and the ability of the tissue to repair sublethal damage. The 
degree of oxygenation of the tumour is also a factor that greatly influences radiation 
sensitivity. It was discovered that repeated low doses of radiation are safer and more 
effective and therefore radiation is now delivered in multiple fractions over a period of 
1-2 months. Radiation dose is governed by the sensitivity of normal tissues and tumour 
and these relative sensitivities detme the potential for curability. 
I. S.l.c Chemotherapy 
Chemotherapy (i.e. systemic therapy using anti-cancer drugs), apart from being 
frequently used in conjunction with surgery and/or radiotherapy to treat residual disease, 
may be the only possible treatment for those types of cancer that are not amenable to 
other forms of treatment (such as leukemias and lymphomas). Most anti-cancer drugs 
interfere with cell division at some particular stage i.e. they are cell cycle dependent, 
either for a particular phase (phase-specific drugs), or for any stage of the cell-cycle 
(cycle-specific drugs). Those drugs that affect cells irrespective of their cycling state are 
called non-cycle active drugs. Anti-cancer drugs are usually grouped by mode of action 
(antimetabolites, antitumour antibiotics, alkylating agents), and/or by origin (plant-
derived drugs, platinum analogs). In most cases drug action has been extensively 
characterized along with modes of drug resistance development. There is a host of factors 
that will affect the onset of chemotherapy, its duration and drug type(s) used. In general 
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however, some of the most significant questions relating to the application of 
chemotherapy include tumour burden (which is often a limiting factor), sensitivity of the 
tumour to the drug used (which usually determines the length of chemotherapy, with 
most adults receiving a maximum of six to nine treatments), the development of drug 
resistance and the toxicity of the chemotherapeutic drug which may be tolerated 
differently by different patients. 
I. 5.2 Immunotherapy (Rosenberg, 1993) 
The biologic therapy of cancer which has more recently emerged as the fourth 
modality for cancer treatment, involves the effort to widely mobilize natural host defence 
mechanisms. Immunotherapy, which is considered a subcategory of biological therapy, 
gained momentum in the '60's, when data from experimental tumour models indicated 
that both specific stimulation of the immune system with antigen-bearing tumour cells and 
non-specific stimulation with bacteria, viruses and other adjuvant-type compounds could 
enhance the immune response and prevent the recurrence, or delay the growth of 
experimentally transplanted tumours. Furthermore, this type of treatment seemed to be 
most effective with small tumour burdens and was considered a possible treatment of 
residual disease. Immunotherapy involves both "active" (attempting to boost the host's 
immune responses against his/her own tumour), and "passive" strategies (involving 
infusion of biologically active agents into the host to mediate an antitumour response). 
Active immunotherapy is further subdivided into specific and nonspecific approaches. 
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Active nonspecific immunotherapy employs immune adjuvants such as bacillus 
Calmette-Guerin (BCG), Corynebacterium parvum and levamisole, which can activate 
monocytes, macrophages and the reticuloendothelial system (RES) to increase tumoricidal 
activity, or induce the production of cytokines. For the most part this form of 
immunotherapy has been unsuccessful in the treatment of advanced cancer. However 
BCG has been found to be effective in the treatment of cutaneous metastases of 
melanoma patients (Morton et al., 1991) and in the treatment of patients with superficial 
bladder cancers (Herr, 1991; Morales et al. , 1976). More recently, recombinant 
cytokines such as interferon and interleukin-2 are administered directly or encapsulated 
in liposomes in order to minimize their toxicity (Rosenberg, 1993). 
Active specific immunotherapy involves host immunization with "cancer 
vaccines" generated either from whole autologous or allogeneic tumour cells using living 
cells, inactivated cells or cell fragments either alone or in combination with immune 
adjuvants or viruses. To date neither pre-clinical studies nor clinical trials (Hoover et al., 
1991; Hoover et al., 1984; Hoover et al., 1985) have produced any significant results 
of therapeutic potential. 
Passive immunotherapy includes the areas of adoptive immunotherapy (the 
transfer of cells with anti-tumour activity to the tumour-bearing host) and serotherapy 
(the use of antibodies, particularly monoclonal, for a more selective tumoricidal effect). 
A number of adoptive immunotherapy studies have been conducted since 1980 
when subpopulations of lymphoid cells capable of lysing fresh tumour but not normal 
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cells were generated from mice and humans (Yron et al., 1980). These lymphokine 
activated killer (LAK) cells are a distinct non-:MHC restricted cell population requiring 
interleukin-2 (IL-2) as the sole signal for their generation. Clinically LAK cells exhibit 
antitumour responses only in combination with IL-2 (Rosenberg et al., 1985; Rosenberg 
et al., 1987). Although since the mid 1980's the availability of recombinant IL-2 made 
such studies feasible, it is required in high doses which result in multiple toxic side 
effects (Rosenberg et al., 1985; Rosenberg et al., 1987). LAK cell-IL-2 treatment has 
mostly been applied to patients with melanoma or renal cell cancer and in those studies 
complete regression of metastatic cancer was observed in approximately 10% of the 
patients and partial regression in 20% . Some regression of metastatic cancer has also 
been observed in colorectal, lung, liver, bone, skin, subcutaneous tissue and circulating 
tumour cells. Another IL-2 stimulated tumour-derived lymphoid cell subpopulation able 
to destroy some autologous tumour cells has also been identified. Tumour-inf'Iltrating 
lymphocytes (TILs) can be isolated from most types of human tumours and have been 
found to be 50 to 100 times more potent than LAK cells in mediating the regression of 
established micrometastases in animals (Rosenberg et al., 1986). To date treatment with 
TILs has only proven effective in the treatment of melanomas (Rosenberg et al., 1988) 
and attempts are being made to increase the specificity of treatment using gene therapy 
techniques (Rosenberg et al. , 1990). 
Serotherapy or monoclonal antibody mediated tumour cell destruction represents 
the only cancer therapeutic approach focusing on selectivity for cancer cells at the 
35 
cellular level. This approach is of paramount importance since the major common factor 
in both conventional radiotherapy and chemotherapy (the major therapeutic modalities for 
combatting metastatic disease), is the lack of specificity of treatment for the cancer tissue 
versus the normal tissue. Given the fact that both modalities are extremely aggressive and 
in addition to "curing" the tumour, they may also result in detrimental side effects on 
normal tissue, it becomes clear that such an alternative treatment, could yield an 
immense therapeutic benefit. 
I. 5.3 Tumour targeting with monoclonal antibodies 
The production of monoclonal antibodies in 1975 initiated a renewed wave of 
interest in the possibility of the use of antibodies for more specific attack on cancer cells 
via their recognition of tumour antigens. Monoclonal antibodies were used either alone 
or conjugated to cytotoxic agents such as radioisotopes, toxins and chemotherapeutic 
drugs, with promising results mostly in transplantation studies. Initial scientific 
enthusiasm gave rise to a large number of attempts to fulfill Ehrlich's early vision of "the 
magic bullet". ·However the inability to discover true tumour specific antigens as well as 
other difficulties associated with the immunotargeting approach quickly discouraged the 
academic community. This is an unfortunate fact, since to date no alternative method 
of specific treatment has been found despite the promise of gene therapy following the 
revolution in the field of molecular biology. Immunotargeting trials are still in progress 
both in experimental and clinical settings and a short account of the progress in the use 
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of immunoconjugates is given in the following sections. 
I. S.3.a Radioimmunotherapy 
In contrast to radioimmunoscintigraphy where a gamma ray emitting radionuclide 
with a relatively long half life is desirable, radioimmunotherapy can take advantage of 
a wide range of nuclides that would be more suitable for the treatment of tumours of 
different size, location and radiosensitivity (Ford et al., 1990; Bast et al., 1993; Cobb 
et al., 1986; Dykes et al., 1987). Currently, beta-emitting radionuclides capable of 
traversing tissue in the range of millimetres to a few centimetres, may be used for larger 
tumours and would facilitate the destruction of neighbouring antigen-negative or poorly 
perfused tumour cells. Beta emitters include 1311, 90y, 188Re, 186Re, 67Cu, and 211At. 
Probably the most widely used beta emitter has been 1311, which, when conjugated to 
either intact antibody or F(ab')2 fragments, has shown very high specificity for tumour 
xenografts (Vacca et al., 1988; Wahl et al., 1983). Substantial numbers of partial and 
complete tumour regressions were observed in radioimmunotargeting experiments using 
athymic rodents (Cheung et al., 1986; Klein et al., 1989; Lee et al., 1988; Sharkey et 
al. , 1987; Chiou et al., 1988; Buchegger et al., 1988). Unfortunately, localization of 
radiolabelled antibodies in clinical studies was reported to be four orders of magnitude 
less than those observed in animal models (Buraggi et al., 1985; Carrasquillo, 1989; 
Colcher et al., 1987b; Epenetos et al., 1986; Farrands et al., 1982; Mach et al., 1981) 
(in the order of 0.005% injected dose per gram of tumour). Despite poor tumour uptake 
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in humans, both partial and complete remissions have been observed in clinical trials with 
hepatomas and Hodgkin's disease (Leichner et al., 1983; Lenhard et al., 1985; Order et 
al., 1985; Dillman et al., 1984). Most of these trials have been performed with 1311-
labelled polyclonal antiferritin antibodies with no toxic side effects. Clinical trials 
involving other antibodies conjugated to the same radionuclide have not produced 
significant results in patients with melanoma (Bjorn et al., 1985), non-Hodgkin's 
lymphoma and recurrent lymphoma (Bernstein et al., 1990). However partial responses 
were achieved in 6/6 cutaneous T-celllymphomapatients treated with 1311-T101 conjugate 
(Rosen et al., 1987), whereas 4/5 patients with leptomeningeal tumours responded to the 
intrathecal administration of a variety of 1311-labelled monoclonal antibodies (Lashford et 
al., 1988). 90y, a beta emitter of a much higher decay energy than 1311, has been shown 
to cause specific anti-tumour effects in the animal model, but its use was also associated 
with bone marrow toxicity (Sharkey et al., 1988). To date, limited clinical trials with this 
nuclide have not shown much promise (Parker et al., 1990). 
In certain cases, such as the treatment of micrometastases, higher and more 
focused radiation might be considered more appropriate. Radionuclides such as 211 At and 
212Bi emit alpha particles which have a very high energy and a short tissue range ( 4-6 cell 
diameters), thus requiring only 2-25 traversals to kill a cell. Their high cytotoxic 
potential along with their oxygen-independent mode of action, would make such nuclides 
very appropriate for the treatment of smaller, easily accessible tumours, such as those 
of the peritoneal cavity or the circulatory system. In vitro and in vivo studies with 212Bi 
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have shown efficacy and specificity in an anti-human IL-2 model (Kozak et al., 1986), 
as well as very high cytotoxic potential (Kurtzman et al., 1988; Macklis et al., 1988). 
Clinical studies have yet to corroborate these results. 
I. 5.3.b lmmunotoxin Therapy 
Toxins are large peptide molecules which can catalytically inactivate protein 
synthesis (Olsnes et al., 1982). The most widely used toxins are ricin and abrin (plant-
derived) and diphtheria and pseudomonas exotoxin (bacterial). The intact molecule 
(holotoxin) consists of a 20-30 kilodalton (kDa) A chain, which makes up the cytotoxin 
portion of the molecule which is covalently linked to a 30-40 kDa B chain, which binds 
normal cell surface receptors (Pappenheimer, 1977; Olsnes et al., 1974). For the 
construction of immunotoxins the holotoxin is modified by removing or blocking the B 
domain binding site (Blythman et al., 1981; Lambert et al., 1990; Jinno et al., 1988; 
Murphy et al., 1986) and the resulting molecule is then linked to monoclonal antibodies 
(usually derivatized to contain a free thiol group), so as to produce a thioether or 
disulfide bond. 
Toxins effect their cytotoxic action in a non-cycle specific fashion, by irreversibly 
blocking the elongation step of protein synthesis. Their ability to kill resting as well as 
cycling cells, and their tremendous cytotoxic potential (one toxin molecule effectively 
internalized, can kill a cell) (Eiklid et al., 1980; Yamaizumi et al., 1978) make it 
imperative that they be administered as selectively as possible. The choice therefore of 
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the monoclonal antibody component of an immunotoxin is of paramount importance, 
since uptake by normal cells should be kept at a minimum, while the immunotoxin should 
still retain the ability to bind avidly to cells, be rapidly internalized and be routed to 
appropriate intracellular compartments for effective translocation into the cytosol (Bjorn 
et al., 1985; Engert et al., 1989; Goldmacher et al., 1989; Press et al., 1988). Due to 
these requirements only 5 % to 25 % of specific monoclonal antibodies screened are found 
adequate for the production of potent immunotoxins (Till et al., 1988). 
Because of their high cytotoxic potential, immunotoxins are probably the 
imrnunoconjugates that have been most extensively evaluated in clinical trials. The irrst 
such trials were performed on patients with refractory solid tumours, including metastatic 
melanoma (Spitler et al., 1987; Oratz et al., 1990), colorectal carcinoma (Byers et al., 
1989), metastatic breast carcinoma (Weiner et al., 1989; Gould et al., 1989) and ovarian 
carcinoma (Pai et al., 1991). The above were phase I trials, with the exception of two 
phase IT trials on metastatic melanoma (Oratz et al., 1990; Spitler, 1988). Although some 
partial and mixed responses were achieved, mostly in the case of melanoma patients 
(where one complete response was also observed), all trials were limited by high 
unexpected toxicities including vascular leak syndrome (VLS), myalgia, aphasia, 
neuropathies, encephalopathies and abdominal pain. In the cases of breast and ovarian 
carcinoma the severe neuropathies were subsequently attributed to possible monoclonal 
antibody cross-reactivity with epitopes on Schwann cells' myelin and cells in the 
cerebellum respectively. Furthermore in all these trials 80% to 100% of the patients 
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treated developed immunological responses either to the ricin A (HARA) component or 
the antibody (HAMA) component of the immunoconjugate, even after treatment with 
cyclophosphamide aimed at reducing the immune response of the patients. 
Clinical trials involving haematologic malignancies have shown more encouraging 
results overall, probably due to a wider selection of monoclonal antibodies which do not 
cross-react with notmal cells, higher accessibility of targeted epitopes and rapid 
replenishment of affected notmal cells. Phase I trials involving patients with non-
Hodgkin's lymphoma (Grossbard et al., 1992; Vitetta et al., 1991), B-cell chronic 
leukemia (Hertler et al., 1989), T-cell lymphoma (Le Maistre et al., 1991) and 
Hodgkin's disease (Le Maistre et al., 1990) have resulted in a higher percentage of 
complete and partial responses as well as a high number of mixed and transient 
responses. Furthetmore toxic side effects were transient and less severe, while HAMA 
and HARA responses ranged from 7% to 85%. 
However, the most successful clinical applications of immunotoxins have involved 
the treatment of graft versus host disease (GVHD) (Byers et al., 1990), where a high 
number of complete and partial responses was induced with tolerable side effects and 
only 26% of the patients developing HAMA and HARA responses. Presently an anti-
CD5-A-Ricin Toxin A (RTA) immunotoxin has been approved for marketing for the 
treatment of GVHD, while a limited number of phase I and phase ll trials involving the 
use of immunotoxins for the treatment of malignancies are under way. 
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I. 5.3.c Chemotherapeutic Drug Immunoconjugates 
Various murine monoclonal antibodies have been linked to a number of 
chemotherapeutic agents (Koppel, 1990; Schlom et al., 1990; Ford et al., 1990; Ghose 
et al., 1987; Pimm, 1988) such as antifolates (Baldwin et al., 1987; Kanellos et al., 
1987; Shawler et al., 1988; Smyth et al., 1987a; Affleck et al., 1992), vinca alkaloids 
(Ford et al., 1987a; Casson et al., 1987; Rowland et al., 1986), anthracyclines (Sheldon 
et al., 1989; Shouval et al., 1988; Smyth et al., 1991; Trail et al., 1992; Yeh et al., 
1992; Iwahashi et al., 1989; Richardson et al., 1989), alkylating agents (Pietersz et al., 
1988; Smyth et al. , 1987b) and neocarzinostatin (Luders et al., 1985; Kitamura et al., 
1992). The most accessible sites for drug attachment onto the antibody carrier are the 
epsilon amino groups of the lysine residues and the carbohydrate moiety of the CH2 
domain (Koppel, 1990). When F(ab')2 fragments are used the lysine residues would be 
the most likely attachment sites since those fragments would lack carbohydrate portions. 
In addition to the need for conserving the antibody's selectivity for the target 
antigen as well as the cytotoxic ability of the drug, the drug should be delivered in large 
enough doses in order to be effective. Since many cell surface antigens have less than 1 OS 
copies per cell it has been estimated that release of 3 x 1 (f' drug molecules at the cell 
surface would be marginally sufficient in eliminating the tumour (Bast et al., 1993). 
Consequently much effort has been concentrated on increasing the number of drug 
molecules attached to the antibody either by direct linkage using spacer molecules (Yang 
et al., 1988), or by linking drug carrier molecules such as dextran {Tsukada et al., 1984) 
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or human serum albumin (HSA, (Ohkawa et al., 1986)) to the monoclonal antibody. Such 
linkage strategies have yielded immunoconjugates (ICs) which in some cases were found 
to be more effective than free drug both in vitro and in vivo. Such ICs include 
doxorubicin (Dox) linked to a Mab via a cis-aconityl spacer molecule (Yang et al., 1988) 
or a dextran linker (Yeh et al., 1992; Shih et al., 1991), daunomycin, fluorouridine or 
methotrexate linked to a monoclonal or poly clonal antibody (Pab) via a dextran bridge 
(Ford et al., 1990 and references within), (Shih et al., 1990; Shih et al., 1988), and 
mitomycin C (MCC) linked to antibody via human serum albumin (HSA) (Ohkawa et al., 
1986; Affleck et al., 1992). 
Another desirable feature of the linker, especially in the case of drugs which act 
intracellularly, is the ability of the linker to release the drug after entering the cell. 
Molecules such as the hydrazone linker, which dissociates in low pH environments (such 
as those of intracellular endosomal or lysosomal compartments) to free the attached drug, 
have been used with doxorubicin or its derivatives and resulted in immunoconjugates 
that, under optimal schedules, were found to be more potent than free drug (Braslawsky 
et al., 1990; Greenfield et al., 1990; Mueller et al., 1990) . 
Although there have been discrepancies in terms of in vivo and in vitro 
performance of such immunoconjugates ( IC' s which have been found to be less effective 
than free drug in vitro are more effective than free drug in vivo (Rowland et al., 1986; 
Casson et al., 1987; Dillman et al., 1986)), in many cases the immunoconjugate is found 
to be less toxic than free drug, thus making possible an increase in tolerated dose (TD). 
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The concept of enzyme-catalyzed prodrug activation is also being explored, in the 
hopes that a Mab-linked enzyme which can accumulate in the target tissue may act in a 
catalytic manner to achieve the conversion of a large molar excess of subsequently 
administered substrate (drug) (Koppel, 1990; Bagshawe, 1989). Enzyme and prodrug 
combinations used to date, include carboxipeptidase G2 and a glutamyl derivative of a 
benzoic acid mustard alkylating agent (Bagshawe et al., 1988), alkaline phosphatase and 
phosphate derivatives of etoposide or mitomycin C (Senter et al., 1989) and a penicillin-
V -amidase and a phenoxyacetamide derivative of doxorubicin (Kerr et al., 1990). In all 
cases the prodrug was at least 50-fold less toxic than the unconjugated active drug in 
vitro against tumour cells, while combinations of the enzyme conjugate and prodrug 
administered to tumour-bearing mice were more effective compared to free drug. 
Given that the use of chemotherapeutic drugs is probably the most widely used 
type of cancer therapy and requires much improvement, it is rather peculiar that patience 
in the scientific world seems to be thinning where drug-Mab immunoconjucates are 
concerned. To date, clinical trials have been initiated with N-acetylmelphalan and 
neocarzinostatin (Takahashi et al. , 1988) conjugated to antibodies reactive with colorectal 
cancer and responses have been noted in 2 out of 8 and 3 out of 8 patients respectively. 
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I. 5.4 Overcoming obstacles to effective tumour targeting 
The main reason for the decline in the original enthusiasm generated by the idea 
of tumour targeting (in addition to the inability to rmd tumour specific antigens), was that 
the use of monoclonal antibodies seemed to introduce a variety of practical problems 
which limited their applicability. Such problems included the existence of shed tumour-
associated antigen, antigenic modulation, heterogeneity of antigen expression, limited 
accessing to tumour sites, immunogenicity of "conventional Mabs" and the variability of 
Mab potential to be internalized. These problems have been addressed extensively and 
a number of strategies to circumvent them are still being developed. 
I. 5.4.a Antigen shedding is a function of tumour size in solid tumours and posed 
a serious targeting problem since levels of circulating antigen were believed to determine 
the feasibility of using the targeting approach. However it has been shown that high 
levels of circulating antigen do not inhibit localization (Goldenberg et al., 1987). The 
hypothesis suggesting that route of administration of immunoconjugates may facilitate the 
preferential accessing of tumour-bound antigen has not been supported by pre-clinical 
or clinical studies for the most part (Ward et al., 1987c; Ward et al., 1987a). Injection 
of radiolabelled Mab in mice with ovarian cancer xenografts as well as in patients with 
ovarian cancer has demonstrated that the intravenous (i. v.) route was superior to the 
intraperitoneal (i.p.) route for solid tumours, although the i.p. route was superior for 
immunolocalization of ascitic cells. Conversely, direct intratumoral injection of a human 
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IgM Mab reactive with the GD2 ganglioside produced partial and complete regression of 
injected cutaneous melanoma nodules in 4 of 8 patients (lrie et al., 1986). Tumour 
nodules that failed to respond to repeated injection had relatively lower levels of antigen 
than did nodules that regressed. Furthermore a mononuclear initltrate was observed at 
the sites of antibody injection. Encouraging results have also been obtained with two- or 
three-step systems. For example, i. p. application of biotinylated Mab in ovarian cancer 
patients, who subsequently received radiolabelled streptavidin generated mean tumour to 
normal tissue radioactivity ratios of 9: 1 for intra-peritoneal and 45: 1 for extra-peritoneal 
samples respectively on the day of surgery, which is 2 to 3 times the usual values 
(Paganelli et al., 1992). A three-step approach currently being investigated for 
immunolocalization (Paganelli et al., 1993; Paganelli et al., 1991), involves injection of 
biotinylated Mab followed by avidin administration. Avidin serves to precipitate 
circulating biotinylated Mab and at the same time targets the tumour cells, thus allowing 
adequate homing in of the subsequently administered biotin. In general, attempts to 
examine the effect of regional drug administration in conventional chemotherapy were 
also discouraging and this approach is currently used only for the prophylaxis or 
management of meningeal metastases . 
I. 5.4.b Antigen heterogeneity (antigen being expressed by only a proportion of 
cells within the lesion) and antigenic modulation (induction of transient disappearance 
of a cell surface antigen due to binding of antibody), are the two direct ways for tumour 
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cells to escape treatment with monoclonal antibodies. The existence of antigenic 
heterogeneity among different tumour lesions has been documented both in experimental 
models using human carcinoma lines and in biopsies (Horan Hand et al., 1983) and 
several studies have demonstrated that the antigenic phenotype of a human cell population 
is the result of dynamic interactions of growth factors, evolution of cell subpopulations, 
influences of stromal and other cellular elements, as well as the diverse genotypes of the 
cell population. The result is a cell population that can intrinsically regulate its antigenic 
phenotype as measured by the binding of Mab. Approaches which attempt to minimize 
escape of tumor cells from Mab recognition via antigenic heterogeneity include the use 
of "cocktails" of antibodies (Durrant et al., 1989) which would take advantage of the 
expression of multiple tumour antigens within a cell population, or the presence of 
different determinants within the same antigen, and the administration of agents that 
interfere with cellular differentiation and can induce an enhancement of the antigen's 
expression (Gasparini et al., 1993). Agents tested for their ability to increase tumour 
antigen expression include retinoids, growth factors, organic solvents, DNA intercalating 
agents, vitamin D and tumour necrosis factors, and the most effective in augmenting Mab 
binding by increasing antigen expression were type I and II recombinant human 
interferons (rHu-IFNs) (Gasparini et al., 1993; Weinstein et al., 1992b). Another 
approach to circumventing antigenic heterogeneity could be the use of high-energy 
radioimmunoconjugates in an effort to extend cell kill to several cell diameters so as to 
affect antigen-negative tumour cells. 
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Similar methods may be used to avoid the disappearance of the antigen from the 
cell surface via antigenic modulation. The ability of most surface antigens to modulate 
however, often proves beneficial in the immunotargeting context since almost all 
immunotoxins and most chemotherapeutic drugs have to be internalized by the cell in 
order to destroy it. Where antigenic modulation is undesirable, the use of antibody Fab 
or F(ab')2 fragments (discussed in section 1.5.4.c) or bispecific antibodies have been 
found to diminish it. Bispecific antibodies are functionally univalent molecules each arm 
of which may recognize different antigens. Apart from their ability to avoid producing 
antigenic modulation these antibodies circumvent the complications introduced by trying 
to chemically link effector molecules onto the antibody. In the immunotargeting context 
bispecific antibodies have been produced, which, after localizing onto the particular 
tumour by virtue of the antigen they recognize, can recognize and "trap" a subsequently 
administered effector molecule with the other Fab arm. To date effector molecules 
recognized by bispecific Mabs include drugs (Corvalan et al., 1987; Reddy et al., 1993), 
toxins (Webb et al., 1985) as well as epitopes on T lymphocytes in order to directly 
mobilize the host's own immune system (Bernards, 1987; Ianzavecchia, 1986; Staerz et 
al., 1985; -Kranz et al., 1984; Barret al., 1987; Staerz et al., 1986b; Staerz et al., 
1986a). 
I. S.4.c Tumour accessing probably poses the most serious barrier to 
immunotargeting in the case of poorly vascularized tumours or large tumour masses with 
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extensive necrotic regions. Monoclonal antibodies are large molecules (150,000 Da) 
which tend to localize on tumour cells adjacent to blood capillaries. Tumour penetration 
of such large molecules is severely limited by poor vascularization and high interstitial 
pressure (Jain, 1990; Durrant et al., 1989). For example, biopsy studies from patients 
who have received labelled antibodies i.v., indicate that only about 0.005% of the 
injected dose of radioactivity is localized per gram of tumour (Zalutsky et al., 1989). 
Strategies devised in order to overcome this problem include the use of antibody 
fragments, external beam irradiation and hyperthermia, use of vasoactive substances and 
regional administration of immunoconjugates. 
Antibody fragments have been generated both by enzymatic and more recently 
by recombinant techniques (Colcher et al., 1990). In in vitro experimental systems 
employing multicellular spheroids F(ab')2 and Fab antibody fragments were found to be 
much more effective in penetrating and binding to CEA targets in human colon 
adenocarcinoma spheroids (Sutherland et al., 1987; Kwok et al., 1988). However more 
rapid penetration of antibody fragments into tumours is combined with more accelerated 
clearance of the fragments from the bloodstream as compared to intact antibodies, 
resulting in a smaller percentage of the injected dose reaching the tumour (Andrew et al., 
1986). This shortcoming combined with the fact that antibody fragments lose the ability 
to mobilize other effectors of the immune system due to the loss of their Fe portion, 
leaves open the question of whether antibody fragments are indeed the optimal carrier 
system for immunoconjugates. 
49 
The attempt to manipulate tumour haemodynamics using either external beam 
irradiation or local hyperthermia has led to controversial results. Although some results 
have suggested that pre-irradiation enhanced tumour uptake (Stickney et al., 1987), a 
more recent study has reported that there was no statistically significant increase in 
uptake of radiolabelled Mab by human colon carcinoma xenografts (Shrivastav et al., 
1989). Analyzing results from this approach is further complicated by the fact that 
external beam irradiation can decrease tumour mass, which can in itself increase antibody 
uptake. Local hyperthermia at 42°C was shown to increase the uptake of a radioiodinated 
F(ab')2 fragment by more than two-fold in a subcutaneous glioma xenograft. Another 
method used to increase penetration has been the administration of .8-adrenergic blocking 
agents in order to increase blood vessel permeability and consequently tumour perfusion 
(Smyth et al., 1987c). 
Localized administration of immunoconjugates has already been discussed briefly 
(section 1.5.4.a). Again, it was hoped that this approach might result in better tumour 
localization and therefore higher tumour uptake. lodine-1311abelled immunoconjugates 
administered i.p. increased uptake in peritoneal colorectallesions by 2 to 7-fold (Colcher 
et al. , 1987a) and 4 to 7-fold in patients with ovarian carcinoma (Ward et al., 1987b) 
relative to i. v. administration. Conversely, use of the intracarotid route in patients with 
malignant glioma did not result in increased intratumoral uptake (Zalutsky et al. , 1990). 
Although randomized therapeutic studies have not been performed to date, non-
randomized studies examining the therapeutic advantage of localized immunoconjugate 
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administration seem to indicate that local administration may be superior for the 
treatment of non-solid or low volume solid tumours. Intrapleural and intrapericardial 
administration of 1311-labelled antibodies to human milk fat globule (HMFG1, HMFG2 
and AUA1) to patients with malignant pleural and pericardial effusions resulted in a 
complete response for 10 out of 13 patients (Pectasides et al., 1986). In the treatment of 
epithelial ovarian carcinoma with 1311 labelled antibodies 8 patients with tumours greater 
than 2 em in diameter did not respond, whereas 9 out of 16 patients with smaller tumours 
had an objective response (Epenetos et al., 1987). Intrathecal administration of 1311-
labelled antibody to patients with leptomeningeal disease resulted in objective therapeutic 
responses in 4 out of 5 patients. 
Finally, advances in Mab labelling methodologies both in metal chelation and 
radiohalogenation, have resulted in more tumour uptake relative to non-specific 
accumulation in normal tissue (Bast et al., 1993). Use of an isothiocyanatobenzyl-
diethylenetriamene-pentaacetic acid (SCN-Bz-DTP A) chelate for labelling antibodies with 
88Y (Roselli et al., 1989), increased tumour uptake in an athymic mouse model more than 
4-fold and decreased bone uptake similarly. Also,the use of an N-succinimidyl-3-(tri-n-
butylstanyl)benzoate intermediate for radioiodination of antibodies increased the radiation 
dose to subcutaneous human glioma xenografts by more than a factor of three compared 
to conventional radioiodination of the same antibody (Zalutsky et al., 1989). 
A new approach to the analysis of tumour penetration is the "binding site barrier" 
notion (Weinstein et al., 1992a; Weinstein et al., 1992b). This theory suggests that 
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macromolecular ligands could be prevented from penetrating tumours by virtue of their 
successful binding to the receptor and their subsequent metabolism. According to this 
hypothesis, the higher the density of target molecules and the higher the antibody 
affmity, the greater the barrier. The binding site barrier theory is currently under 
investigation. 
I. 5.4.d Immunogenic responses of the patient to foreign epitopes on monoclonal 
antibodies produced from rodent (mostly mouse) B-lymphocytes limit the possibility of 
repeated dosing, because subsequent doses of the foreign antibody or immunoconjugate 
would be rapidly removed from the circulation by the neutralizing antibody (Dykes et al., 
1987; Meeker et al., 1985). Although some advantages are to be gained by the 
development of anti-idiotypic responses (Traub et al., 1988) and rapid clearance where 
non-specific irradiation is concerned, the human-anti-mouse response (HAMA) has been 
a major concern in immunotargeting. Efforts to eliminate this problem include attempts 
to produce human monoclonals and chimaeric or humanized mouse monoclonal 
antibodies. The production of human monoclonal antibodies has proven extremely 
difficult due to their instability, low titer, specificity, isotype and low affmity (James et 
al., 1987). Despite these problems such antibodies have been produced against breast 
cancer (Kjeldsen et al., 1988), lung cancer (Saito et al., 1988), lipid A (Ramachandra 
et al., 1988) and various T-cell dependent antigens (Borrebaeck et al., 1988). An 
alternative approach has involved molecular engineering of murine and human 
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immunoglobulin genes to produce chimaeric antibodies with human constant and mouse 
variable domains or human constant and framework regions with mouse hypervariable 
regions only (Boulianne et al., 1984; Morrison et al., 1984; Morrison, 1985a; Morrison 
et al., 1989; Morrison, 1985b; Verhoeyen et al., 1988; Jones et al., 1986; Riechmann 
et al., 1988). Such Mabs reduce the HAMA response while retaining the ability to result 
in anti-idiotypic responses. Furthermore, it is possible to construct such recombinant 
antibodies with constant regions derived from any immunoglobulin subclass to 
accommodate any desired effector function (Neuberger et al., 1984; Bruggemann et al., 
1987). A humanized version of the mouse Mab 17-lA, which reacts with colon 
carcinomas, did not evoke any HAMA response in 9 out of 10 patients even following 
multiple administrations (Stickney et al., 1987). 
The problem of immunogenicity is particularly serious in the use of immunotoxins 
since both the antibody and the toxin are immunogenic. In that case humanization of the 
antibody would not overcome the immunogenicity of the immunotoxin. Consequently, 
the only alternative to date in both animal and human studies has been the use of 
immunosuppressive agents (Spitler et al., 1989; Pai et al., 1990). 
I. S.4.e The question of immunoconjugate internalization is particularly relevant 
in the case of immunotoxins, where the cytotoxic moiety of the immunoconjugate has to 
enter the tumour cell in order to effectively destroy it. This is not the case for most 
radioimmunoconjugates and particularly the high energy ones, whose path length can 
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span many cell diameters, resulting in the destruction of both targeted cells and 
neighbouring ones. Since the chemotherapeutic drugs currently in clinical or experimental 
use have very diverse modes of action, internalization of chemoimmunoconjugates may 
or may not be a prerequisite for their effectiveness. It is therefore important that the 
internalization potential of each conjugate be determined before its therapeutic potential 
can be assessed. The topic of internalization will be discussed more analytically in the 
following section. 
I. 6. Internalization 
One of the most essential functions for the suiVival of living organisms is the 
transport of metabolically important substances into and out of the cell (Bilej et al., 
1989). Such substances must cross the dynamic barrier of the cell's semipermeable 
membrane which seiVes to separate the integral cellular compartment from the 
surrounding environment. The currently accepted model describing membrane structure 
is the "fluid mosaic model" (Singer et al., 1972), in which the cementing framework of 
the membrane is the lipid bilayer and in which attached or embedded proteins interact 
with each other and with the lipids, while retaining their capacity to move laterally in the 
fluid phase. According to this model the predominant types of interactions are 
hydrophilic and hydrophobic ones. 
Transmembrane transport occurs via four main routes, namely free diffusion, 
passive transport, active transport and endocytosis (reviewed in Bilej et al., 1989). 
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I. 6.1 Types of transport of materials into cells 
Free diffusion takes place along a concentration gradient, with a rate of substance 
flow directly proportional to their solubility in lipids and no requirement for energy or 
any particular translocation apparatus. More lipid-insoluble substances (often encountered 
in bacterial transport), may make use of carrier proteins such as periplasmic permeases, 
while ions such as Na+ and K+ are transported through specific membrane channels. 
Passive transport (or facilitated diffusion) is a process in which the substances 
move across the membrane in a reversible combination with "carrier" membrane 
proteins, which form an integral part of the membrane structure and are highly specific. 
This "one way" type of translocation is highly specific and is used by amino acids, mono 
and disaccharides and some ions which, after penetration, move along the concentration 
gradient. 
Active transport refers to the movement and accumulation of substances against 
a concentration gradient and consequently it is driven by metabolic energy. Examples of 
such a type of transport are the sodium pump, glucose transport coupled to Na + ions or 
purine and pyrimidine transport coupled to protons. 
Endocytosis is the means by which larger materials move into and out of the cell. 
Originally the endocytic process, (which is phylogenetically very ancient), served 
primarily nutritional needs of the cell. During Metazoan evolution however, endocytosis 
became highly specialized serving mostly as a mechanism for the elimination of 
undesirable exogenous or endogenous materials and as a defence against pathogenic 
ss 
microorganisms and viruses. For practically all eukaryotic cells endocytosis is one of the 
most important and efficient processes for the host's defence. 
During non-specific endocytosis, material binds to the cell membrane without the 
aid of specific receptors and, after crossing the membrane, is rapidly delivered to the 
lysosomes through fusion with the incoming endosomes. The entire plasma membrane 
will eventually participate in the process with a tum-over rate of 1-2 hours. 
Receptor-mediated endocytosis refers to internalization of materials following 
attachment to specific cell receptors mostly found on the cell surface. This most efficient 
mechanism for the uptake of macromolecules from the extracellular fluid, was rrrst 
demonstrated by the uptake of yolk proteins into mosquito oocytes via specialized regions 
of the membrane described by Roth and Porter as a "bristle coat" (Roth et al., 1964). 
This lattice-like coating exists on less than 2% of the cytoplasmic face of the membrane 
where there exist discontinuities in the micrortlament network closely associated with the 
membrane. This coating was later identified as composed of a single 180-kDa protein 
called clathrin (Pearse, 1975; Pearse et al., 1990) and associated adaptors (Pearse et al., 
1990). 
I. 6.2 
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Membrane components necessary for receptor-mediated 
endocytosis 
Clathrin makes up a "honeycomb" -like coat lattice while an inner shell of the coat 
is made up by adaptors which in tum interact with the cytoplasmic domain of cell surface 
receptors. Immunofluorescence studies show that clathrin and adaptors are co-localized 
both in the Golgi region and on the plasma membrane with a dotted distribution 
indicating thousands of coated pits and vesicles per cell (Robinson, 1987). The basic 
structural unit of clathrin is a complex of three molecules of clathrin heavy chain 
(180kDa) and three molecules of clathrin light chain (LC, 30-40 kDa) in a three legged 
structure termed triskelion (Kirchhausen et al., 1981). The clathrin heavy chain is highly 
conserved among different species, with 99% homology between human, rat and bovine 
brain clathrins (Lemmon et al., 1991; Keen, 1990). There are two structurally distinct 
types of clathrin light chains (Lc" and Lcp) which are encoded by different genes 
(Kirchhausen et al., 1987). Light chains are not required for in vitro assembly of the 
lattice structure (Winkler et al., 1983) and their absence does not seem to affect lattice 
stability (Schmid et al., 1984), but they have been found to bind calcium in a 1:1 molar 
ratio (Mooibroek et al., 1987) and to stimulate phosphorylation of the AP-2 adaptor 
polypeptide in coated vesicles. Although their functional significance has not yet been 
determined, their strong conservation among different species and numerous tissue-
specific differences in light chain messages (Kirchhausen et al., 1987; Jackson et al., 
1988) are strong indications that each light chain plays a critical and specialized role in 
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cellular coated membrane functions, which may be related to detennining the precise 
shape of individual triskelia. 
Triskelia are symmetric structures with three 45-50 run legs joined at a common 
hub, with each leg having a characteristic bend about 16-19 run from the central hub 
(Keen, 1990). Deep-etching electron microscopy of clathrin adsorbed to mica surfaces 
has shown that all the legs in a given triskelion display a uniform clockwise bend when 
viewed from the cytoplasmic perspective. The legs have a uniform thickness of 
approximately 2-4 run but a completely folded globular domain (terminal domain) 
approximately 5-8 run in diameter exists at the distal end of each leg. This domain 
contains about 25 % of the total mass of the heavy chain leg and is thought to be attached 
by a flexible linker to the triskelion leg since it can be readily released into solution by 
various proteases (Kirchhausen et al., 1984). The triskelion is thought to have a "resting" 
non-planar conformation with the legs hanging beneath a raised vertex. 
Clathrin triskelia are induced to assemble into complete lattices by interaction with 
another group of proteins, termed adaptors (Pearse et al., 1981) (the terms assembly 
proteins, associated proteins and the abbreviation AP have also been used (Keen, 1990)). 
Two distinct adaptors HA-l and HA-2 (or AP-1, AP-2) were identified and so named due 
to their ability to be separated from each other by hydroxyl-apatite chromatography 
(Pearse et al., 1984; Keen, 1987). A third protein AP180 is specific to the brain. HA-l 
adaptors are found in coated vesicles derived from the Golgi complex (Robinson, 1987), 
whereas HA-2 adaptors are associated with coated pits on the plasma membrane. Both 
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molecules are heterotetramers and appear by freeze-etch electron microscopy to consist 
of a central head flanked by two smaller appendages or ears (Heuser et al., 1988). The 
HA-l adaptor is composed of a "Y adaptin, a {:J' adaptin (subunits of 100-110 kDa), a 47 
kDa protein and a 20 kDa polypeptide. The HA-2 adaptor is a 270 kDa tetramer 
consisting of an a and {3 adaptin (subunits of 100-110 kDa) and two polypeptides of 50 
and 17 kDa. There is little homology between the a, {3 and "Y polypeptides of the two 
adaptors but the {3 and {:J' adaptin subunits are closely related. Limited sequence 
similarities exist between the a-adaptin of the HA-2 adaptor and the "Y adaptin of the HA-
l adaptor but only in the N-terminal region, which suggests that it is information within 
the C-terminal region that targets the a adaptin to coated pits and the 'Y adaptin to the 
Golgi apparatus. Adaptor molecules are only found associated with their specific target 
membranes but it is believed that a sequence binding to cytoplasmic tails of receptors 
may be present in the C-region of these molecules. The role of the adaptor molecules in 
linking clathrin to the membrane was demonstrated with elastase-treated isolated coated 
vesicles. When these vesicles were stripped of clathrin and subsequently treated with 
elastase, to which the 100-kDa proteins are very sensitive, clathrin would not rebind to 
the vesicles in contrast to non-elastase-treated vesicles (Unanue et al., 1981; Virshup et 
al., 1988). The suggested role of adaptors linking the cytoplasmic tail of receptors to 
clathrin was investigated by in vitro reconstitution studies with the mannose-6-phosphate 
receptor (Pearse, 1985) and purified clathrin, as well as the Low Density Lipoprotein 
(LDL) receptor that was shown to bind HA-2 adaptors in a competitive fashion (Pearse, 
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1988). Most adaptins have now been cloned and a transfection system for the expression 
of cloned adaptins in intact cells has been developed (Robinson, 1990), which is hoped 
will aid in the precise identification of adaptor targeting sequences. 
I. 6.3 Signals for ligand receptor recognition 
The order in which clathrin, adaptor molecules and ligand receptors combine prior 
to internalization has not yet been elucidated. A likely hypothesis is that receptor tails 
bind to adaptors, followed by attachment to the triskelion. The resulting coated pits have 
been shown to exclude resident membrane proteins such as Thy-1 (Bretscher et al., 
1980), which lacks a cytoplasmic tail, whereas receptors such as the ones transferring 
nutrients into the cell (eg. LDL and transferrin receptors) are found in plasma membrane 
coated pits in high concentrations (Pearse et al., 1990). Furthermore, deletion of the 
cytoplasmic tail of receptors reduced the efficiency with which these receptors internalize 
to about 10% or less of the wild-type receptor (Goldstein et al., 1985; Rothenberger et 
al., 1987; Mostov et al., 1986). Cell surface receptors which are constitutively recycling 
(such as the LDL, transferrin, asialoglycoprotein, polymeric Ig and mannose-6-phosphate 
receptors) and which typically have a large ligand binding extracellular domain, a single 
helix traversing the membrane and a small cytoplasmic portion, have been found to 
contain internalization signals in their cytoplasmic tails. 
Initial information on such internalization signals was obtained through the LDL 
receptor, when mutations resulting in truncations of its cytoplasmic tail inhibited 
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internalization (Lehrmann et al., 1985). Furthermore, genomic DNA analysis of the 
terminal exons of an LDL receptor derived from skin fibroblasts of a patient suffering 
from familial hypercholesterolemia, showed that it differed from its wild-type counterpart 
by a single base substitution at residue 807 (18 residues from the membrane), which 
converted a tyrosine codon to a cysteine codon. Although this mutant was identical to the 
wild-type receptor in both size and charge, introduction of the mutation into a eDNA 
clone of the wild-type receptor resulted in a reduction of internalization to 25 % of the 
normal receptor. Later studies indicated that the LDL internalization signal consists of 
a four amino acid motif which structurally forms a tight tum (Chen et al., 1990; Bansal 
et al. , 1991). This tight tum was also found to fit the secondary structure formed by the 
four codon internalization signal (YXRF) of the transferrin receptor (Collawn et al., 
1990), as well as the hexapeptide PGYRHV which promotes internalization of lysosomal 
acid phosphatase (LAP) (Lehmann et al., 1992). Again, the critical element of this 
receptor's signal seems to be the presence and position of the tyrosine residue (Eberle 
et al., 1991). 
The importance of the tyrosine residue for internalization was further 
demonstrated when the replacement by tyrosine of a specific cysteine at position 543 of 
the influenza virus haemagglutinin, which is not normally internalized, resulted in its 
efficient internalization (Lasarovits et al., 1988). Furthermore, these experiments clearly 
showed that it was not only the presence of tyrosine but also the context in which it was 
presented that promoted internalization. 
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A critical tyrosine residue also appears in the cytoplasmic portion of the poly Ig 
receptor (Breitfield et al., 1989). In this case a second tyrosine found 16 residues from 
the membrane spanning region in a position analogous to the crucial tyrosine of the LDL 
receptor, does not seem to be important for its internalization. This is not the case for 
the mannose-6-phosphate receptor which seems to contain two crucial tyrosines in its 163 
residue-long cytoplasmic tail. The two tyrosines in this receptor seem to be part of two 
distinct sorting signals, in agreement with the dual function of this receptor. One, 
contained in the region proximal to the membrane, is necessary and sufficient for 
efficient endocytosis of secreted lysosomal enzymes and insulin-like growth factor II 
(Kornfeld, 1987), while the other, found in the distal region of the tail, makes possible 
the sorting of lysosomal enzymes from the trans-Golgi network to a pre-lysosomal 
compartment (Oka et al., 1986). Furthermore, part of the hexapeptide YKYSKV in 
positions 24-29 required for rapid internalization, (specifically its most essential peptides 
YSKV), could be moved to a more proximal region of the cytoplasmic tail with only a 
modest loss of activity (Jadot et al., 1992). The same work also showed that the signal 
could be replaced by the four residue signals of seven other receptors and membrane 
proteins known to undergo rapid endocytosis, without serious compromise in 
internalization capacity. These results suggested that at least such 4-residue signals are 
interchangeable even among Type I and Type II membrane proteins. 
In agreement with information on commonalities of signals for such receptors, a 
generic tyrosine internalization signal of 8-10 aminoacids which is both necessary and 
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sufficient for internalization has been proposed (Ktistakis et al., 1990). This hypothesis 
proposes that a tyrosine residue should be located in the segment of the sequence furthest 
from the membrane. In addition, within the sequence, there exist a number of polar or 
positively charged residues at conserved positions. 
Recent studies on other plasma membrane receptors such as the group of G-
protein-coupled receptors (GPCRs), have provided less conclusive data in terms of 
consensus signals, although their internalization signals seem to also be located in their 
cytoplasmic tail (carboxyl terminus) (Bouvier et al., 1988; Strader et al., 1987; Hertel 
et al., 1990; Rodriguez et al., 1992). One GPCR, the /32-adrenergic receptor has been 
shown to be internalized and recycled via the same pathways used for the transferrin 
receptor (Von Zastrow et al., 1992) and interestingly, it was also shown that truncation 
of this receptor at position 365 caused the mutant to internalize to a greater extent than 
wild type. Similarly, truncation of 21 and 43 aminoacids from the cytoplasmic tail of the 
luteinizing hormone/ chorionic gonadotropin receptor resulted in increased internalization 
versus wild type, whereas deletion of 58 aminoacids from this region resulted in a 
receptor that was not expressed on the plasma membrane. Recently, using site-directed 
mutagenesis, the thyrotropin-releasing hormone receptor (TRHR) complex was found to 
contain two dissimilar domains in its cytoplasmic tail (between residues 335-368) which 
are necessary for efficient interna1ization (Nussenzveig et al., 1993). Furthermore the 
presence of a proximal cysteine residue was found to be critical. In the case of 
muscarinic cholinergic receptors an intracellular domain rich in serine and threonine 
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residues seems to regulate internalization (Moro et al., 1993). Such small domains, 
containing multiple SIT residues and necessary for receptor internalization, have also 
been found in several other GPCR receptors, such as catechol and peptide ones. 
Internalization in this group of receptors is believed to serve in down-regulating the 
relevant hormones. 
Internalization seems to serve a similar function in the case of growth factor 
regulation, the most well-studied of which is the epidermal growth factor (EGF). 
Internalization of the EGF receptor complex is preceded by a complex array of events 
leading to signal transduction. Despite detailed know ledge of these events however, the 
requirements for the onset of internalization are not well understood. Interestingly, a 
region of this receptor's complex cytoplasmic tail, containing a negatively charged 18 
aminoacid helical segment (Chen et al., 1989), shows about 30% identity to the region 
containing the tyrosines in the mannose-6-phosphate receptor. 
Most endocytosed receptors exhibit protein kinase activity and contain potential 
phosphorylation sites, which led many investigators to believe that this may be the trigger 
to initiate the process of internalization. However, this hypothesis has created a lot of 
controversy. Mutation of phosphorylation sites in the LDL (Davis et al., 1987) and 
transferrin receptor (Rothenberger et al., 1987) did not seem to impair their 
internalization or recycling properties. In the insulin receptor model there are studies that 
both support (Graco et al., 1992), and dispute (Margolis et al., 1989), the requirement 
for an active tyrosine kinase for internalization. In the case of the asialoglycoprotein 
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receptor which contains the Y5-~-N7-F8 internalin~tion signal in its cytoplasmic tail 
(Ozaki et al., 1993), a protein kinase inhibitor abrogated its endocytosis (Fallon et al., 
1992). 
Interestingly, a reverse type of internalization signal seems to operate in the case 
of the CD4 glycoprotein. This glycoprotein is constitutively internalized and recycled in 
nonlymphoid cells, but is excluded from the endocytic pathway in lymphocytes. 
Inhibition of CD4 endocytosis is dependent on CD4 expressing an intact cytoplasmic 
chain and is only observed in cells where CD4 can interact with the protein tyrosine 
kinase p561c\ a member of the src gene family (Pelchen-Matthews et al., 1992; Sleckman 
et al., 1992). 
Internalization signals for lymphocytes and antigen-presenting cells (APCs) still 
remain elusive. It was recently shown that endocytosis of the antigen receptor surface Ig 
(slg) on B lymphocytes is a process independent of B lymphocyte activation, since 
calcium (Ca2+) and protein kinase C (PKC) were found not to be involved in the 
endocytic process of cross-linked slg (Shuler et al., 1993). Internalization by APCs is an 
extremely active process mostly undertaken by macrophages, B lymphocytes and, as 
shown recently, by dendritic cells to an equal degree (Levine et al., 1992). A recent 
study on internalization and antigen presentation via type m receptors for IgG (Fe-y RII) 
demonstrated that a tyrosine-containing motif that transduces cell activation signals also 
induces internalization. Macrophage Fc-yRll receptors consist of a (ligand binding) and 
'Y (signal-transducing) subunits. When murine Fc-yRlll was transfected into Fc-yR-
.. 
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negative antigen-presenting B-lymphoma cells it mediated rapid ligand internalization and 
strongly increased the efficiency of antigen presentation when antigen was complexed to 
Ig. This process furthermore, was dependent on a structural motif containing two tyrosine 
residues present in the cytoplasmic domain of associated -y chains (Amigorena et al., 
1992). The hypothesis proposed by these researchers is that, since high affmity IgE 
receptors (FceRI), as well as T- and B-cell antigen receptors contain subunits structurally 
related to those on Fc-yRIII, there may be a general role for these associated chains in 
the internalization of multimeric receptors. The relation, if any, between initiation of 
internalization and signal transduction in this system however remains to be found. 
Recognition of receptor signals is the first stage in the endocytic process, which 
begins with transmembrane transport and is followed by intracellular transport and 
possible recycling of components of the receptor-ligand complex. Both endocytic steps 
in eukaryotic cells also require the cooperation of the cytoskeletal network, which is 
interconnected with the plasma membrane. 
I. 6.4 Association of the cytoskeleton with the endocytic process 
The cytoskeletal network, which consists of microtubules, microfilaments, 
intermediate ttlaments and associated proteins, forms a three-dimensional array in the 
cytoplasm of all eukaryotic cells. The membrane-bound cytoskeleton is believed to be 
involved in the undertaking of processes such as cellular contact, endocytosis and the 
organization of the membrane structure (reviewed in Bilej et al., 1989). Some 
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cytoskeletal components are integral membrane proteins and may affect the functional 
properties of the plasma membrane such as motional freedom of membrane domains, 
electrical properties, activity of ion channels and membrane permeability. Furthermore, 
cytoskeletal structures have also been found associated with various intracellular 
organelles such as endosomes, lysosomes, Golgi elements and elements of the 
endoplasmic reticulum (ER). 
Microtubules are hollow cylinders 18 to 30 nm in diameter, usually consisting 
of 13 protortlaments running parallel to the tubule axis, and consist of protein subunits, 
named a- and {3- tubulin, which polymerize into microtubules. Tubulin is believed to be 
an integral part of certain kinds of membranes and as such it is distinct from soluble 
tubulin (2). Although the function of membrane tubulin is not yet well understood, it has 
been found that the microtubule system can directly influence membrane microvicosity 
and fluidity (Berlin et al., 1977). Furthermore, microtubule depolymerization results in 
increased motional freedom of membrane proteins and alters the membrane potential 
(Aszalos et al., 1986). Intracellularly, microtubule depolymerization has induced the 
fragmentation of the Golgi apparatus and the dispersion of its elements throughout the 
cell, which has led to the conclusion that microtubules may serve as tracks directing the 
vectorial transport of Golgi elements and secretory vesicles to the plasma membrane. 
Saltatory lysosome movement is also associated with the integrity of microtubules. 
Microf"Ilaments are composed of actin subunits (a 42 kDa globular protein), 
helically arranged in a double-stranded tilament with a diameter of 4 to 7 nm. These are 
67 
the major structures responsible for cellular mobility. Membrane-microfilament 
interactions have also been reported in a wide variety of cells ( (Bilej et al., 1989) and 
references within). 
Intermediate riiaments (IF)' include five classes of proteins which share a 
common ultrastructure. They are insoluble cytoplasmic fibers of about 10 nm in diameter 
and they exist in all differentiated cells. Their function is still unclear, since there is no 
known specific inhibitor of their polymerization. However, this system is believed to be 
involved in a tissue- and cell-cycle specific interaction between the genetic apparatus and 
the outer environment of the cell. Since the IF network breaks down during mitosis, the 
expression of IF proteins is tissue-specific and IF-membrane associations have been 
found. 
The role of the cytoskeletal network in the intramembrane and intracellular stages 
of endocytosis will be discussed in the following section (1.6.5). 
I. 6.5 The endocytic process 
The mechanism of endocytosis may be divided into four interrelated stages. 
Cross-Jinking of cell surface receptors via attachment of ligand (for non-constitutively 
endocytosed receptors), results in the fonnation of clathrin lattices on the plasma 
membrane. Growth of such lattices in tum results in the invagination of the "pit". 
Secondly, deeply invaginated coated pits are released into the cytoplasm following 
membrane scission. Thirdly, the coated vesicle is rapidly uncoated and is believed in 
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most cases to fuse with endosomes for initial sorting of receptors and ligands. Finally, 
released ligands may be delivered to lysosomes for degradation, other endocytic 
compartments for processing and presentation at the cell surface (antigen presenting 
cells), or they may be transported to storage granules for cell consumption. Similarly, 
released receptors may be targeted to lysosomes for degradation or may be re-routed to 
the cell surface to repeat the process. 
I. 6.S.a Coated-pit formation and invagination 
Following binding of the adaptor molecules to the receptor tails and clathrin 
triskelia (in an order that is as yet undetermined), the resulting complex diffuses in the 
membrane until it encounters other such complexes in a nucleation site for the formation 
of a new pit. Such assembly sites have already been found in sonicated fibroblasts 
(Moore et al., 1987). Triskelia then polymerize to form a planar array of hexagons. Pits 
are thought to invaginate by the conversion of hexagons to pentagons, with a possible 
heptagon intermediate (Heuser et al., 1980). The appearance of new coated pits and their 
scission to form coated vesicles (but not invagination), were shown to be dependent on 
ATP and cytosol addition using perforated A431 cells (Smythe et al., 1989). The use of 
stage-specific assays in the same system, tracing the fate of transferrin ligands, also 
showed that a combination of purified adaptors, cytosolic clathrin and unidentified 
cytosolic factors stimulate coated pit assembly and ligand sequestration into deeply 
invaginated coated pits, whereas their addition does not affect later endocytic events. In 
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a different system using isolated human fibroblast membranes attached to a solid 
substratum by their extracellular surface, addition of coat proteins extracted from purified 
bovine-coated vesicles resulted in the formation of new coated pits which were identical 
to the native ones (Mahaffey et al., 1989). This system also required the presence of 
cytoplasm as a source of clathrin (and possibly other cytoplasmic components), but in 
contrast to the previously described experiment, the addition of A TP was not required. 
Formation of coated pits in this system was also inhibited by low pH conditions. 
Recently, the requirement for GTP-binding proteins for the processes of coated pit 
assembly, invagination and coat vesicle budding was studied using stage-specific assays. 
In this study, which used perforated A431 cells, coated pit invagination and coated 
vesicle budding were both stimulated by the addition of GTP and inhibited by GDP{jS 
(Carter et al., 1993). Furthermore, antagonists of G protein function such as GTP-yS, 
A1F 4- and mastoparan inhibited late events involved in coated vesicle budding. 
Involvement of GTP-binding proteins has also been addressed in a second class 
of transport vesicles, referred to as "nonclathrin-coated vesicles" or "COP-coated 
vesicles" (COP-CV) (Carteret al., 1993), which have been shown to mediate vesicular 
traffic along the exocytic pathway (Orci et al., 1986). The coat constituents of COP-CV 
include polypeptides of 160 (a-cop), 110 {{j-cop), 98 (-y-cop) and 68 (o-cop) kDa 
subunits, smaller subunits of 36 and 35 kDa (Maholtra et al., 1989) as well as ADP-
ribosylation factor (ARF), a 20 kDa GTP-binding protein (Serafini et al., 1991). Both 
classes of coated pits assemble from a cytosolic pool of coat proteins. In contrast 
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however to clathrin and adaptors which exist as distinct soluble pools that appear to 
assemble _sequentially to form clathrin-coated pits (Mahaffey et al., 1990; Smythe et al., 
1992), COPs are present in the cytosol as a large multimeric precursor, termed a 
"coatomer" which presumably self-assembles onto membranes to form COP-coated pits. 
These COP-coated pits appear to be nonselective, mediating bulk-flow transport events, 
and although they were identified very recently, their mechanism of transport is probably 
better understood than the clathrin-mediated one (Schmid, 1992). 
The process of invagination has proven more difficult to study due to the lack of 
specific inhibitors and the constitutive nature of endocytosis. However, it has been shown 
that invagination does not require ATP or cytosolic factors. Recently, the observation 
that endocytosis in mammalian cells is inhibited during mitosis (Fawcett, 1965), was used 
to demonstrate that coated pits are arrested during mitosis at all stages of invagination, 
suggesting the iterative action of one enzyme or a set of enzymes (Pypaert et al., 1987). 
Researchers now hope to identify these enzymes via a reconstruction of this inhibition 
on perforated cells using either mitotic cytosol or cyclin B-p34 cdc2 kinase complex ( cdc2 
kinase)(Pypaert et al., 1991). 
The release of a coated vesicle is mediated by an energy-dependent membrane 
scission event. The 100 kDa protein dynamin (van der Bliek et al., 1991), with GTPase 
activity and an in vitro microtubule sliding action, has been implicated in this event, 
using the temperature-sensitive shibire mutant of Drosophila melanogaster (Kosaka et al., 
1983). After the pulling effect imposed by dynamin, it is possible that other cytosolic 
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factors may act as a 'collar' bringing the membrane bilayers together so that they can 
internet and pinch off (Smythe et al., 1991). 
I. 6.S.b Intracellular endocytic events 
Following membrane scission, the resulting coated vesicle is rnpidly uncoated due 
to the action of an "uncoating ATPase", an enzyme which has the ability to release 
clathrin from isolated vesicles in an ATP-dependent manner (Schlossman et al., 1984), 
although it is not yet clear how it differentiates between coated vesicles and coated pits 
that are still membrane bound. Uncoating occurs in less than one minute after vesicle 
formation and requires the presence of clathrin light chains for the initial attachment of 
the enzyme. Uncoating ATPase exists in a 3:1 excess over cytosolic clathrin and has a 
higher affinity for lattice-bound clathrin, so that the enzyme rnpidly dissociates from 
clathrin once the latter is released from the lattice (Schmid et al., 1985). Adaptor 
molecules are not removed during this initial phase of uncoating, but since they are 
known to recycle back to the plasma membrane, they are thought to become uncoated 
in a later, as yet unidentified stage. 
Only a decade ago, vesicle fomation and the inttacellular transport of enttapped 
materials were the focus of much speculation. The lack of markers to identify 
inttacytoplasmic vesicles and their composition led to speculation on both the fate of 
clathrin after invagination of the coated pit and the formation of further vesicles. 
Contrnry to popular scientific belief at the time, favouring the pinching off of coated pits 
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to fonn coated vesicles, Pastan and Willingham (Pastan et al., 1983) raised doubts as to 
the recycling of clathrin based on the inability of current work to show any appreciable 
amounts of soluble clathrin and the inability of anti-clathrin antibodies to trap and 
precipitate clathrin in the cytosol. Furthermore they suggested that coated pits are stable 
structures always associated with the cell surface and that "receptosomes" (a tenn which 
has been used alternatively to early endosomes), fonn directly from coated pits by 
pinching off from the region adjacent to coated pits, into which the receptor ligand 
complexes somehow slide. However, the almost parallel demonstration of the existence 
of endocytic coated vesicles as independent organelles (Petersen et al., 1983), defied this 
hypothesis. 
During the same year Helenius et al. (Helenius et al., 1983) put forth two 
alternative possibilities for the transport of endocytosed material through different 
endosomal and lysosomal compartments. The maturation model, suggested that the 
endosomes are transient structures which undergo maturation as they continually carry 
the dissociated ligand, until they deliver it by fusion with a lysosome. Conversely, the 
vesicle shuttle model, suggested that endosomes are stable structures through which the 
internalized material passes by fusion of incoming vesicle and budding of leaving 
vesicles. Evidence favouring the vesicle shuttle model was produced by labelling 
endosomal proteins of highly purified early and late endosomes and showing that there 
were no significant levels of proteins common to both plasma membrane and late 
endosomes (Schmid et al., 1988), which should have been the case if endosomes were 
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derived from the plasma membrane. Conversely, there was a subset of proteins common 
to both early and late endosomes, which suggests that late endosomes may arise from 
early ones (Gruenberg et al., 1989). Presently, the endocytic network for the transport 
of material internalized through RME has been shown to consist of the following set of 
vesicles. 
Early endosomes are tubulo-vesicular structures with vesicular structures of 0.4 -
1 /Lm and tubular projections of several micrometres. Kinetically they are detmed as the 
trrst compartment to be reached by endocytic tracers. Similar to all other endosomal-
lysosomal compartments, they retain an acidic environment generated by means of an 
ATP-driven proton pump (Galloway et al., 1983). In the case of early endosomes this 
acidification is modulated by a Na +, K+ -ATPase which reduces the degree of 
acidification relative to late endosomes and lysosomes. This early endosomal pH between 
5-6, seems to be optimal in promoting dissociation of a large number of ligand/receptor 
complexes, following which receptors are recycled back to the cell surface. 
The process by which segregation of receptors from ligands is accomplished is 
not clear. Earlier immunolocalization studies on the separation of asialoglycoprotein 
from its receptor, demonstrated that receptors were clustered into tubular elements away 
from the vacuolar portions where the ligand remains (Geuze et al., 1983). This gave rise 
to the speculation that segregation may involve either interaction of receptor tails with 
cytoskeletal elements or aggregation of receptors. 
Fusion between endosomal compartments has been monitored by measuring the 
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ability of ligands to fuse with another population of vesicles after being internalized for 
various intervals. It was found that only those populations internalized for short time 
periods retained the ability to fuse (Diaz et al., 1989). It was not clear however, whether 
the loss of fusogenic ability was due to maturation of an early endosomal compartment 
or to transport to later endosomal vesicles which don't have this ability. Although some 
evidence to support the second possibility was produced (Gruenberg et al., 1989), it was 
recently shown that delivery of ligands from early (sorting) to late endosomes occurs by 
maturation of sorting endosomes (Dunn et al., 1992). In this study, the properties of 
individual endosomes were examined by digital image analysis, to distinguish between 
the two mechanisms for entry of ligands into late endosomes. Using LDL as a marker 
it was shown that a pulse of fluorescent LDL is retained by individual sorting endosomes 
and that, with time, sorting endosomes lose their ability to fuse with primary endocytic 
vesicles. These data were consistent with a maturation mechanism where the sorting 
endosome retains and accumulates lysosomally directed ligands until it loses its ability 
to fuse with newly formed endocytic vesicles and matures into a late endosome. A 
specific early endosomal marker, the rab5 protein which is a member of the rab family 
of GTP binding proteins, has recently been identified (Chavrier et al., 1990). Another 
member of this family, the rab7 protein, has also been identified as a marker for late 
endosomes. 
Late endosomes are mostly located in the perinuclear region of the cell. They are 
large spherical structures that are frequently found to have deep membrane invaginations 
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giving rise to multivesicular bodies. As with early endosomes, late endosome-lysosome 
interactions have been reconstituted in cell-free systems, such as the one using rat liver 
late endosomes interacting with lysosomes when incubated at 37°C in the presence of 
cytosol and an ATP generating system (Mullock et al., 1989). Their major function 
seems to involve the transport of ligand to the lysosomal compartment (Schmid et al., 
1988), presumably using the microtubular network, since nocodazole, a microtubule-
disrupting agent, inhibited the transport of a marker molecule from an endosomal 
compartment to pre-lysosomes (Gruenberg et al., 1989). 
Pre-lysosomes differ from late endosomes in that they are rich in acid hydrolases. 
This compartment was distinguished from the endosomal compartment by virtue of the 
fact that it was not labelled by endocytic tracers in cells held below 200C, a temperature 
at which the transfer of materials from endosomes to lysosomes is inhibited (Helenius et 
al., 1983). Mmphologically, pre-lysosomes have been shown to have deep membrane 
invaginations in normal rat kidney (NRK) cells (Griffiths et al., 1988) and it was 
postulated that this structure may represent the site of overlap of the endocytic and 
biosynthetic pathways where newly synthesized lysosomal enzymes are delivered. The 
receptor for mannose-6-phosphate (which is involved in the transport of newly 
synthesized lysosomal enzymes) is present in pre-lysosomes and it provides a way of 
distinguishing this compartment from lysosomes which do not carry this receptor 
(Kornfeld et al., 1989). 
Lysosomes are dense organelles found in the perinuclear area. They have a pH 
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of about 4.5 and are rich in acid hydrolases. They are the last compartment reached by 
internalized material in the endocytic pathway and play a digestive role. Endosomes are 
known to move along microtubular "tracks", and lysosomal saltatory movements are 
similarly correlated with the integrity of the microtubular system, as shown in indirect 
immunofluorescence experiments with cultured fibroblasts (Collot et al., 1984). 
I. 6.S.c Inhibitors of endocytosis 
In view of the extensive and varied network involved in the endocytic process, 
it is not sutprising that inhibitory agents can block this process at practically every stage. 
Inhibitory agents can act in a specific way to block transport through particular 
compartments, or they can act in a general fashion, for example by abolishing energy 
requirements, necessary at most internalization stages. Indeed, endocytic inhibition has 
been shown to occur at the level of the membrane, elements of the cytoskeletal network, 
endosomal and lysosomal compartments, as well as the Golgi network. Although the 
particulars on the different types of inhibition are beyond the scope of this thesis, a brief 
account will be given on the most important types of inhibitors and their level of action. 
Several processes can be specifically inhibited at the membrane level. Primary 
amines and transglutaminases have been shown to block clustering of ligands (Pastan et 
al., 1981; Davies et al. , 1980). Inhibition of clathrin-lattice formation or budding of 
clathrin-coated vesicles has been achieved through a variety of methods affecting cellular 
potassium levels and intracellular pH. Hypotonic shock and potassium depletion were 
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shown to reduce viral endocytosis in Hep2 cells (Madshus et al., 1987), whereas cytosol 
acidification by several methods, such as pre-pulsing with ammonium chloride, addition 
of small amounts of acetic acid and addition of ionophores such as nigericin and 
valinomycin, was shown to inhibit endocytosis via coated pits (Sandvig et al., 1988), as 
well as transport from the trans-Golgi network to the cell surface (Cosson et al., 1989). 
Cytoplasmic acidification affects clathrin lattice morphology by promoting the formation 
of unusually spherical lattices with empty microcages around their edges. Hypotonic 
media and retention of a neutral pH with nigericin or cell sticking on culture dish 
surfaces with polylysine produces a preponderance of unusually flat lattices, whereas 
potassium depletion and hypertonicity seem to cause surface pits to disappear with 
cytoplasmic clathrin precipitates into unusually small microcages (Heuser, 1989; Heuser 
et al., 1989). Using immunofluorescence microscopy it was recently demonstrated that 
cytosol acidification does not affect clathrin or adaptor molecules but interferes with 
budding of clathrin-coated vesicles from the plasma membrane as well as from the trans-
Golgi network. Conversely, potassium depletion and exposure to hypertonic media 
remove membrane-associated clathrin lattices by preventing clathrin-adaptor interactions 
(Hansen et al., 1993). 
As previously mentioned, the cytoskeletal network affects various components of 
the endocytic mechanism, and several agents which disrupt cytoskeletal functions have 
an inhibitory effect on endocytosis, mostly by disrupting intracellular trafficking. 
Colchicine, a drug isolated from Colchicum autumnale, inhibits endocytosis by binding 
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to the a-tubulin subunit thus inhibiting microtubule polymerization. Other drugs with 
similar antimicrotubule properties include nocodazole, podophyllotoxin, rotenon, 
steganacin and the vinca alkaloids vincristine, vinblastine and vindesine (strangely, 
another alkaloid, taxol has a microtubule stabilizing effect) (Bilej et al., 1989). In 
contrast to the variety of antimicrotubule agents, the only agents known to disrupt 
micrortlaments belong to a class of fungal metabolites, the cytochalasins. Cytochalasin 
B reduces the rate of actin polymerization by inhibiting monomer addition to the barbed 
end of actin itlaments (Bilej et al., 1989). 
On the intracellular level, transfer of internalized ligands from endosomes to 
lysosomes is reportedly delayed by carboxylic ionophores such as monensin and nigericin 
(Manske et al., 1989; Tartakoff, 1983). Ligand degradation can be inhibited by 
neutralizing intralysosomal pH using both carboxylic ionophores (Carriere et al., 1985) 
and lysosomotropic amines such as chloroquine, ammonium chloride and amantadine 
(Ziegler et al., 1982; Krogstad et al., 1987), or by inhibiting lysosomal enzymes such 
as leupeptin (Chang et al., 1984; Press et al., 1990). 
In systems such as the asialoglycoprotein receptor one, where coated pit receptor-
mediated endocytosis is believed to be modulated by the activity of protein kinases and 
protein phosphorylation, protein kinase inhibitors such as staurosporine were found to be 
potent and rapid inhibitors of receptor trafficking by a yet unknown mechanism, which 
was found to be independent of the inhibition of protein kinase C (Fallon et al., 1992). 
Inhibitors of endocytosis have recently been used to dissect the endocytic process on the 
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cell surface of polarized epithelial cells (Gottlieb et al., 1993). Using cytochalasin D the 
specific inhibitor of actin micrortlaments, it was possible to show that these 
microfilaments play a critical endocytic role in the apical but not the basolateral surface 
of these cells. Similarly, receptor-mediated phospholipase C activation in cultured rat 
proximal tubule cells, was shown to require cytoskeleton-dependent endocytosis for apical 
but not basolateral surfaces. 
Finally, some evidence pointing to possible similarities between the endocytic and 
biosynthetic pathways, was produced by a comparison of the action of the fungal 
antibiotic brefeldin A (BFA) on the Golgi network and on endosomes (Hunziker et al. , 
1992; Low et al., 1992). BFA inhibits protein secretion and causes the breakdown of the 
Golgi network presumably by dissociating a non-clathrin cytoplasmic coat from Golgi 
membranes through the redistribution of at least three components of the coat material, 
namely {j-COP, ADP ribosylation factor and "Y-adaptin from the Golgi membrane to the 
cytosol. Both {j-COP and "Y-adaptin share significant homology with the {j-subunit of the 
clathrin adaptor complex of endocytic coated vesicles and BFA has been found to 
significantly increase the tubular appearance of the early endosomal compartment 
involved in the recycling of internalized transferrin receptors. However BFA does not 
markedly affect internalization, recycling or delivery of internalized ligands from early 
endosomes to degradative endocytic compartments. Currently the role of BFA in the 
exocytic and endocytic pathway is an area of intense interest. 
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I. 7 Antibody Internalization 
Initial interest in the ability of antibodies to be internalized was generated 
following the observation that antibodies can induce the disappearance of membrane 
antigens from the cell surface using immunofluorescence techniques (Chatenoud et al., 
1984). This phenomenon of antigenic modulation was trrst described in 1963 (Boyse et 
al., 1963), when it was found that thymic leukaemia cells expressing the TL antigen lost 
their sensitivity to the complement-mediated cytotoxic action of anti-TL antibodies when 
they had been previously exposed to this antibody. 
A decade ago the study of antibody-induced antigenic modulation had progressed 
to the point of awareness of processes taking place on the cell membrane following 
exposure to antibodies against surface immunoglobulins and a limited number of other 
surface antigens such as T-cell differentiation antigens (mostly those already identified 
as leukaemic markers) (Chatenoud et al., 1984 and references within). The stages 
identified following exposure to anti-Ig antibodies included: 
a) patching, or the clustering of surface Ig into "patches" on the membrane within 1-2 
minutes after exposure, a process which was energy independent, inhibited by low 
temperatures and influenced by valency of the ligand; 
b) capping, or the concentration of patches at a cell pole (the uropod) over the Golgi 
region within 3-4 minutes, a process which is energy dependent and thus inhibited by 
inhibitors of the respiratory chain (eg. sodium azide and dinitrophenol) or of glycolysis 
(eg. fluoride, iodoacetamide) and, 
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c) endocytosis (and subsequent degradation) of surface lg which is again energy 
dependent. Cytoskeletal elements were found to be involved in the lateral mobility of 
cellular determinants as well as capping although there have been contradictory results 
with inhibitors of both microtubules and micrortlaments, some of which seem to inhibit 
while others seem to promote capping. 
The two rrrst stages (patching and capping), were identified by 
immunofluorescence, whereas endocytosis was identified by loss of anti-Ig induced 
cytotoxicity and could not be effectively differentiated from loss of surface markers by 
shedding. Furthermore, the same process applied to the modulation of the other surface 
antigens studied, except for the stage of polarized capping, since other surface antigens 
did not exhibit a preferential membrane capping region. Also, other antigens exhibited 
variable degrees of endocytosis. It was also observed that antibody fragments do not 
generally induce antigenic modulation whereas antibody crosslinking (eg via the use of 
a second antibody), enhances the process. The type of cell and antigen involved in this 
type of endocytosis was found to have a profound effect on the process, since it was 
noted that histocompatibility antigens internalize following this mechanism only in non-
lymphoid cells (eg fibroblasts), and then only after extensive cross-linking (Pernis, 1985). 
During the same period the effects of antigenic modulation were conimned in the 
therapeutic setting, when antigenic modulation observed with indirect 
immunofluorescence, was induced by the murine TlOl antibody (recognizing the T65 
antigen on normal and neoplastic human T cells), on cells of patients with chronic 
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lymphocytic leukemia and T cell lymphoma (Shawler et al., 1984). 
With more extensive studies on the use of monoclonal antibodies as mediators of 
more specific anti-cancer action (either as carriers of cytotoxic agents or as mobilizers 
of components of the host's immune system), it became increasingly apparent that both 
their ability to induce antigenic modulation and to internalize had profound effects on 
their use in targeting (see discussion). Aspects of antigenic modulation have been widely 
studied (as discussed in the context of immunotargeting, section 1.5.4.b), however 
intense interest in the internalizing ability of the antibody, irrespective of the induction 
of antigenic modulation has only developed since the mid 1980's. Presently, the 
internalizing potential of the antibody(ies) used in various immunotargeting models is 
an area of increasing interest. The potential for, and characteristics of, antibody 
internalization, is of particular importance in cases where the antigen being targeted is 
not well characterized in terms of endocytic potential, as is the case with CEA, which 
serves as the target antigen throughout this project. 
I. 8 · CEA structure and anticipated function 
An extensive amount of literature is devoted to CEA, but despite the fact that this 
antigen has been well characterized, there has been no evidence for the triggering of a 
ligand-induced internalization mechanism as is the case with a number of other receptors 
discussed previously. 
As previously mentioned (section 1.4.2), CEA is the primary tumour marker 
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associated with colorectal cancer, the second most lethal neoplastic disease in North 
America. Its primary clinical use is in monitoring response to therapy and tumour 
reccurence, and CEA serum levels are followed by most surgeons prospectively after a 
potentially curative resection (W oolfson, 1991; La Rocca et al., 1992; Tabuchi et al. , 
1992). This tumour marker is also extensively used for early detection of other tumours 
of epithelial origin including lung, breast and ovarian carcinoma (Kim et al., 1992), and 
more recently as a prognostic marker in mY-related pneumonias (Bedos et al., 1992), 
in addition to its role as a target antigen for immunotargeting. 
The CEA gene family belongs to the immunoglobulin supergene family due to the 
fact that the main backbone of all CEA-related molecules is made up of a variable 
number of immunoglobulin-like domains. This gene family can be divided into two main 
subgroups based on sequence comparisons, namely the CEA subgroup, containing the 
genes encoding the membrane-anchored molecules CEA, the CEA cross-reacting antigens 
(such as NCA) and the biliary glycoprotein 1 (BGP1), and the PSG subgroup containing 
the genes encoding the pregnancy specific glycoproteins which are secreted (Thompson 
et al., 1991 and references within). 
In humans the CEA gene family is clustered on the long arm of chromosome 19 
and consists of approximately 20 genes. The general structure of the human CEA 
subgroup (Thompson et al., 1991; Hefta et al., 1992), consists of a 34 aminoacid signal 
peptide (leader), which is used to direct nascent proteins to the plasma membrane and 
is cleaved in the mature protein. The leader peptide is followed by one N-terminal 
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domain (108-110 aminoacids long) whose secondary structure reveals homology to 
immunoglobulin-like variable domains. This domain is followed by immunoglobulin-like 
constant domains of 92-96 amino acids (A domains) or 86 amino acids (B domains), the 
number of which is highly variable among CEA-like molecules. Finally, nascent CEA-
like peptides contain a hydrophobic membrane domain which is replaced by a glycosyl 
phosphatidylinositol moiety post-translationally, seiVing as a membrane anchor. 
Although the relevance of GPI anchorage (Cross, 1990) is still unknown, GPI-
anchored proteins reveal a more rapid lateral mobility on membranes than integral 
membrane proteins (Cross, 1990), with probable functional consequences, and they also 
seem to mediate a selective sorting mechanism, since they are more often found to be 
located toward the apical than the basal region in polarized cells (Lisanti et al., 1990). 
Conversely BGP-like peptides contain a hydrophobic transmembrane domain which is 
followed in most cases by a cytoplasmic domain. 
CEA family members are heavily glycosylated (60% glycosylation in mature 
CEA). All of the 28 potential glycosylation sites in CEA are thought to be glycosylated 
with average carbohydrate chains of about 20 monosaccharide residues, considering the 
molecular weight of CEA (180 kDa). However, there is a large degree of variability in 
oligosaccharide structures of CEA molecules depending on their source, resulting from 
post-translational modifications. Through sequence comparisons to the immunoglobulin 
superfamily it was anticipated that CEA-like molecules would seiVe as cell adhesion 
molecules (Thompson et al., 1991). Indeed, it has been extensively demonstrated that 
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CEA mediates homotypic Ca2+ -independent cell aggregation (Benchimol et al., 1989). 
This function of CEA as an intercellular adhesion molecule, is dependent on its N-
domain since N-domain deletion mutants lose their adhesion properties (Eidelman et al., 
1993). Recently the third internal repeat domain of CEA was shown to be essential for 
CEA mediated cell adhesion (Zhou et al., 1993). The model derived from this study 
proposed interactions between immunoglobulin supergene family members in which 
especially strong binding seems to be effected by double reciprocal interactions between 
the V-like domains and C-like domains of antiparallel CEA molecules on apposing cell 
surfaces. Furthermore, expression of functional CEA on the cell surface blocks terminal 
differentiation and maintains cell proliferative potential (Eidelman et al., 1993). 
Generally the high expression of this cell adhesion molecule in embryonic tissue is 
essential for intercellular interactions involved in organogenesis (Thompson et al., 1991), 
whereas its elevated expression in malignancy is believed to play an important role in the 
creation of metastases, especially to the liver, by increasing hepatic retention of tumour 
cells via binding onto specific Kuppfer cell receptors (Thomas et al., 1990; Jessup et al., 
1993). The role of CEA in the maintainance of proliferative potential of malignant cells, 
as well as its relation to the reversion of adult epithelial architecture to an embryonic 
(multilayered) one, is currently being investigated (Eidelman et al., 1993). 
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I. 9 Aims of this project 
A number of studies clearly showed that different antigen-antibody systems exhibit 
considerable quantitative and qualitative differences in internalization processes. 
Studies examining unconjugated antibodies targeting different antigens expressed on 
malignant cells, revealed that those antibodies which internalize, do so at considerably 
variable rates (Press et al., 1989; Wang et al., 1987; Sutherland et al., 1987; 
Aboud-Pirak et al., 1988; Matzku et al., 1987; Matzku et al., 1988b; Matzku et al., 
1988a; Matzku et al., 1990; Matzku et al., 1986; Della Torre et al., 1987). However, 
those of the studies performed in an immunological context, were mostly focused on the 
functional outcome rather than the mechanics of endocytosis and did not emphasize 
dissection of the process and understanding the differences which would account for such 
variabilities. In general, very similar techniques were used in studies of internalization 
and often a number of indirect techniques inadvertantly inco1p0rated artifacts which were 
not accounted for, or alternatively disregarded the biochemistry of ligand-receptor 
interactions. Thus these techniques started from a basis of inaccurate assumptions (see 
section m.2 and Tsaltas et al., 1993). 
In view of the foregoing the aims of this project were to: 
1) examine whether the anti-CEA monoclonal antibody used in a CEA-targeting 
model system, is internalized by CEA-expressing human cancer cell lines. This basic 
information on the model system is necessary in order to optimize the effect of anti-CBA 
immunoconjugates being produced in this laboratory. 
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2) determine an accurate and efficient way to study antibody internalization, and 
in so doing compare the accuracy and efficiency of some of the most established 
methods (past and current) used in similar studies. 
3) use inhibitors of endocytosis, to study the CEA endocytic mechanism at the 
cell surface level. 
The model used throughout this project, consists of a CEA anti-CEA targeting 
system, along with CEA-expressing human cancer cell lines. The monoclonal anti-CEA 
antibody studied (11-285-14) has been well characterized previously (Ford et al, 1987a) 
and has been extensively evaluated for immunotargeting in vitro (Allum et al., 1986b; 
Gatter et al., 1982), in vivo (Pimm et al., 1985; Macdonald et al., 1986; Rowland et al., 
1984; Casson et al., 1987; Richardson et al., 1989), and clinically (Hockey et al., 1984; 
Allum et al., 1986a). This antibody is produced and purified in the Oncology Research 
laboratory and it has already been used to produce vindesine immunoconjugates which 
have been extensively evaluated (Ford et al., 1987a; Casson et al., 1987; Ford et al., 
1990). Doxorubicin-11-285-14 immunoconjugates have also been produced and 
characterized in this laboratory (Richardson et al., 1989), while further such conjugates 
are currently being produced here, using alternative conjugation methods. 
CHAPTERll 
MATERIALS AND METHODS 
n. 1.0 Cell lines 
Cancer cell lines used in this study were of human origin and were propagated 
in culture in the Oncology Research Laboratory. The human lung cancer line BENN was 
obtained from Dr. M. Ellison, Ludwig Institute for Cancer Research (Sutton, U.K.) and 
the other lines were obtained from the American Type Culture Collection (Rockville, 
Maryland, U.S.A.). 
I Cell lines utilised and their source 
I Cell line I Source 
LS174T Human Colon Adenocarcinoma 
SKC01 Human Colon Adenocarcinoma 
COL0320DM Human Colon Adenocarcinoma 
BENN Human Lung Carcinoma 
11-285-14 Murine hybridoma 
P3-X63-Ag8 Murine Myeloma 
I 
I 
The above cell lines have been extensively characterized in terms of CEA 
expression in the same laboratory,using three monoclonal antibodies which recognize 
different epitopes of the CEA molecule (Ford et al., 1987a). Cell lines were aliquoted 
in 1. 8 m1 NUNC cryotubes (Inter Med, Rocksilde, Denmark) at 4-6 x H:f cells per 
sample and were kept frozen in liquid nitrogen cannisters (Minnesota Valley Engineering 
Inc., New Prague, :MIN.). Cell growth was supported by the media and supplements 
listed in table 3. 
Table 3: Cell Culture Media • 
Cell line 
LS174T 
SKC01 
Medium 
Mininmm 
essential medium 
(500 ml) 
Minimum 
essential medium 
(500 ml) 
RP:MI-1640 
COL0320DM (500 ml) 
BENN M199 (250 ml) 
Dulbecco's 
(250 ml) 
11-285-14 FU?MI-1640 
(500 ml) 
P3-X63-Ag8 Dulbecco's 
modification of 
Eagle's medium 
Supplements 
50ml fetal calf serum (8.8%) 
6 m1 glutamine 
6 m1 non essential 
aminoacids 
12 m1 penicillin-
streptomycin 
50ml fetal calf serum (8.8%) 6 m1 
glutamine 
6 m1 non essential 
aminoacids 
12 m1 penicillin-
streptomycin 
50ml fetal calf serum (8.8%) 
6 m1 glutamine 
12 m1 penicillin-
streptomycin 
50ml fetal calf serum (8. 8%) 
6 ml glutamine 
12 m1 penicillin-
streptomycin 
50ml fetal calf serum · (8. 8%) 
6 m1 glutamine 
12 ml penicillin-
streptomycin 
50ml fetal calf serum (8.8%) 6 ml 
glutamine 
12 ml penicillin-
sreptomycin 
4.5 g/lit glucose 
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• All media were supplied by either Flow laboratories (McLean, Virginia, U.S.A.), or 
Gibco laboratories (Life Technologies Inc., Grand Island, N.Y., U.S.A.). 
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n. 1.1 Cell Culture Maintenance 
The cell lines were grown as monolayers in 75 cm2 perspex tissue culture flasks 
(Falcon, Becton-Dickinson), and maintained in a 5% carbon dioxide atmosphere at 37>C, 
in a humidified incubator. Cell growth was monitored by viewing the monolayer under 
an inverted viewing phase microscope (Diavert, Leitz). Fresh medium was supplied as 
needed to support optimal cell growth. On average, 25-30 m1 of medium were added 
twice per week depending on cell growth. Cells were always handled under sterile 
conditions, using a laminar air flow enclosure (Contamination Control Inc.), sterile 
equipment and standard techniques such as flaming the containers and equipment and 
avoiding their contact with work surfaces. 
n. 1.2 Trypsinization 
When cells in the tissue culture flasks became confluent the cell monolayer was 
detached from the bottom of the flask by trypsinization and a cell suspension was 
prepared. A small cell sample was then removed in order to perform a count of the 
number of viable cells in the suspension. 
n. 
(1) 
1.2 (a) Materials 
Phosphate buffered saline (PBS) pH 7.2, 0.15 M. 
PBS tablets (Oxoid Ud.,Hampshire, England), were dissolved in distilled water 
as per manufacturer's instructions and sterilized by autoclaving. 
(2) 
n. 
(1) 
(2) 
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Trypsin-EDTA (Gibco); 1:10 dilution in PBS. 
1.2 (b) Method 
Medium in culture flasks was poured off under sterile conditions and discarded. 
The cell monolayer was washed twice with approximately 20 m1 PBS and the PBS 
was then discarded. 
(3) 5.0 ml trypsin-EDTA/PBS solution were added to the flask, which was 
then incubated for 10 min at 37°C. 
(4) The trypsin solution containing the cells was then poured into a 15 ml sterile 
centrifuge tube (Falcon) to which approximately 5-6 m1 PBS were added in order 
to wash off any remaining cells from the flask. 
(5) The cells were then centrifuged for 5 min at 200 x g (IECHN-SII centrifuge, 
Damon!IEC). 
(6) The supernatant was discarded and the cell pellet was resuspended by tapping the 
tip of the tube. 
(7) 10 m1 of the appropriate medium was then added to the cells and a cell count was 
performed. 
n. 1.3 Cell Count 
The cell concentration in the suspension was calculated using a Neubauer 
haemocytometer. Cell viability was determined by viewing the cells under a fluorescence 
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microscope after staining them using the dyes acridine orange (which stains viable cells 
brilliant green) and ethidium bromide (which stains dead cells brown). 
n. 
(1) 
(2) 
(3) 
1.3 (a) Materials 
Haemocytometer (Neubauer) with cover slip. 
Acridine orange, AO (#A-6014, Sigma Chemical Co., St. Louis, Missouri). 
Ethidium Bromide, EB (#E-8751, Sigma Chemical Co.). 
AO and EB used as a 0.001% solution and mixed together, were stored in 1 m1 
aliquots at -20°C. 
(4) Fluorescent microscope (Ortholux ll, Lietz, with a 50 watt mercury vapour 
lamp). 
n. 1.3 (b) Method 
Cells from the culture flask were transferred to 15 m1 or 50 m1 sterile conical 
tubes and centrifuged at 175 x g for 10 minutes. The supernatant was discarded and the 
pellet of cells in the bottom resuspended in the appropriate dilution of medium (usually 
5 to 10 ml). One drop of the cell suspension was added to one drop of AO/EB and the 
mixture was placed under the coverslip of a haemocytometer. Viable and non-viable 
cells were counted under the fluorescence microscope and the percentage of viable cells 
was calculated using the following formula. 
% Viability = (Total AO cells/Total cell count) x 100%. 
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n. 1.4 Cryopreservation of cells 
n. 1.4 (a) Materials 
Medium for freezing cells: 
10% (1:10) solutionofDimethylSulphoxide (DMSO, #10323, BDH Chemicals, Toronto, 
Canada) in fetal calf serum (FCS, Gibco), was iJltered through a 0.22 p.m millipore iJlter 
(Millipore Products Division, Bedford MA) and stored in a freezer (-7CJ'C) in 5 to 10 ml 
aliquots. 
n. 1.4 (b) Method 
(1) The number of cells to be frozen were counted. 
(2) The cell suspension was centrifuged at 1000 rpm 
(175 x g) for five minutes and the supernatant was discarded. The pellet was 
shaken to mix well. 
(3) Depending on the number of cells, the appropriate quantity of cold medium for 
freezing (kept in a bucket of ice) was added to the pellet of cells. 1 m1 of the 
medium was used to freeze 4 to 6 x 1<1 cells. 
( 4) 1 ml of the cell suspension was aliquoted into each appropriately labelled vial. 
(5) The vials were transferred in a bucket of ice to the freezer and stored at -70°C. 
(6) A day later (usually), the vials were submerged in a liquid nitrogen tank. 
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n. 1.5 Thawing cells 
(1) Using a sterile syringe, 9 ml ofRPMI-GLN-FCS medium were placed in a 15 ml 
centrifuge tube. 
(2) The vial of cells was removed from liquid nitrogen and thawed quickly in a 37°C 
waterbath. 
(3) With a few frozen cells remaining in the vial, it was transported on ice to the 
sterile hood. 
( 4) The cells were removed with a syringe and added to a sterile tube containing 
medium. 
(5) This was immediately centrifuged at 1000 rpm (175 x g) for 5 min. 
(6) The supernatant was discarded. 
(7) Using a syringe, 5 ml fresh medium was added and the suspension was poured 
into a sterile 50 ml flask (Falcon), reserving a little for the cell count. 
(8) After performing the cell count, the percentage yield was calculated. 
n. 2.0 -Antibodies 
The test antibody used throughout this project was a protein-A purified murine 
anti-CEA monoclonal IgG1 (Corvalan et al., 1984). This antibody which is identified 
by the code number 11-285-14 has been extensively evaluated for immunotargeting in 
vitro (Allum et al., 1986b; Gatter et al., 1982), in vivo (Pimm et al., 1985; Macdonald 
et al., 1986; Rowland et al., 1984; Casson et al., 1987; Richardson et al., 1989), and 
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clinically (Hockey et al., 1984; Allum et al., 1986a). Purified ascitic fluid from the P3-
X63-Ag8 mouse myeloma (American Type Culture Collection), was used as a control. 
P3-X63-Ag8 myeloma secretes an IgGl ('y,K) of unknown binding specificity (the code 
identifying this antibody is Ag8). 
The control ascites was a commercial product purchased from Bethesda Research 
Laboratories (Life Technologies Inc., Gaithersburg, Maryland). The ascites fluid was 
produced by injecting MOP2-21 plasmocytoma cells into BALB/c mice. This fluid 
contained IgG immunoglobulin, as well as all the other substances normally induced 
during the inflammatory response to the growth of plasmacytoma cells. Control ascites 
fluid shows low reactivity in an EUSA, making it a suitable control for immunological 
tests in which other ascites fluids are being used, notably, hybridoma testing. Control 
ascites is supplied in lyophilized form in three vials, each containing 0.5 ml of 
lyophilized ascites. 
Certain assays required that antibodies be iodinated e251) or conjugated to an 
enzyme (horseradish peroxidase or HRP) or a fluorochrome (fluorescein). The secondary 
antibody used in most indirect assays was rabbit-anti-mouse immunoglobulin conjugated 
to horseradish peroxidase (RAM-HRP, Dako Corporation, Santa Barbara, CA, U.S.A), 
whereas some radiolabelling assays required the iodination of rabbit-anti-mouse 
immunoglobulins (Dako Corporation). 
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n. 2.1 Purification of antibodies 
n. 2.1 (a) Materials 
(1) 0.5 M Phosphate buffer pH 8.0. 
Sodium di-hydrogen phosphate/hydrate (NaH2P04H20, BDH Chemicals Ud, 
Toronto) 69.0 g/1. 
Di-sodium hydrogen phosphate, anhydrous (Na2HP04 , Mallinckrodt Inc., Paris, 
Kentucky, U.S.A) 71.0 g/1. 
Prepare stock solutions of each salt in water and add 0.01% sodium azide (BDH) 
as a preservative. Store at room temperature. 
Mix the two solutions to obtain the required pH using a pH meter and then adjust 
to the desired molarity. 
(2) 0.1 M Citrate Acid buffer pH 3.5 and pH 6.0 
Citric acid (CJI8P7 .1H20, BDH) 0.1 M (21.01 g/1) 
Di-sodium hydrogen phosphate (N~HP04, Mallinckrodt Inc.) 0.1 M (14.2 g/1). 
For pH 6.0 titrate phosphate with citric acid; for pH 3.5 titrate citric acid with 
phosphate. 
(3) Protein A-Sepharose C1-4B Affmity Gel (Pharmacia, Uppsala, Sweden). 
The freeze-dried powder was swollen in the 0.1 M sodium phosphate pH 8. 0 
buffer and washed on a 15 m1 sintered glass ltlter funnel. This gel was poured 
into a Pharmacia C16/20 column with one adaptor at the base and a conical RC16 
packing reservoir. Gel volume was approximately 50 m1 and the reservoir held 
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approximately 100 ml. 
( 4) Spectrophotometer. 
(5) Magnetic stirrer. 
( 6) pH meter. 
(7) 4 oc cooling chamber. 
(8) Pharmacia programmable fraction collector FRAC-300 with a peristaltic pump. 
The pump was set at 5.0 and the tubing internal diameter was 2.1 mm. This 
delivers a flow rate of 1 drop I 5 sec. 
(9) 1.0 M Tris-hydrochloric acid buffer pH 9.0 
Tris (hydroxymethyl) aminomethane (Sigma) 1 M (1.21 g/1) 
Hydrochloric acid 1M, pH 9.0. 
25 m1 of 1 M tris was mixed with 2.5 m1 1 M HCI. 
(10) Amicon concentrator with PM10 ttlter membrane (Amicon Co1p0ration, 
Lexington, Mass.). 
(11) Dialysis tubing (Spectrum Medical Industries Inc., Los Angeles, CA., U.S.A.). 
(12) Phosphate buffered saline pH 7.2. 
(13) Millipore ttlters 0.8, 0.45 and 0.22 ~m (Millipore Corp., Bedford, Mass.). 
n. 2.1 (b) Method 
(1) Clots were removed from the ascitic fluid, which was clarified by centrifugation 
followed by !titration through millipore ttlters, starting with 0.8 then through 0.45 
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and f"mally 0.22 JLm. 
(2) The clarified fluid was transferred to a graduated cylinder and 3 volumes of 0.1 
M phosphate buffer pH 8. 0 were added with magnetic stirring; the pH was 
adjusted to 8.1 with 1.0 M tris at room temperature and the fluid was stored at-
20°C in approximately 100 ml aliquots. Aliquots were eventually thawed to 4°C 
to run through the column. 
(3) The Protein A column was equilibrated with phosphate buffer pH 8.0 at 4°C. 
One aliquot (1 00 ml) of diluted fluid was added to the conical reservoir - the 
fraction collector was run for 250 min. All material was allowed to run into the 
gel. 
(4) The unadsorbed fraction was collected, labelled and stored at -20"C to be put 
down the column again. 
(5) 100 ml of 0.1 M phosphate buffer pH 8.0 was added with the fraction collector 
set for 250 min. This material was collected, labelled wash #1 and stored at-
20°C for recycling. 
(6) The column was flushed with pH 8.0 phosphate buffer by lilling the conical 
reservoir and a 1 litre plastic bottle with buffer and making sure the system was 
air tight. The fraction collector was set to 999 min. The O.D. was checked at 
280 nm for about 10 ml of eluate after about 600 ml had washed through the 
column. When O.D. was less than 0.04 the lg was eluted. 
(7) Bound IgG1 was eluted with 0.1 M citrate/phosphate buffer pH 6.0 
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(approximately 100 ml). The fraction collector was set to 250 min. 
About 0.5 m1 Tris pH 9.0 was added to the collecting pot to adjust the pH to 7.0. 
This material was labelled pH6 ELUTED and stored at -20°C. 
(8) Remaining Ig was eluted from the gel with 100 m1 of 0.1 M citrate buffer 
pH 3.5. 
(9) The column was re-equilibrated with phosphate buffer pH 8.0. 
(10) All eluted pH 6.0 material was pooled and concentrated using the Amicon. 
(11) The concentrate was dialysed against 3 changes of PBS to remove the azide. 
(12) It was then f"Iltered through a 0.22 JLm millipore f"tlter and the optical density was 
read at 280 nm. 
The protein concentration was calculated using the formula: 
O.D. X dil = O.D. X dil 
B.C. 14.3 
B.c.~: (extinction coefficient) = 14.3 for IgG 
n. 2.2 Conjugation of antibodies to HRP 
The conjugation of antibodies to HRP was performed according to the method of 
Wilson and Nakane (Wilson et al., 1978). The application of enzymes as markers for 
antibodies was introduced in 1966 by Nakane and Pierce (Nakane et al., 1966). Since 
then the coupling of HRP to antibodies has been achieved using a variety of one-step or 
two-step methods. The one-step method involves mixing the antibody, HRP and the 
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coupling agent, following which the reaction either stops spontaneously or is terminated 
by an agent. The two-step method, which is more controlled and provides a more 
homogeneous conjugate, involves activating the enzyme or the antibody with a coupling 
agent. The excess coupling agent is then removed, the other reactant is added to the 
activated protein and the reaction is allowed to proceed. The coupling agents usually have 
two active groups, one coupling to the protein, the other coupling to the second reactant. 
Both the 11-285-14 and Ag8 antibodies were conjugated to HRP using sodium 
periodate as a coupling agent. This agent oxidizes the sugar moieties on the 
polysaccharide shell of HRP so that aldehyde groups are introduced. The HRP-aldehyde 
then reacts with the amino groups of the antibody thus forming the HRP conjugate. 
n. 
(1) 
(2) 
2.2 (a) Materials 
Horseradish peroxidase (HRP), RZ = 3 (Sigma). 
Sodium periodate 0.1 M (Nal04 , Analar, BDH Ltd, Poole, England). 
2.14 g Nal04 in 100 ml distilled water. 
(3) Sodium acetate buffer 0.001 M, pH 4.4 (Fisher, New Jersey, U.S.A) 
0.136 g sodium acetate in 1 litre distilled water. 
(4) Sodium carbonate (N~C03 , Fisher). 
(5) Sodium bicarbonate (NaHC03 , Fisher). 
(6) Sodium carbonate-bicarbonate buffer 0.2 M, pH 9.5. 
2.12 g N~C03 dissolved in 100 ml distilled water. 
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1.68 g NaHC03 dissolved in 100 ml distilled water. 
N~C03 solution was added to NaHC03 solution at a ratio of approximately 1:3 
until the pH was raised to 9.5. 
(7) Sodium carbonate-bicarbonate buffer 0.01 M, pH 9.5. 
Prepared by further diluting ( 6). 
(8) 11-285-14 or Ag8 antibodies. 
(9) Freshly prepared sodium borohydride (NaB~, Baker, New Jersey, U.S.A.); 
4 mg/ml distilled water. 
(10) Sephadex G200 supenme (Pharmacia). 
II. 
To prepare a 100 em x 2 em column (approximately 40 ml of material), 2 g 
Sephadex were allowed to swell in distilled water for 48 hours at 4°C. The 
column was then packed using a peristaltic pump at 25 ml/hour. 
2.2 (b) Method 
(1) 4 mg HRP were dissolved in 1 ml distilled water. 
(2) 200 JLl of 0.1 M Nal04 were added and mixed gently for 20 minutes. 
(3) Reactants were dialysed in 0.001 M sodium acetate pH 4.4 at 4°C for 20 hours 
to remove any excess sodium periodate. 
( 4) The pH was then raised to 9. 5 through the addition of 20 JLl of 0. 2 M sodium 
carbonate-bicarbonate buffer pH 9.5. 
(5) 8 mg antibody dissolved in 1 ml of 0.01 M sodium carbonate-bicarbonate buffer 
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pH 9.5 were immediately added, the solution was mixed gently and the coupling 
reaction was allowed to proceed for 2 hours at room temperature. 
(6) The reaction was terminated by the addition of 0.1 ml fresh sodium borohydride. 
The solution was again left to stand for 2 hours at 4°C. 
(7) The conjugate was chromatographed using a Sephadex G200 superf'me gel bed at 
an approximate flow rate of 4 ml/cm2/ hr. Forty 2 ml fractions were collected and 
read on a spectrophotometer at wavelengths of 280 nm (antibody detection) and 
403 nm (enzyme detection) and the conjugate was pooled and stored in 1 ml 
aliquots at 4 oc. 
n. 2.3 Iodination of antibodies 
Both 11-285-14 and RAM antibodies were radiolabelled with 125lodine for use in 
two different internalization assays. The Chloramine T method (Hudson et al., 1980) was 
selected since it introduces the radioactive tracer without significantly altering the 
immunological properties of the labelled molecules and previous work had shown that 
it could be used with 11-285-14 and Ag8 antibodies (Ford et al., 1987a). 
n. 2.3 (a) Materials 
(1) 400 p,g antibody diluted in phosphate buffered saline (PBS) at 1:2 dilution factor; 
total volume 200 p,l. 
(2) Sodium phosphate buffer (NaP04 , Baker) 0.05 M, pH 7.5. 
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(3) Chloramine T (Amersham Corp., 4 mg/ml in 0.05 M NaP04 buffer pH 7.5). 
(4) Potassium Iodide (KI, Sigma) 4 mg/ml in PBS. 
(5) Sodium bisulfite (Na2S20 4 , Sigma) 10 mg/ml in PBS. 
(6) 1% bovine serum albumin (BSA, Sigma) in PBS. 
(7) Sodium 125Iodine (Amersham Corp.). 
(8) Sephadex G-25 medium (Pharmacia), 6 gin 20-25 m1 PBS. 
n. 2.3 (b) Method 
(1) A 25 ml glass pipette was mounted on a stand and plugged with a very small 
amount of glass wool. 
(2) The Sephadex column was poured and equilibrated with 1 % BSA in PBS. 
(3) The antibody was placed into a 1.5 m1 Eppendorf tube and 1 mCi of Na1251 was 
added. 
(4) 200 1-'1 Chloramine T were added and the tube was shaken for 1 minute. 
(5) 200 J.tl freshly made sodium bisulfite were added. 
( 6) 400 1-'1 potassium iodide were then added and the reaction was applied onto the 
pre-equilibrated column. 
(7) 26 x 2 m1 fractions were collected and a radioactivity count was taken. 
(8) The samples included in the rrrst peak were pooled and the percent bound 
radioactivity was determined using the trichloroacetic acid (TCA) precipitation 
method described below (section ll.2.3 (b) supplement). 
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ll. 2.3 (b)supplement: TCA precipitation 
(1) A 1:200 dilution of a small sample of the pooled fractions in 1% BSA I PBS 
( 5 ~-tl sample in 995 ~-tl diluent), was prepared. 
(2) A 250 ~-tl aliquot of (1) was then removed and labelled sample A {representing 
total [bound + nonbound] radioactivity. 
(3) Another 250 ~-tl aliquot was removed from solution in (1). 250 ~-tl TCA 
(20 % weight/volume) were added to it. 
(4) Sample was vortexed and let to stand 15 - 20 min, following which it was 
centrifuged at 350 x g (Beckman TJ-6 centrifuge), at 40C for 5 minutes. 
(5) 250 ~-tl were then removed from the supernatant and labelled sample B 
{representing non protein bound radioactivity). 
( 6) Radioactivity counts were obtained for samples A and B using a gamma counter, 
and the percent protein bound radioactivity was obtained using the following 
formula: % bound activity = 100 - 2 x (B/ A) x 100. 
n. 2.4 Labelling of Antibodies With Fluorescein 
11-285-14 antibody as well as control ascites were labelled with a fluorochrome 
(fluorescein isothiocyanate - FITC) in order to perform internalization assays employing 
flow cytometric techniques. During those assays commercially available anti-FITC was 
used to quench surface fluorescence in order to make possible the differentiation between 
surface and internalized activity. 
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n. 2.4 (a) Materials 
(1) Sodium carbonate buffer, NaHC03 (0.1 M), pH 9.0, 16.8 g (Mallinckrodt Inc. 
Paris, Kentucky) prepared in 2 litres of distilled water. 
(2) Fluorescein-5-isothiocyanate, FITC, (1.3 mg) (# F-143, Lot # 1121-4, Molecular 
Probes Inc. Pitchford Ave. Eugene, OR.) 
(3) Dimethylsulphoxide, DMSO, (1.2 mi) (AnalaR, BDH Chemicals, Toronto). 
(4) Sephadex G-25 (1.0 g) added to 10 ml of PBS (Pharmacia Fine Chemicals AB, 
Uppsala, Sweden). 
(5) Phosphate Buffered Saline (PBS) pH 7.2 (Oxoid. Unipath Ud. Basingstoke, 
Hampshire, England). 
(6) NaOH (2 N) (Fisher Scientific Company). 
(7) Spectrapor Membrane dialysis Tubing (10mm x 50ft) (Spectrumedical Industries 
Inc. 60916 Terminal Annex, Los Angeles 90054). 
(8) 11-285-14 antibody at 1.68 mg mi-1 
n. 2.4 (b) Method 
(1) A 2 litre 0.01 M NaHC03 solution was made up and equilibrated. 
(2) 11-285-14 was added to dialysis tubing at a concentration of 1.68 mg mi-1 and was 
dialysed in the NaHC03 buffer for 24 hours at 4°C with continuous stirring. 
(3) A 1.2 mg mi-1 solution of FITC-DMSO was prepared. 
(4) 300 p.l of this was added to the 11-285-14 sample in 10 p.l aliquots, wrapped in 
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foil and stored at room temperature for 5 hours. 
(5) The purified conjugate was obtained by layering the conjugate mixture in 1 m1 
aliquots over swollen G-25 Sephadex beads. These beads were packed in a 5 ml 
syringe and were then centrifuged for 1 minute at 560 x gat 0°C. 
(6) The eluent containing the FITC-conjugated monoclonal antibody was then 
collected. 
(7) The fluorescein/protein (antibody), FIP, ratio of the collected conjugate was 
determined by reading optical densities at 280 nm and 495 nm. These readings 
were then inco1p0rated into the following equations: 
Molar Concentration of protein P= 00280 - 0.35 x 00495 I 1.43 
1.43 = Molar Absorption Coefficient of IgG at 280 nm 
Molar Concentration of Fluorescein F = 00495 I 0. 7 x lOS 
(Haaijman, 1983). 
(8) The product was then aliquoted out (0. 743 mg ml1) into Eppendorf tubes and 
stored at -20°C. 
(9) An identical procedure as the one described above was used to label the control 
ascites. 
10 mg ml-1 of ascites was used in the dialysis. The dialysis product was stored at 
1.0 mg mi-1 at -20°C. 
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ll. 3.0 Immunoadsorbent CEA Purification 
Carcinoembryonic antigen was extracted from liver metastases and purified 
according to the method of Ford et al. (Ford et al., 1987b), which utilizes a monoclonal 
anti-CEA affmity column. 
n. 3.1 Preparation of immunoadsorbent column 
The anti-CEA monoclonal antibody 11-285-14 was used for the preparation of an 
immunoadsorbent column to be employed in the last stages of carcinoembryonic antigen 
purification. 
n. 
(1) 
(2) 
(3) 
(4) 
(5) 
(6) 
(7) 
3.1 (a) Materials 
Semi-purified 11-285-14 (see section ll.2.1). 
Cyanogen bromide-activated Sepharose 4B column (C26/40, Pharmacia, Canada). 
HCl solution, 1 mM. 
Ethanolamine solution 1M, pH 8.0. 
Borate buffer (Fisher) 0.1 Min 0.5 M NaCl pH 8.0. 
Acetate buffer (Fisher) 0.1 Min 0.5 M NaCl pH 8.0. 
Acetate buffer (Fisher) 0.1 Min 0.5 M NaCl pH 4.0. 
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n. 3.1 (b) Method 
(1) 11-285-14 was semi-purified from ascitic fluid by precipitating with ammonium 
sulphate and then desalting and buffer exchanging on Sephadex G25, as described 
in section n.2.1.a. 
(2) 15 g cyanogen-bromide-activated Sepharose 4B were swollen and washed with 
1 mM HCl. 
(3) The semi-purified monoclonal antibody was mixed at a concentration of 1 mg/ml 
with the activated gel and rotated overnight at 4°C. 
(4) Remaining activated groups were blocked with 1M ethanolamine, pH 8.0, and 
excess uncoupled protein was washed off by alternating buffers; irrst 0.1 M 
borate buffer pH 8. 0, then 0.1 M acetate buffer pH 8. 0 and imally 0.1 M acetate 
buffer pH 4.0, for a total of 3 times each. 
(5) The gel was then equilibrated with the borate buffer and a C26/40 column was 
prepared with a gel bed of 2.6 x 7.5 em. 
n. 3.2 CEA purification 
200g liver metastasis from a primary colonic adenocarcinoma were minced under 
sterile conditions and homogenised in 800 ml ice-cold distilled water in an Polytron 
homogeniser (Brinkmann Instruments, Wexdale, Ontario). Carcinoembryonic antigen was 
then extracted from the tumour homogenate as follows: 
n. 3.2 (a) Materials 
(1) Phosphate buffered saline (PBS; 0.1 M phosphate, 0.2 M NaCl pH 5.5). 
(2) Glass fibre filter (GFA, Whatman). 
(3) IDtraf""tltration PM10 Diaflo membrane (Amicon Cotp., Lexington, Mass.). 
(4) IDtrattltration cell (Amicon Cotp.). 
(5) Borate buffer (Fisher) 0.1 M, pH 8.0 in 1 M NaCl. 
(6) Sephadex G25 column (Pharmacia). 
(7) 0.45 p.m filter (Millipore Cotp., Bedford, Mass.). 
(8) Acetic acid 1 M. 
(9) Sodium Carbonate anhydrous (Fisher), 3 M. 
(10) Fraction collector. 
( 11) Spectrophotometer. 
(12) Spectrapor molecularporous dialysis tubing (Spectrum Cotp.). 
(13) IDtracentrifuge. 
n. 3.2 (b) Method 
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(1) Liver homogenate was extracted on ice for 30 min with an equal volume of 
phosphate buffered saline and centrifuged at 13,000 x g for 30 min at 4°C. 
(2) The supernatant was ttltered through a glass fibre filter (GFA, Whatman) until 
clear and then concentrated by ultrattltration to 100 ml (1 ml/g original tumour) 
with a PM10 Diaflo membrane. 
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(3) Successive aliquots were buffer-exchanged on Sephadex G25 equilibrated with 0.1 
M borate buffer in 1M NaC1 pH 8.0 and pooled fractions re-concentrated to 
1 mil g original tumour. 
(4) After filtration (0.45 JLm, Millipore) successive aliquots were run into the 
immunoadsorbent column until protein was just detectable at the outflow. The 
column was stopped each time for 20 min to allow any unbound material to be 
washed through with borate buffer. When all the material had been added to the 
column it was washed with borate buffer until the absorbance of the eluate 
at 280 nm was zero. 
(5) CEA was eluted with 1 M acetic acid and, after rapid neutralization with sodium 
carbonate, the pooled fractions were dialysed against distilled water, lyophilised 
and weighed after dessication. 
n. 4.0 Immunoperoxidase assays 
Immunohistochemical techniques were introduced as early as 1934 (Marrack, 
1934) when it was recognized that antibodies could be suitable histochemical reagents 
provided that they could be linked to appropriate markers in a manner that would not 
impair their capacity to react with specific antigens. Initially only fluorescent dyes proved 
to be strong enough markers but in 1966 Wilson and Pierce (Nakane et al., 1966) 
successfully applied enzymes as antibody markers, while in the same year the enzyme 
horseradish peroxidase was introduced as one of the most powerful markers. Since that 
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time the tenn "immunoperoxidase methods" has been reserved for the demonstration of 
antibodies using HRP as a marker, a method used routinely in immunocytochemistry 
(Ford et al, 1981). 
n. 4.1 (a) Materials 
(1) Air-dried, ethanol-ltxed smears of human cancer line cells. 
(2) Xylene. 
(3) Ethanol : Absolute, 75%, 60%, 30%. 
(4) Hydrogen peroxide (H20 2 , Mallinckrodt Inc., Paris, Kentucky, U.S.A) 7.5% in 
distilled water. 
(5) Periodic acid (BDH), 2.28% in water. 
(6) Potassium borohydride (BDH), 0.02% prepared fresh in water. 
(7) Phosphate buffered saline (PBS). 
(8) Bovine serum albumin (Sigma), 1% (w/v) in PBS (1% BSA). 
(9) Brij 35 (BDH), Non-ionic detergent. 
(10) Rabbit-anti-mouse immunoglobulins conjugated to horseradish peroxidase 
(Dako Cotp.). 
(11) Nonnal rabbit serum pool. 
(12) 3, 3'-Diaminobenzidine (DAB, Sigma), 0.5 mg ml-1 in PBS + 0.03% H20 2 • 
(13) Mayers haemalum stain (BDH). 
(14) Lithium carbonate (BDH) saturated aqueous solution. 
n. 
(1) 
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4.1 (b) Method 
The slides were bleached for 5 minutes with 7.5% H20 2 and washed with tap 
water. 
(2) Endogenous peroxidase was blocked using 2.28% periodic acid for 5 minutes 
followed by washing in tap water. 
(3) Aldehyde groups were blocked with freshly made 0.02% potassium borohydride 
for 2 minutes. Slides were washed with tap water followed by PBS. 
( 4) 100 J.tl normal rabbit serum diluted 1/25 were incubated on the sections for 10 
minutes in a moist chamber to block non-specific binding of conjugate. The 
slides were washed with PBS. 
(5) The slides were transferred to a wash bath containing PBS and 0.001% Brij and 
were agitated for 5 minutes. 
(6) 100 J.tl of the rrrst test anti-CEA antibody (11-285-14) were added to the slide 
with appropriate positive (for example liver metastases) and negative (for example 
control ascites in 1% BSA diluent) controls. 
(7) Following a 30 minute incubation in a moist chamber the rrrst antibody was 
washed off using PBS. 
(8) The slides were transferred to a wash bath containing PBS-Brij and were agitated 
for 15 minutes. 
(9) 100 J.tl of appropriate enzyme (HRP) labelled antibody directed against the first 
antibody and appropriately diluted in PBS (usually 1150 or 11100), were incubated 
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on the sections for 30 minutes in a moist chamber. This secondary labelled 
antibody was washed off using PBS. 
(10) The slides were transferred to a wash bath containing PBS-Brij and were agitated 
for 15 minutes. 
(11) Freshly prepared diaminobenzidine in PBS was incubated on the slides for 5 
minutes and was then washed off with PBS. 
(12) Mayer's haemalum was used to counterstain the sections followed by blueing in 
saturated lithium carbonate. 
(12) Sections were dehydrated through the alcohols, cleared in xylene and mounted. 
n. 5.0 Enzyme linked immunosorbent assays (ELISAs) 
Use of this solid phase immunoassay makes possible the immobilization of 
proteinaceous substances such as antigens or antibodies by adsorption onto a solid surface 
such as a polystyrene bed or a plastic microtitre plate. Antigen, (purified or cell-bound), 
is usually adsorbed to the solid phase irrst, followed by the addition of the antibody being 
tested. This antibody is then detected by a second labelled antibody directed against the 
irrst one. Both radioisotopes and enzymes have been used as labels on the detector 
(secondary) antibody, however enzymes are both safer in terms of handling and can be 
stored for very long periods of time so that they are now almost exclusively used in 
routine ELISAs. Outlines of some representative ELISAs are presented at the end of this 
section (figure 1). 
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n. 5.1 Materials 
(1) 0.5%, 1% or 2% bovine serum albumin (BSA, Sigma) in PBS/Tween (Sigma) 
(0.5, 1 or 2 g BSA in 100 ml PBS + 100 1'1 Tween). 
(2) Carbonate - bicarbonate buffer, pH 9.2 (1.59 g sodium carbonate (NazC03 , 
Fisher) + 2.93 g sodium bicarbonate (Na2HC03 , Fisher) dissolved in 1 litre of 
distilled water). 
(3) 1% BSA in carbonate - bicarbonate buffer (1 g BSA in 100 ml carbonate-
bicarbonate buffer). 
(4) Citrate-phosphate buffer (BDH), pH 4.0 ( 9.06 g citric acid (CJI8~.H20} + 
8.16 g disodium hydrogen phosphate (NaJIP04 , BDH) dissolved in 1 litre 
distilled water). 
(5) Sodium chloride ( Fisher)/ 1% Tween (Sigma) wash solution 0.15 M (8. 76 g 
sodium chloride + 1 1'1 Tween dissolved in 1 litre distilled water). 
(6) 2,2-azino-di-3-ethylbenzthiazoline sulphonic acid (ABTS, Sigma; 100 J'l of a 
27.8 mg mi-1 stock diluted in 12.5 ml citrate-phosphate buffer + 11'1 hydrogen 
peroxide (BDH)). 
(7) Linbro 96 well sterile enzyme immunoassay plates (Flow Laboratories). 
(8) Soft round bottom polyvinyl chloride (PVC) 96 well plates (Dynatech). 
(9) Glycine-HCl buffer 0.05 M, pH 2.8 in 0.1 M NaCl (5.844 g NaCl in 1 litre 
distilled water+ 3.753 g glycine (ammonia-free Glycine, Sigma, St. Louis, Mo., 
U.S.A. or 98% pure glycine, Aldrich, Milwaukee, Wis., U.S.A.). 
(10) Polylysine (PLL, 1 mg ml-1 in PBS). 
(11) 11-285-14 and Ag8 antibodies. 
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(12) Rabbit anti-mouse antibody conjugated to horseradish peroxidase (RAM-HRP, 
section ll.2.2). 
(13) Live or fixed CEA expressing cells derived from the human cancer cell lines 
LS174T, SKC01 or BENN (section ll.l.O). 
(14) CEA derived from human liver metastases and purified in the Oncology Research 
Laboratory, Memorial University, NF (section ll.3.0). 
(15) Bio-Tek EL31 0 EUSA plate reader. 
ll. 5.2 Method: ELISA on live cells (Morris et al., 1982) 
(1) Cells from all three lines were grown overnight on soft PVC plates at a 
concentration of 5 x lOS cells mi-1 (100 #-'1/well or 5 x 10" cells/well). 
(2) Cells were washed x 3 in 0.5% BSA/PBS by centrifugation at 200 x g for 5 
minutes. 
(3) 100 #-'1 11-285-14 (test) or Ag8 (control) antibody in 2% BSA/PBS at a 
concentration of 5 #-'g ml-1 were added to the appropriate wells and incubated for 
2 hours at 37°C. 
(4) Wells were washed x 4 in 0.5% BSA/PBS and 100 #-'1 glycine-HCl buffer (test) 
or 0.1 M NaCl (control) were added to the appropriate wells and incubated either 
at room temperature or 37°C for 20 minutes. 
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(5) Wells were washed again x 4 and 100 J.tl RAM-HRP diluted 1: 1000 in 2% 
BSA/PBS were added to the wells and incubated for 2 hours at 37°C. 
(6) Wells were washed x 4 and the soft plates were snap-fitted onto rigid UNBRO 
EIA plates which had been previously coated with 100 J.tl polylysine for 30 
minutes at room temperature. 
(7) Holes were punched in the center of the wells with an 8 gauge needle and the 
plates were centrifuged causing the cell suspension to be transferred onto the rigid 
plates. 
(8) The ABTS substrate solution was added and incubated for 1 hour at room 
temperature. 
(9) Absorbance at a wavelength of 405 nm was then measured on the platereader. 
n. 5.3 Method: ELISA on f"IXed cells 
(1) LS174T, SKC01 and BENN cells (2.5x10S cells ml-1) were plated out in UNBRO 
tissue culture plates at 100 J.tl I well and incubated overnight at 37°C. 
(2) Cells were itxed by incubation in methanol for 5 minutes at room temperature. 
(3) Uncoated plastic was then blocked with 1 % BSA in carbonate-bicarbonate buffer 
at 200 J.tllwell, for 1 hour at 37°C. 
(4) Wells were washed x 6 with 0.15 M NaCl and 100 J.tllwell test (11-285-14) or 
control (Ag8) antibodies at a concentration of 20 1-'g ml-1 were added and 
incubated for 90 minutes at 37°C. 
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(5) Wells were washed x 6 again and 100 #-'1 glycine-HCl buffer were added in the 
appropriate wells and incubated for 20 minutes at room temperature or at 37°C. 
(6) Cells were washed again x 6 and, in some assays, test antibody was re-applied 
in certain wells for another 90 minutes followed by six further washes. 
(7) RAM-HRP (diluted 1:1000 in 1% BSA/PBS) was then applied to the wells at 
100 #-'1/well and was incubated for 3 hours at 3~C. 
(8) Cells were again washed x 6 and 100 #-'1 ABTS substrate solution were added to 
each well and incubated for 1 hour at room temperature. 
(9) Absorbance at 405 nm was then measured as in section 11.5.2 above. 
n. 5.4 Method: ELISA using antibody-HRP conjugates 
(1) Linbro plates were coated with 100 #-'1/well 11-285-14-HRP (test) or Ag8-HRP 
(control) antibodies (section 11.2.2) in carbonate-bicarbonate buffer at a 
concentration of 1 #-'g ml-1• 
(2) The plates were incubated at 37°C for 3 hours and left at 4°C overnight. 
(3) The same procedure as for ttxed cells was then followed (section 11.5.3 (3)-(9)). 
n. 5.5 Method: ELISA using purified CEA coated plates (Reddy et al, 1993). 
(1) Linbro plates were coated with 100 #-'1 purified CEA (2.5 #-'g ml-1 in carbonate-
bicarbonate buffer, pH 9.2). 
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(2) The same procedure as for antibody-HRP conjugates (section 11.5.4 (2) onward), 
was used. 
(3) After application of the glycine-HCl buffer and thorough washing (x6) to remove 
dissociated antibody, test and control antibodies were applied for a second time 
in some groups of wells in order to examine the degree of antibody reassociation 
to antigen. 
Schematic drawings of some representative EUSA assays perfonned, are provided 
on the following page (Figure 1). 
ELISA& testing the dissociating effect of 
Glyclne-HCI 
RAM-HAP 
GLY-HCI 
aCE A 
CELL......._---' 
A:l nd lraot-Cella 
on antigen-~Ab bonds 
RAM-HAP J:-t 
GLY-HCI ·~ aCE A GLY-HCI 
CEA 
B1Direot-Cella Cdndlreot-CEA 
Figure 1 
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n. 6.0 Rad.ioimmunoassays 
To estimate amount of antibody internalized by CEA-expressing cancer cell lines, 
two types of radioimmunoassays were employed. The first, referred to as the "glycine-
HCl internalization assay" makes use of a low pH glycine buffer to dissociate surface 
antigen-antibody bonds. The second, referred to as the "double labelling assay" makes 
use of a secondary antibody which detects surface anti-CEA antibody at any time 
interval. Both assays make use of iodine-125 labelled antibodies and they both provide 
semi-quantitative estimates of internalized antibody. 
n. 6.1 Glycine-HCI Internalization Assay 
Uptake and internalization of iodinated 11-285-14 antibody were measured by a 
modified internalization assay (Matzku et al., 1986). Cells were incubated with 
radiolabelled antibody for various time intervals after which glycine-HCl buffer was 
applied to test groups in order to dissociate surface antigen-antibody bonds. In these 
groups remaining radioactivity after buffer treatment was presumed to reflect internalized 
(ie. non buffer accessible) antigen-antibody complexes. 
A graphic representation of this assay is provided in Figure 2 (following page). 
lycine-HCI Assay 
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n. 6.1 (a) Materials 
(1) LS174T human colorectal cancer cells. 
(2) 1251 labelled 11-285-14 anti-CEA MAb (section ll.2.3.). 
(3) 1% fetal calf serum (FCS, Gibco) in PBS. 
(4) Glycine-HCl buffer 0.05 M, pH 2.8 (section ll.5.1 (9)) 
(5) Beckman G 7000 gamma counter. 
ll. 6.1 (b) Method 
( 1) LS 17 4 T cells were dispensed into Eppendorf tubes (2. 5 x 1 OS cells per tube in 
100 p.l medium at RT). Controls consisted of tubes containing medium only. 
(2) Iodinated antibody in saturating doses determined in previous assays (10 p.l of 
200 p.g/ml antibody) was immediately dispensed into each tube. 
(3) Duplicate tubes were placed either at 37°C or ooc and were subsequently removed 
at half hour intervals and processed as follows: 
( 4) Cells were washed three times with 1 ml of 1 % FCS in PBS and supernatants 
were discarded at the end of each wash. 
(5) Cell pellets were resuspended in 1 ml glycine buffer (0.05 M glycine-HCL pH 
2.8 in 0.1 M NaCl) for a period of 20 minutes at RT, after which time a 
radioactivity count was taken for each sample. 
(6) The samples were then washed again three times with 1 ml of 1 % FCS in PBS 
in order to wash off antibody released due to treatment with the glycine buffer. 
(7) A second radioactivity count of the cell pellet was then taken to be used as a 
123 
measure of the amount of remaining cell bound antibody. In some assays 100 p.l 
medium along with 10 p.l 1251 labelled Mab were added to the samples which were 
then incubated at ooc for 30 min. 
(8) Following incubation cells were washed 3 times with 1 % FCS in PBS and 
radioactivity counts of cell pellets were taken. These samples were used to 
evaluate the effect of glycine buffer on antigenic sites (or the degree of CEA 
re-expression). 
n. 6.2 Double Labelling Assay for Internalization (Rosenthal et al., 1980) 
This assay indirectly estimates the amount of internalized anti-CEA antibody 
through the use of a radiolabelled secondary antibody which depicts the amount of 
surface anti-CEA at the end of each incubation interval. Anti-CEA (test) or Ag8 (control) 
antibody treated cell samples were separated into two groups. All samples of the lrrst 
group were treated with secondary radiolabelled antibody so that their radioactivity levels 
at the end of each incubation period would be indicative of both surface-bound and 
internalized antibody. Samples of the second group are treated with secondary antibody 
at the end of each incubation time interval so that radioactivity levels in that case would 
be indicative of surface bound antibody only. Subtracting second group radioactivity 
counts from lrrst group counts could then be used as a measure of internalized (residual) 
antibody for each time interval. An outline of the double labelling assay is provided on 
the following page (Figure 3). 
GROUP 1 
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n. 6.2 (a) Materials 
(1) LS174T colorectal cancer cells (section ll.l.O) 
(2) 11-285-14 and Ag8 antibodies (section ll.2.0) 
(3) 125Iodine labelled rabbit-anti-mouse antibody (section ll.2.3) 
( 4) 2% fetal calf serum (FCS, Gibco) in PBS. 
(5) 1.5 ml plastic Eppendorftubes (polypropylene microcentrifuge tubes,Bioplas Inc). 
(6) Gamma counter (Beckman LS-7500). 
n. 6.2 (b) Method 
(1) 100 J.'l of LS174T cells at a concentration of 2.5 x le1 cells mi-1 were dispensed 
into Eppendorf tubes (2.5 x lOS cells/tube) at RT. 
(2) Test antibody (11-285-14) or control antibody (Ag8) were added to respective 
tubes at 2 J.'g/tube. In certain tubes to be used as controls for nonspecific binding 
of secondary antibody, no primary antibody was added. 
(3) To establish initial antibody binding, all tubes were incubated at 37°C for 30 
minutes. 
(4) Following this incubation period, samples were washed x 3 in 1 m12% FCS/PBS, 
divided into two groups and treated as follows: 
(5a) Secondary 1251-labelled RAM antibody was added to all tubes of one group (1 J.'g 
RAM or 20.8 f'l per tube based on previous saturation assays) and incubated at 
room temperature for 30 min to allow binding of the secondary antibody. This 
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group of tubes (Group 1) would eventually be used for assessment of total 
antibody binding. 
(5b) After the 30 min incubation period samples were washed 3 times in 1 ml of 2% 
FCS in PBS and were then divided into subgroups - to be incubated either at 4°C 
or at 37°C. 
(5c) Samples were subsequently retrieved in duplicate at pre-specified time intervals, 
were washed again x 3 and radioactivity counts of the cell pellets were taken. 
(6) The second group of tubes (Group 2) was treated as follows: 
(6a) Samples were left at 37°C for pre-specified incubation intervals (same as for 
Group 1). 
(6b) At the end of each interval duplicate samples were retrieved and 12~ labeled RAM 
was added to each (1 1-'g/tube). 
(6c) Samples were incubated for 30 min at RT, and were then washed 3 times in 1 m1 
of 2% FCS-PBS. 
(6d) Radioactivity counts of the cell pellets were then taken. This group of samples 
would be used for the assessment of surface Ab binding during each time 
interval. 
(7) Radioactivity counts obtained for group 2 tubes (surface antibody) were then 
subtracted from counts obtained for group I tubes (total antibody) for each 
time interval. 
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ll. 7.0 Electron microscopy assays. 
Direct visualisation of internalized antibody was made possible by the use of 
electron microscopy. Localization of intracellular proteins (such as antibodies), normally 
requires that the antibody be labelled with an electron-opaque (eg. ferritin) (Singer, 1959; 
Sternberger, 1967), or heavy metal marker ( eg. uranium or colloidal gold) (Sternberger, 
1967; Sternberger et al., 1965). The introduction of methods for conjugating enzymes 
to antibodies (Nakane et al., 1966) has opened up the possibility of using enzymic labels 
for electron microscopy. Horseradish peroxidase has a number of properties which make 
it particularly suitable for such applications such as ease of detection, commercial 
availability, low endogenous peroxidase levels in biological tissue and small size relative 
to most other labels currently available. Consequently the label of choice for the electron 
microscopic assays was horseradish peroxidase conjugated to the anti-CEA and control 
antibodies. 
n. 
(1) 
(2) 
7.1 (a) Materials 
SKC01 colorectal cell line. 
11-285-14 and Ag8 antibodies conjugated to horseradish peroxidase (section 
ll.2.2). 
(3) Millicell-HA membranes (0.45 I-'m culture plate insert, 12 mm diameter, 
Millipore, Bedford, MA). 
( 4) Sterile PBS. 
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(5) Half-strength Kamovsk:y's solution (Merivac Ud. Halifax, Nova Scotia). 
(6) Cacodylate buffer 0.1 M (Merivac Ud.). 
(7) Diaminobenzidine (DAB, Sigma) 0.5 mg ml-1• 
(8) Tris-HCl buffer 0.2M, pH 7.4 + 0.0009% hydrogen peroxide. 
(9) 1 % osmium tetraoxide (Merivac Ud.). 
n. 7.1 (b) Method 
(1) SKC01 cells at a concentration of 4 x 106 cells ml-1 in medium were applied onto 
membranes at 100 ~1/membrane, and incubated overnight at 37°C. 
(2) Following incubation the cells were washed x 3 in PBS and 200 ~1 test 
(11-285-14-HRP), or control (Ag8-HRP) antibodies diluted in sterile PBS at 
concentrations of 25, 50 or 100 ~g ml-1, were dispensed on each membrane. 
(3) A two-hour incubation period at 37°C followed, after which the membranes were 
washed x 3 in PBS and fixed in half-strength Kamovsk:y's solution for 15 min. 
(4) Membranes were then washed x 2 by rocking in 0.1 M cacodylate buffer, 
and suspended in 225 ~1 diaminobenzidine in 0.2 M Tris-HCl buffer (pH 
7. 4) with 0. 0009% hydrogen peroxide (H20 2). 
(5) After another 15 min incubation at 4°C the membranes were washed, postiiXed 
in 1 % osmium tetraoxide and processed for EM: analysis. 
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n. 8.0 SDS/PAGE on membrane and cytosolic portions of 
solubilized cells 
An alternative method of visualizing surface-bound and internalized antibody 
involved the separation of cellular components (plasma membrane from cytosol) followed 
by the electrophoresis and blotting of these components for the identification of pre-
incubated antibody. 
Following incubation of cells with either CEA-specific or non CEA-specific 
antibodies, cells were broken open and separated into solubilized membrane and cytosol. 
Such samples were then electrophoretically separated into their protein components and 
Western blotted. Relevant antibodies were then identified by immunostaining. 
n. 8.1 Separation of plasma membrane from cytosol 
The separation process took place following incubations of cells with the 
appropriate antibodies for pre-specified time intervals, therefore the description of 
incubations will be included in the present section. 
n. 8.1 (a) Materials 
(1) LS174T, SKC01, BENN and COL0320DM cell lines. 
(2) 11-285-14 and Ag8 antibodies. 
(3) Sonicator (Virsonic Cell Disrupter 16-850, Virtis Co, Gardiner, N.Y.). 
(4) Ultracentrifuge (Beckman 1..5-65). 
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(5) TNEN buffer, pH 8.0 (0.242 g Tris base+ 0.585 g NaCl + 0.037 g EDTA + 
n. 
(1) 
(2) 
(3) 
(4) 
50 1-'1 Nonidet P40 in 100 ml distilled water). 
8.1 (b) Method 
LS174T, SKCOl, BENN and COL0320 cells were grown as described above and 
divided into samples of 1 x 1 OS cells each. 
Samples were incubated with 11-285-14 or Ag8 (200 1-'g/sample) for incremental 
half hour time intervals, at 37°C. 
Samples were then washed 3 times in 1 ml PBS and frozen at -700C. 
Cells were subsequently solubilized and membrane and cytosolic portions were 
extracted as follows: 
(5) Cells were sonicated twice for 15 sec on ice and then centrifuged at 
100,000 x g for 1 hr at 4°C. 
(6) The supernatants (cytosolic portions) were then stored at -700C whereas 1 ml 
TNEN was added to the pellets which were again sonicated twice for 15 sec on 
ice. 
(7) The sonicated pellets were then centrifuged again for 1 hr at 100,000 x g at 4 oc, 
and the supernatants (membrane portions) were stored at -700C. 
(8) Protein concentrations for all samples were then calculated in a Bio Rad protein 
assay kit. 
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ll. 8.1 (b) supplement: Bio Rad protein assay 
(1) Seven dilutions (140 }-'g-20 J.'g) of protein standard (lyophilised bovine gamma 
globulin), were prepared. 
(2) 100 J.'l of standards and appropriately diluted samples were placed in clean, dry 
test tubes. 
(3) 100 J.'l sample buffer was placed in "blank" test tube. 
(4) 5 ml of diluted dye reagent (1 volume of Dye Reagent Concentrate diluted with 
4 volumes of high quality distilled or deionized water and rtltered through a 
Wbatman No. 1 paper) were added to the samples which were immediately 
vortexed. 
(5) Following a 1 hour incubation optical density at a wavelength of 595 nm was 
measured versus the reagent blank. 
(6) 00595 versus concentration of standards was then plotted and the unknowns were 
read from the standard curve. 
ll. 8.2 SDS-PAGE 
n. 8.2 (a) Materials 
(1) Acrylamide (Bio Rad). 
(2) N,N,-Methylene-bis-Acrylamide (Sigma). 
(3) TIIAM {Tris Hydroxymethyl) Aminomethane (Fisher). 
(4) SDS (sodium dodecyl sulfate) (BDH) or lauryl sulfate (Sigma). 
(5) Ammonium persulfate ((NH4) 2S20 8, Analar). 
(6) TEMED (N,N,N,N-Tetramethylethylenediamine,(Sigma)). 
(7) STOCK SOLUTIONS 
A. Acrylamide: BIS (30%T, 2.67%C) 
29.2 g acrylamide (Bio Rad). 
0.8 g N, N, - Methylene-bis-acrylamide (Sigma or Bio Rad). 
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Brought to a imal volume of a 100 m1 with distilled water. Filtered and stored at 
4°C in the dark for a maximum of 30 days. 
B. 1.5 M Tris-HCI, pH 8.8 
18.15 g Tris base (Sigma). 
50 ml distilled water. 
Adjusted to pH 8.8 with 1M HCl and brought to a tmal volume of a 100 ml with 
distilled water. 
C. 0.5 M Tris-HCI pH 6.8 
3.0 g Tris base. 
20 ml distilled water. 
Adjusted to pH 6. 8 with 1 M HCl and brought to a imal volume of 50 ml with 
distilled water. 
(8) Separating Gel Preparation -10.7 Gel, 0.4 M Tris, pH 8.8 
Distilled water 27.0 m1 
1.5 M Tris-HCl pH 8.8 (B) 20.0 m1 
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10% (w/v) SDS (sodium dodecyl sulfate, BDH) 0.8 ml 
Acrylamide : BIS (30%T, 2.67%C) (A) 26.7 ml 
10% ammonium persulfate (fresh) 0.2 ml 
TEMED 0.04 ml 
(9) Stacking Gel Preparation 4.8% Gel, 0.154 M Tris, pH 6.8, 1.5 mm thick 
stacking gels 
Distilled water 8.2 ml 
0.5 M Tris-HCl, pH 6. 8 (C) 5.0 ml 
10% (w/v) SDS (BDH) 0.2 ml 
Acrylamide : BIS (30%T, 2.7%C) (A) 2.6 ml 
10% ammonium persulfate (fresh) 0.2 ml 
TEMED 0.02 ml 
(10) Sample Buffer 
Distilled water 4.0 ml 
0.5 M Tris-HCl, pH 6.8 1.0 ml 
Glycerol (Sigma) 0.8 ml 
10% (w/v) SDS 1.6 ml 
2-Mercaptoethanol 0.4 ml 
0.05% (w/v) Bromophenol Blue 0.2 ml 
(11) Electrode Buffer, pH 8.3 
Tris base 
Glycine 
SDS 
12 g 
57.6 g 
4g 
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pH to 8.3 with 1 M HCl, bring to a imal volume of 2 litres with distilled water 
and dilute 1 : 1 with distilled water to run gel. 
(12) Protean Cell apparatus (Bio Rad). 
ll. 8.2 (b) Method 
(1) To prepare the monomer solutions (separating gel and stacking gel), all reagents 
except the ammonium persulfate and TEMED were combined and de-aerated 
under vacuum for 5-15 minutes. 
(2) To initiate polymerization, the ammonium persulfate and TEMED were added and 
swirled gently to mix. 
(3) The Protean Cell instructions were followed for casting the gel. 
(4) The separating gel was allowed to polymerize overnight. 
(5) The next day the stacking gel was allowed to polymerize for 30-45 minutes. 
( 6) Samples were diluted with sample buffer so as to achieve a imal protein 
concentration of 0.1 mg/ml for all samples and were added at 50 ~Ll I well. 
(7) The gel was run at 100 rnA per 1.5 mm slab gel (usually overnight). For two gels 
of the same thickness, the run was performed at 190 rnA overnight. 
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(8) Once the run was completed the power was turned off and the glass plates were 
removed from the chamber. 
(9) The sandwich clamps were removed and one plate was prodded out using a third 
spacer as a wedge. When one plate was removed distilled water from a squirt 
bottle was used to pry the gel from the second plate. 
(10) The gel was then placed in transfer buffer for Western blotting. 
ll. 8.3 Transfer Procedure (Western Blotting) 
n. 8.3 (a) Materials 
(1) Transfer Buffer 
Tris 
Glycine 
SDS 
*Methanol 
*Pure Grade Fisher A-4128 
1000 ml 
3.0 g 
14.4 g 
l.Og 
200 m1 
(2) Filter paper (Whatman #3), 24.0 em. 
(3) Nitrocellulose membrane (Schleicher & Schuell) pore size 0.45 p.M. 
( 4) Bio Rad Transfer system with cooling element. 
(5) Bio Rad Model250/2.5 power supply. 
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ll. 8.3 (b) Method 
(1) After completing the electrophoresis run, the gel was placed in transfer buffer 
to pre-equilibrate (pre-equilibration facilitates the removal of contaminating 
electrophoresis buffer salts and neutralization salts i.e. salts resulting from the 
denaturation of nucleic acids prior to transfer). 1.5 mm gel thickness requires 
about 60 minutes in transfer buffer at room temperature. 
(2) Transblot chambers were tilled with buffer. 
(3) Scotch-brite pads were soaked with transfer buffer. Whatman #3 tt.lter paper and 
nitrocellulose membranes were also soaked before using (gloves were used for the 
handling of nitrocellulose membranes). 
( 4) The nitrocellulose membrane was placed over the gel (gel and membrane were 
kept wet with transfer buffer) and all air bubbles were removed. 
(5) Water was run through the chilling unit and a stirring bar was placed inside the 
transfer cell to maintain uniform conductivity and temperature during 
electrophoretic transfer. 
(6) The transfer was performed at a constant current of 750 mA for 5-6 h. 
n. 8.4 lmmunoblotting 
Blotting was performed according to the method of Tow bin et al., 1979, with 
some modifications. 
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n. 8.4 (a) Materials 
(1) 3% BSA in PBS + 0.1% Tween. 
(2) 0.1% BSA in PBS + 0.1% Tween. 
(3) Horseradish peroxidase-conjugated rabbit-anti-mouse immunoglobulins (Dako 
Corp., 1:1000 dilution in (2)). 
( 4) Methanol. 
(5) Tris-HCl 50 mM, pH 7 .4; Trizma base (Tris hydrohymethyl aminomethane, 
Sigma), pH to 7.4 with HCI. 
(6) Hydrogen peroxide (Mallinckrodt). 
(7) 4-Chloronaphthol (Sigma). 
n. 8.4 (b) Method 
(1) After protein transfer from the gel to nitrocellulose membranes, blots were 
blocked by incubation in 3% BSA, 0.1% Tween 20 in PBS for 1 hr. 
(2) Blots were then incubated overnight in RAM immunoglobulins linked to HRP 
(100 ml of 1:1000 solution). 
(3) After washing the blots 3 times in PBS the enzyme reaction was developed by the 
addition of substrate (30 mg 4-chloronaphthol in 1.5 ml methanol + 50 J.tl50 mM 
Tris-HCl pH 7.4 + 25 J.tl hydrogen peroxide), for approximately 30 minutes 
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n. 9.0 Flow Cytometry 
Flow cytometry is a sophisticated analytical tool with current clinical applications 
in haematology and in cellular immunology (Melamed et al., 1990). It is also an 
analytical method of choice for classifying leukaemias and lymphomas. It involves the 
use of fluorescent cell markers to identify specific cells and cell components. The major 
advantages of flow cytometry are rapid cell processing, cell-by-cell analysis and the 
simultaneous evaluation of multiple markers (Stewart, 1992). The marker is detected as 
right -angle light scattering of an argon laser beam as it passes perpendicularly through 
a water jet containing labelled cells (Steen, 1990). 
n. 9.1 Internalization assays using flow cytometry 
The fluorochrome of choice for our internalization assays was fluorescein 
isothiocyanate which emits a green fluorescence. The advantage of using fluorescein in 
such assays had been established previously in the Oncology Research laboratory (Hopper 
et al., 1990; Osborne, 1992). 
Cell samples treated for flow cytometric processing were run in parallel with 
samples prepared for solubilization and analysis using SDS gels and Western blots for 
comparative purposes. In order to keep conditions identical for the two sets of samples, 
slight modifications were introduced in the incubation protocol for the samples to be used 
for Western blotting. Otherwise these samples were processed as described in section 
ll.8. The concentrations of all antibodies used for flow cytometry (fluoresceinated 11-
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285-14 and control ascites as well as anti-FITC antibody) had been determined previously 
(Osborne, 1992). The concentrations of antibodies used on Western blot samples were 
as previously determined (section ll.8). 
Flow cytometry was perfonned with a Becton -Dickinson FACStar analyzer with 
a 100 mW air-cooled argon laser at 488 nm. Power was at 40 mW for each test. Filters 
used were 560 DM reading green fluorescence at 530 +I- 30 nm. Acquisition was in list 
mode on 3.5" floppy disks. Fluorescence settings were adjusted to obtain suitable 
fluorescence histograms. 
n. 
(1) 
(2) 
(3) 
(4) 
9.1 (a) Materials 
LS174T, SKC01 and COL0320 cells cultured as described in section ll.l. 
Fluorescein labelled 11-285-14 antibody (see section ll.2.4). 
Control ascites labelled with FITC (Bethesda Research Laboratories, Life 
Technologies. Gaithersburg, Maryland) (see section ll.2.4). 
Anti-fluorescein antibody (H+L) (Anti - FITC) (# A-889, Lot # 68131, 
Molecular Probes Inc. 4849, Pitchford Ave. Eugene, OR) 
(5) Minimal essential medium (see section ll.l.O, Table 2) 
(6) Propidium iodide, (PI),(5 JLl) (Sigma) 
(7) Phosphate buffered saline (PBS) pH 7.2 (Oxoid, Unipath Ud, Basingstoke, 
Hampshire, England). 
(8) Pasteur pipettes. 
(9) Cotton wool. 
(10) Centrifuge (Beckman TJ-6 with TJ-R refrigeration unit). 
(11) FACStar analyzer. 
n. 9.1 (b) Method 
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In all cases, cell samples which were to be used for either Western blotting or 
FACS analysis were incubated with antibodies in parallel, under identical conditions. 
(1) LS174T, SKC01 and COL0320 cells were grown as described above and divided 
into samples of 1 x Hf cells (for Western blots) or 1 x 106 cells (for FACS 
analysis) each. 
(2) Samples were incubated with either FITC-conjugated (100 ~-tlfsample at 1 ~-tg/ml 
for the FACS analysis) or unconjugated (200 ~-tl at 1 mg/ml for Western Blots), 
11-285-14 antibody or control ascites for 30 minutes on ice in order to allow 
antibody uptake while inhibiting internalization. The antibody concentrations used 
were previously determined in appropriate titration assays. 
(3) Samples were then washed in 1 ml cold PBS x 2 by centrifugation at 560 x g , 
followed by the addition of 1 ml cell medium and incubation for 0, 30 and 90 
minutes at 37°C. Incubations were staggered to ensure ~imultaneous performance 
of the final step of the assay. 
(4) Following antibody incubations, cells were washed with PBS x 1. Samples which 
were to be used for Western blots were frozen at -70°C for later processing, while 
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samples destined for FACS analysis were processed immediately. 
(5) FACS Analysis 
Following incubation with the anti-CEA Mab, test samples were incubated with 
100 p.l of anti-FITC antibody (anti-fluorescein IgG, Molecular Probes) at a 1:20 
dilution in PBS, based on previous titration assays, whereas positive control 
samples were incubated with 100 p.l PBS for 30 minutes on ice. An additional cell 
sample which had not been previously exposed to antibody treatment was 
resuspended in 100 p.l control ascites (1 p.g/ml) and incubated similarly. 
(6) After the incubation, cells were centrifuged at 560 x g for 5 minutes and 
resuspended in 1 ml PBS. 
(7) 5 p.l propidium iodide (Sigma) were added to all samples 
(8) Samples were then f"Iltered in pasteur pipette/ nylon wool f"Ilters and were 
analyzed immediately using a Becton-Dickinson FACStar analyzer. 
ll. 9.2 Use of Flow cytometry to detect possible inhibition of clathrin-mediated 
anti-CEA Mab internalization 
A variety of biochemical approaches have been used to dissect the process of 
internalization (see section 1.6.5.c), however the ones that seem to affect clathrin 
assembly and invagination (i.e. the very f"rrst stages of the endocytic process), basically 
include three approaches: that of the use of potassium depletion coupled to cell bathing 
in hypertonic media, that of cytosol acidification, and f"mally simple exposure to 
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hypotonic media (Heuser, 1989; Heuser et al., 1989; Hansen et al., 1993). Since the fate 
of CEA-anti-CEA complexes has only been classified within the large group of reactions 
involved with antigen-antibody complex internalization, the studying of such surface 
phenomena seemed rather appropriate. In addition, the flow cytometric assay we 
currently employ is exclusively suited to studying surface phenomena alone. With the 
above in mind, we decided to make use of the method employing hypertonic medium to 
inhibit clathrin-mediated internalization, both due to its relative simplicity and minimal 
cell manipulation, as well as because in that case endocytic arrest should occur 
exclusively on or under the cell surface (further reasoning of this choice will be provided 
in section 4- Discussion). 
11-285-14 Mab was again FITC labelled (see section ll.2.4), and optimal concentrations 
were again determined in flow cytometric titration assays (and occasionally through the 
use of fluorescence microscopy). Optimal concentration was also re-established similarly 
for anti-FITC. SKC01 was the cell line of choice since it had previously shown the 
highest anti-CEA Mab uptake and was easily "manageable" experimentally. 
n. 
(1) 
(2) 
(3) 
9.2 (a) Materials 
SKCO 1 cells cultured as described in section ll.1. 
Fluorescein labelled 11-285-14 antibody (see section ll.2.4). 
Anti-Fluorescein Antibody Rabbit IgG (H + L) fraction 
(Anti- FITC) (# A-889, Lot# 5541-1, Molecular Probes Inc. 4849, Pitchford 
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Ave. Eugene, OR) 
(4) Minimal essential medium (see section ll.l.O, Table 2). 
(5) Sucrose, grade I crystalline, anhydrous, M. W. 342.3 
(Sigma F-9378, Lot 13F-0021). 
(6) 
(7) 
(8) 
(9) 
(10) 
(11) 
n. 
(1) 
(2) 
Minimal essential medium containing 0.45 M sucrose. 
Propidium iodide, (PI), (5 J.tl) (Sigma) 
Pasteur pipettes. 
Nylon wool. 
Centrifuge (Beckman TJ-6 with TJ-R refrigeration unit). 
FACStar analyzer. 
9.2 (b) Method 
SKCOl cells were grown as described before and left to incubate in medium for 
30 min. at 37°C prior to aliquoting. 
Cells were then separated in 1 x lif' cell aliquots and were washed once in 1 ml 
either minimal essential (regular) or regular medium containing 0.45 M sucrose 
(hypertonic), by centifuging at 560 x g for 5 min at 4°C. 
(3) Cells were then incubated in respective media (regular or hypertonic), for 30 min. 
at 37°C (treatment samples specified in the results section 3. 7). 
(4) Cells were centrifuged as before and 100 J.tl of 1 J.'g ml1 11-285-14-FITC in 
either regular or hypertonic medium was then added to the appropriate tubes, 
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while the remaining tubes received the same amount of regular or hypertonic 
medium. 
(5) All samples were washed as before twice in respective media. 
( 6) 200 JLl respective medium was then added in the tubes and the appropriate samples 
were incubated either at 37°C (to allow internalization), or on ice (to arrest 
internalization), for the pre-detmed time intervals (0 min., 30 min., and 90 min.). 
(7) All samples were again washed once in respective media. 
(8) 100 JLl anti-FITC at a dilution of 1:20 was added to the appropriate samples, with 
the remaining samples receiving an identical quantity of either regular or 
hypertonic medium as necessary. All samples were incubated on ice for 30 min. 
(9) All samples were centrifuged, the supernatant was discarded, and 1 ml of regular 
medium was added to all tubes followed by 5 JLl PI. 
(10) All samples were ttltered in pasteur pipette I nylon wool ttlters and were analyzed 
immediately using a Becton-Dickinson FACStar analyzer as before. 
n. 9.2 supplement: Alternative method 
(a) In order to examine the effect on cell Mab uptake, of the pre-treatment of the 
cells with hypertonic medium, steps (1) to (3) were omitted. The remainder of the assay 
proceeded as before. 
m. 1. 
CHAPTER ill 
RESULTS 
Initial Radioimmunoassay For The Estimation Of 
Internalized anti-CEA Antibody 
(employing a low pH glycine-HCl buffer) 
Until recently this assay had been the one most frequently employed for the 
determination of internalized antibody (see section IV.3 and Tsaltas et al., 1993). It 
relies on the assumption that a low pH environment is disruptive to previously formed, 
surface antigen-antibody complexes. Since internalized antibody is inaccessible to the low 
pH buffer, the residual activity lines in Figures 1.1, 1. 2 and 1. 3 (a, b) are assumed to 
represent internalized antibody. In our initial experiment (Figures 1.1. a, 1.1. b) 
incubation of cells at ooc (a temperature at which internalization is inhibited) (Figure 
1.1.a), resulted in moderate antibody uptake throughout the incubation intervals whereas 
residual (internalized) activity was below control levels, suggesting that antibody was not 
internalized. Conversely, when cells were incubated at 37°C, total antibody uptake 
increased significantly (more than doubled) and modest residual activity was observed 
(Figure 1.1.b). Furthermore the peak of "internalization" at 37°C, was reached after an 
incubation interval of 90 minutes at which point residual radioactivity represented 
approximately 30 percent of total antibody uptake. The same incubation period of 90 
minutes represented the highest point of antibody internalization in the case of samples 
incubated at ooc (Figure 1.1. a). The decrease in radioactivity values (indicating 
decreased antibody uptake beyond the 90 [0°C], or 120 [37°C], minute interval), which 
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was observed during this experiment, was not seen in a subsequent experiment (Figures 
1.2, a and b). Here, antibody uptake continued to increase throughout all the incubation 
intervals at both temperatures. Furthermore, although the uptake profile was similar to 
that of the previous experiment for the trrst 2 hours of incubation (uptake at OOC 
approximately half that of 37>C), there was a large increase in uptake at OOC during the 
last interval. Residual activity (representing internalized antibody) was observed at both 
temperatures and in general seemed to increase with higher antibody uptake. Residual 
activity in this case seemed to account for approximately 30-40% of total antibody 
throughout the incubation intervals at 37°C. Antibody uptake at 37°C was considerably 
lower for a subsequent assay (Figures 1.3 b), while residual activity was at control levels 
at both temperatures. It is not clear whether this was due to decay of the radiolabel (since 
this assay was performed approximately two weeks following radio labelling), or an 
uncharacteristically low antigen expression on the particular passage of LS174T cells. In 
this assay radiolabelled antibody was re-applied onto the 90 minute samples after glycine 
treatment in order to examine the possibility of its re-association with antigenic sites 
(Table 1. 4). The 90 minute samples were chosen since a high degree of residual activity 
relative to antibody uptake was generally observed at this time interval. Radioactivity 
counts of the treated samples increased to pre-glycine treatment levels following a second 
antibody treatment, suggesting that binding of Mab to CEA was not affected by treatment 
with the low pH buffer. The actual radioactivity readings obtained for the three assays 
discussed above, are incoq>Orated in Tables 1.1, 1.2 and 1.3 (a and b), which are 
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presented opposite the respective figures (following). Table 1.4 contains reassociation 
values for the anti-CEA Mab following exposure of Mab-treated cells to the glycine-HCl 
buffer and a second incubation with the same Mab, as described in the legend of this 
table. 
Figures 1.1, 1.2 and 1.3 (a and b) 
Radioimmunoassays investigating the kinetics of total uptake and residual (post 
glycine-HCl buffer treatment) binding of 11-285-14 Mab. 
2.5 x lOS LS174T cells/sample were incubated with 2 p,g ofl125 labelled 11-285-
14 Mab for the time intervals shown. Control samples (cell medium only) establish the 
background for non specific Mab adherence to plastic. 
(a) Incubations at 0°C. 
(b) Incubations at 37°C. 
The corresponding tables opposite each figure include the actual radioactivity readings 
in counts per minute ( cpm) for each sample (test sample values are the average of 
duplicate tube readings) 
I 
Table 1.1.a 
RIA employing Glycine-HCl to Estimate Mab Internalization(0°C); Experiment 1 
Means of duplicate tubes 
TIME(min) I SAMPLE I COUNT 1 I COUNT2 
5 1 28792 11250 
lc 12360 9727 
30 2 27568 9843 
60 3 33992 10852 
90 4 64186 26202 
4c 31063 25247 
120 5 51721 13288 
150 6 29846 8150 
6c 9275 6910 
Control sample tube : c 
COUNT 1 : radioactivity counts taken prior to treatment with the glycine-HCl buffer. 
COUNT 2 : counts taken after buffer treatment. 
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I TIME( min) 
5 
30 
60 
90 
120 
150 
Table 1.1.b 
RIA employing Glycine-HCl to Estimate 
Mab lnternalization(37C) 
Experiment 1 
Means of duplicate tubes 
I SAMPLE I COUNT 1 
7 29264 
7c 8987 
8 47811 
9 90788 
10 94687 
10c 9459 
11 121184 
12 98586 
12c 9128 
Control sample tube : c 
I COUNT2 
13500 
11264 
13766 
24566 
27846 
9081 
22278 
22602 
8113 
COUNT 1 : radioactivity counts taken prior to treatment with the glycine-HCl buffer. 
COUNT 2 : counts taken after buffer treatment. 
I 
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Table 1.2.a 
RIA employing Glycine-HCl to Estimate Mab lnternalization(0°C); Experiment 2 
Means of duplicate tubes 
TIME( min) SAMPLE COUNT 1 COUNT2 
5 1 19173 17428 
1c 23844 14390 
30 3 30398 26070 
60 5 36352 16940 
90 7 54104 26707 
7c 11637 11091 
120 9 42922 22458 
150 11 118318 45498 
11c 12214 10066 
Control sample tube: c 
COUNT 1 : radioactivity counts taken prior to treatment with the glycine-HCl buffer 
COUNT 2 : counts taken after buffer treatment. 
. 
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TIME( min) 
5 
30 
60 
90 
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Table 1.2.b 
RIA employing Glycine-HCl to Estimate 
Mab lnternalization(3T'C) 
Experiment 2 
Means of duplicate tubes 
SAMPLE COUNT 1 
2 64759 
2c 54592 
4 76004 
6 83370 
8 88353 
8c 25049 
10 110582 
12 150798 
12c 19928 
Test sample tubes : a, b 
Control sample tube : c 
COUNT2 
38633 
27142 
34800 
35587 
39448 
22408 
51762 
56525 
17143 
COUNT 1 : radioactivity counts taken prior to treatment with the glycine-HCl buffer. 
COUNT 2 : counts taken after buffer treatment. 
TIME( min) 
5 
30 
60 
90 
120 
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Table 1.2.b 
RIA employing Glycine-HCl to Estimate 
Mab Internalization(3'rC) 
Experiment 2 
Means of duplicate tubes 
SAMPLE COUNT 1 
2 64759 
2c 54592 
4 76004 
6 83370 
8 88353 
8c 25049 
10 110582 
12 150798 
12c 19928 
Test sample tubes : a,b 
Control sample tube : c 
COUNT2 
38633 
27142 
34800 
35587 
39448 
22408 
51762 
56525 
17143 
COUNT 1 : radioactivity counts taken prior to treatment with the glycine-HCl buffer. 
COUNT 2 : counts taken after buffer treatment. 
Table 1.3.a 
RIA employing Glycine-HCl to &timate Mab Internalization(O"C); Experiment 3 
Means of duplicate tubes 
I TIME(min) I SAMPLE I COUNT 1 I COUNT2 
5 1 38129 25870 
1c 17763 17712 
30 3 41256 24177 
60 5 45107 26722 
90 7 42120 24090 
7c 20292 17074 
120 9 42162 23410 
150 11 35208 20402 
11c 19979 15704 
Control sample tube : c 
COUNT 1 : radioactivity counts taken prior to treatment with the 
glycine-HCl buffer. 
COUNT 2 : counts taken after buffer treatment. 
Table 1.4.a 
Effect of second Mab incubation after glycine treatment 
90 minute sample (OOC) 
Tube Numbers Means of counts 
7a, 7b 37920 
7c 26384 
I 
Immediately following the second radioactivity count 100J.Ll cell medium with 10J.Ll 
iodinated Mab were added to indicated samples and incubated at OOC for 30 minutes. 
Cells were then centrifuged, washed x 3 with 1 % fetal calf serum in PBS and 
counted. Counts from this table should be correlated to respective counts in table 
1.3.a (90 min samples). 
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Table 1.3.b 
RIA employing Glycine-HCl to Estimate Mab Internalization(37'C) 
Experiment 3 
Means of duplicate tubes 
I TIME( min) I SAMPLE I COUNT 1 I COUNT2 I 
5 2 25068 16231 
2c 36682 31003 
30 4 33821 19616 
60 6 46968 27116 
90 8 37378 20674 
8c 11011 9262 
120 10 45760 25282 
150 12 41136 22210 
12c 13207 11718 
Control sample tubes: c 
COUNT 1 : radioactivity counts taken prior to treatment with the glycine-
HCl buffer. 
COUNT 2 : counts taken after buffer treatment. 
Table 1.4.b 
Effect of second Mab incubation after glycine treatment 
90 minute sample (37°C) 
Tube Numbers Means of counts 
Sa, 8b 30613 
8c 15974 
Immediately following the second radioactivity count 100J.tl cell medium with 10J.tl 
iodinated Mab were added to indicated samples and incubated at O"C for 30 minutes. 
Cells were then centrifuged, washed x 3 with 1 % fetal calf serum in PBS and 
counted. Counts from this table should be correlated to respective counts in table 
1.3.b (90 min samples). 
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m. 2. Investigation of the effectiveness of the Glycine-HCI Buffer in 
dissociating Antigen-Antibody Bonds 
160 
Preliminary results of .radioimmunoassays employing the low pH glycine-HCl 
buffer to dissociate antigen-antibody bonds of surface complexes (section m.l), raised 
some doubt as to the ability of this buffer to completely dissociate such bonds. For 
example, although assays 1.1 and 1.2 both showed a low to moderate level of residual 
activity as a percentage of total antibody uptake at 37'C, assay 1.2 also yielded low 
residual activity (due to internalization) at OOC, a temperature which inhibits active 
internalization processes. The relatively uncomplicated nature of this assay and the 
fact that no other major inter-assay inconsistencies were observed, suggested the 
possibility of inconsistencies in the dissociating effect of the buffer, resulting in non-
dissociated, surface-bound antibody being mistakenly taken as internalized antibody, 
leading to inaccurate internalization estimates. Therefore, before expanding this assay 
to study various questions of Mab internalization in our model system it was 
necessary to accurately establish the effectiveness of this buffer in dissociating 
antigen-antibody bonds. To that end, a number of immunoperoxidase and EUSA 
assays were performed using both fixed and live cells. 
m. 2.1 Immunoperoxidase Assays Assessing the Effect of the Glycine-HCI 
buffer on f"o:ed cells 
Both direct and indirect immunoperoxidase assays were performed employing 
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the anti-CEA Mab conjugated to HRP, or unconjugated anti-CEA Mab followed by a 
second incubation with RAM-HRP. There was no indication of an antigen-antibody 
dissociation effect on LS174T and SKC01 cells treated with 11-285-14 or 11-285-14-
HRP antibodies and exposed to a 20 min incubation with the buffer as shown in Table 
2.1 (summarized data). 
Table 2.1 
Summary of the Effect of Glycine-HCl buffer 
on Ag-Ab bonds on irxed cells by Immunoperoxidase 
%level of staining 
CELLUNE ANTIBODY Pre-buffer Post-buffer 
Treatment Treatment 
LS174T 11-285-14 20 20 
11-285-14-HRP 20 20 
SKC01 11-285-14 
I 
90 
II 
90 
I 11-285-14-HRP 95 75 
Immunoperoxidase assay results (105 cells/slide). Antibodies used at 1 J.'g/slide 
(optimal antibody concentration determined in previous saturation assays). Control ascites 
and/or Ag8 or Ag8-HRP were used as controls at the same concentrations and produced 
no staining. Incubation time for the glycine-HCl buffer was 20 min at RT. Brown-
stained cells counted in 3 fields (200 cells per field). 
A reduction in staining (- 20%) was observed only in the case of the conjugated 
antibody on the SKC01 cells. The possibility of this effect being due to the dissociation 
of HRP from Mab rather than antigen-antibody bond dissociation, was then further 
investigated using antibody coated plates in an ELISA (see section m.2.2). 
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m. 2.2 ELISAs Assessing the Effect of the Glycine-HCI buffer 
EUSAs were designed to investigate the dissociating effect of this buffer on ftxed 
and live cells derived from human cancer cell lines, as well as its dissociating effect on 
Mab-HRP bonds and antigen-antibody bonds when purified antigen is used. Both assay 
results as well as summaries of averaged data are provided where appropriate. 
m. 2.2.a ELISAs on Fixed Cells 
In order to complement the results obtained by the immunoperoxidase method, 
three CEA-expressing cell lines were tested in a number of EUSAs employing methanol-
fiXed cells {Tables 2.2.a.1, 2.2.a.2, 2.2.a.3, 2.2.a.4 and 2.2.a.5). The dissociating 
effect of glycine-HCl was correlated to a reduction in absorbance readings following 
treatment with this buffer. To test the possibility of reduction in absorbance readings due 
to cells washing off, 11-285-14 Mab was reapplied on a test group after treatment with 
the glycine-HCl buffer. The derivation ofMab reassociation potential was also attempted 
using this group. The additional non-specific sticking factor due to the second antibody 
incubation, was eventually taken into consideration by including a control group with 
secondary antibody only (RAM-HRP). 
Legend for table 2.2.a.l and 2.2.a.2 
All plates were coated with 2.5 x lOS cells mi-1 of each cell line and the antibody 
was detected by RAM-HRP as described in section ll.5.3. Optimal Mab concentration 
was detennined in previous saturation assays (not shown). A general control group 
testing non-specific sticking of RAM-HRP to the wells was subtracted from all values. 
All O.D. readings represent the average of five wells. Groups included in Table 2.2.a.1 
are as follows: 
Set 1: Total Mab (2 l'glwell) binding to cells 
Set 2: Mab (2 l'glwell), followed by a 20 minute incubation with glycine-HCI; 
measures effect of the buffer on Ag-Mab bonds 
Set 3: Mab (at 2 l'glwell) followed by a 20 minute incubation with glycine-HCI, followed 
by a second incubation with Mab (2 l'glwell) 
%Res: % residual binding = (Set 2 I Set 1) x 100% 
% Diss:% Ag-Mab bond dissociation = 100- %Residual 
% FB : % Final Binding (Mab binding after incubation with glycine-HCI and second 
Mab) = (Set 3 I Set 1) x 100% ; measures whether original Mab binding levels can be 
achieved again 
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Table 2.2.a.l 
Effect of glycine-HCI on Ag-Mab bond dissociation and reassociation on riXed 
cells at room temperature (RT) 
l~y I Cell line I Set I Set I Set I % I % 1.: I 1 2 3 Res Diss 
377 LS174T .192 .074 38.5 61.5 
SKC01 .455 .262 57.6 42.4 
BENN .180 .078 43.3 56.7 
379 LS174T .139 .061 43.9 56.1 
SKC01 .345 .184 53.3 46.7 
BENN .117 .065 55.6 44.4 
380 LS174T .321 .047 14.6 85.4 
SKC01 .339 .114 33.6 66.4 
BENN .319 .049 15.4 84.6 
386 LS174T .344 .343 .365 99.7 0.3 106.1 
SKC01 .408 .334 .339 81.9 18.1 83.1 
BENN .107 .072 .152 67.3 32.7 142 
387 LS174T .142 .092 .170 64.8 35.2 119.7 
SKC01 .244 .142 .166 58.2 41.8 109 
BENN .064 .03 .088 46.9 53.1 137.5 
388 LS174T .147 .097 .222 66 34 151 
SKC01 .458 .395 .470 86 14 103 
BENN .114 .088 .172 77.2 22.8 151 
499 LS174T .074 .037 .103 50 50 139.2 
SKC01 .291 .131 .366 45 55 125.8 
BENN .091 .044 .188 48.3 51.7 206.6 
l~y I 
382 
386 
387 
388 
499 
Table 2.2.a.2 
Effect of glycine-HCI on Ag-Mab bond dissociation and 
reassociation on f"o:ed cells at 3TC 
Cell line I Set I Set I Set I % I % 1 2 3 Res Diss 
LS174T .402 .344 85.6 14.4 
SKC01 .441 .398 90.2 9.8 
BENN .273 .327 119.8 -
LS174T .315 .225 .375 71.4 28.6 
SKC01 .376 .205 .271 54.5 45.5 
BENN .103 .054 .144 52.4 47.6 
LS174T .167 .061 .172 36.5 63.5 
SKC01 .308 .114 .234 37 63 
BENN .054 .036 .108 66.7 33.3 
LS174T .114 .058 .153 50.9 49.1 
SKC01 .435 .306 .433 70.3 29.7 
BENN .114 .092 .175 80.7 19.3 
LS174T .056 .029 .173 51.8 48.2 
SKC01 .165 .058 .291 35.1 64.9 
BENN .259 .217 .424 83.8 16.2 
Set 1: Total Mab (2 J.tglwell) binding to cells 
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I~ I 
119 
72.1 
140 
103 
76 
200 
134.2 
99.5 
153.5 
308.9 
176.4 
163.7 
Set 2: Mab (2 J.tglwell), followed by a 20 minute incubation with glycine-HCI; measures 
effect of the buffer on Ag-Mab bonds 
Set 3: Mab (at 2 J.tglwell) followed by a 20 minute incubation with glycine-HCI, followed 
by a second incubation with Mab (2 J.tglwell) 
% Res: % residual binding = (Set 2 I Set 1) x 100% 
% Diss:% Ag-Mab bond dissociation = 100- % Residual 
% FB :% Final Binding (Mab binding after incubation with glycine-HCI and second 
Mab) = (Set 3 I Set 1) x 100% ; measures whether original Mab binding levels can be 
achieved again 
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Because of the greater than 100% values obtained for FB in assays 386, 387 and 
388 (which could not be attributed to initial incomplete saturation of antigenic sites, as 
the antibody was used at a saturating concentration determined on previous titration 
experiments), an additional control group (Set 4), was added to monitor the effect of the 
second incubation with Mab without any incubation in glycine buffer (i.e. cells + Mab 
+ Mab + RAM-HRP). This group would in effect provide the "non-specific" binding 
factor caused by a second incubation. A correction factor was then derived by dividing 
Set 1 values by Set 4 values (since Set 4 would now actually represent total Mab binding) 
and actual final binding values (% FBc) would be calculated by multiplying previous 
Final Binding values by this correction factor. 
Corrected estimates are given in Tables 2.2.a.3 and 2.2.a.4. 
Table 2.2.a.3 
Corrected values for the estimation of Mab reassociation 
(RT) 
I Assay# I Cell line I Set 1 I Set 4 I %FB 
499 LS174T .074 .221 139.2 
SKC01 .291 .456 125.8 
BENN .091 .296 206.6 
Correction factor (CF) = (Set 1 I Set 4) 
%Corrected Final Binding(% FBc) = % FB x CF 
I CF 
.335 
.638 
.307 
I %FBc I 
46.6 
80.3 
63.4 
Table 2.2.a.4 
Corrected values for the estimation of Mab reassociation 
(37°C) 
I Assay# I Cell line I Set 1 I Set 4 I %FB 
499 LS174T .056 .216 308.9 
SKC01 .165 .372 176.4 
BENN .259 .493 163.7 
Correction factor (CF) = (Set 1 I Set 4) 
%Corrected Final Binding(% FBe) = % FB x CF 
I CF 
.259 
.443 
.525 
167 
I %FBe I 
80 
78.2 
86 
Note: Final Binding values reflect derivations based on the actual absorbance at 405 run 
(amount of Mab) detected after incubation with buffer and antibody, and not the 
additional absorbance at 405 run (amount of Mab) detected after the second incubation. 
If the corrected Final Binding values are now compared to the amount of residual 
absorbance (Mab attached after glycine-HCl treatment), any additional Mab that may 
have been attached after the second incubation (i.e. a reassociation value), can be 
estimated by subtracting Residual binding values from corrected Final Binding values. 
Mab reassociation estimates derived in this manner are shown in Table 2.2.a.5. 
Table 2.2.a.S 
Estimation of reassociation of Mab after glycine-HCl treatment 
and a second incubation with Mab 
Cell Line RT 3'rC 
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%Res FBe %Reas %Res FBC %Reas 
LS174T 50 46.6 nil 51.8 80 28.2 
SKC01 55 80.3 25.3 35.1 78.2 43.1 
BENN 51.7 63.4 11.7 83.8 86 2.2 
% Reas = % Reassociation = FBc: - %Res 
The perfonnance of the glycine-HCl buffer in dissociating Ag-Mab bonds is 
summarized in Table 2.2.a.6, which contains the average dissociation values of the 
previously tabulated assays. Reassociation values are provided for assay #499. 
Table 2.2.a.6 
Summary of the effect of Glycine-HCl buffer on 
11-285-14-treated methanol flxed cells* 
%Diss %Reas 
CELL LINE RT 3'rC RT 3'rC 
LS174T 46.1 (7) 40.8 (5) nil 28.2 
SKC01 40.6 (7) 42.6 (5) 25.3 43.1 
BENN 49.4 (7) 23.3 (5) 11.7 2.2 
*Numbers in parentheses indicate number of repeat assays. Reassociation estimates 
were derived solely from assay #499 due to lack of correction factors for the other 
assays. As before %Diss (% dissociation) indicates % reduction in absorbance 
readings after buffer treatment whereas %Reas (% reassociation) indicates relative 
increase in absorbance readings after buffer treatment and second antibody incubation. 
169 
If the decrease in absorbance readings is correlated to dissociation of Ag-Ab 
complexes due to the effect of the buffer it is obvious that the glycine-HCl buffer 
causes, on average, dissociation of less than 50% of Ag-Ab bonds in all three lines. 
Furthermore, an increase in temperature from RT to 37oc does not seem to affect Ag-
Ab bond dissociation to any appreciable level (other than causing a decrease in the 
BENN cell line). Although values after a second incubation with antibody did not 
usually return to their original levels, there was a general increase in staining 
indicating some degree of reassociation with CEA expressed on the cell lines. 
ill. 2.2.b ELISAs on Live Cells 
Since the characteristics of antibody uptake and dissociation from cell surface 
antigens may be significantly affected by itxing those cells, assays investigating the 
dissociating capacity of the glycine buffer were also performed on live cells. During 
these assays we employed both HRP-conjugated anti-CEA Mab (direct CELIS A) and 
unconjugated anti-CEA detected by commercially available RAM-HRP (indirect 
CELIS A). The results obtained with live cells using the same cell lines as before are 
shown in Tables 2.2.b.l and 2.2.b.2. 
Assay# 
468 
*469 
472 
I 522 
Table 2.2.b.1 
Effect of glycine-HCI buffer on Ag-Mab bonds 
on Live Cells at RT 
Cell line Setl Set2 %Diss Set3 Set4 
(unc) 
LS174T .062 .062 0 .072 .057 
SKCOl .355 .396 0 .691 .287 
SKCOl .453 .545 0 1.267 .596 
BENN .162 .085 47.5 .389 .115 
LS174T .274 .118 57 .286 .104 
LS174T .293 .105 64.2 .278 .112 
SKCOl .499 .350 29.9 .397 .124 
1:::1 1.108 
.207 
1.143 
.116 1: 1: 1: 
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%Diss 
(con) 
20.8 
59.8 
53 
70.4 
64 
59.5 
68.8 
1: I 
A control group consisting of cells incubated with PBS followed by RAM-HRP 
was averaged and subtracted from all other groups. Most assays also included an 
additional negative control which used the non-CEA specific Ab Ag8. As with test 
groups this antibody was also treated with the glycine-HCl buffer. In all assays values 
for these groups were at the levels of general (RAM-HRP) control values and were not 
included in the calculations. 
Cell concentration: 5 x lOS cells ml1 
Mab concentration : 5 p.g mi-1 except for assay #469(*) where Mab concentration was 
10 p.g ml1 (determined in previous saturation assays) 
Setl : Tota111-285-14 Mab binding to cell line 
Set2 : Residual 11-285-14 Mab binding after Glycine-HCl treatment 
%Diss(unc): (% dissociation of unconjugated Mab) 
= 100- ((Set2 I Setl) * 100 %) 
Set3 : Totalll-285-14-HRP Mab binding to cells 
Set4 : Residual11-285-14-HRP Mab binding 
%Diss(con): (% dissociation of HRP conjugated Mab) 
= 100 - ((Set4 I Set3) * 100 %) 
ND :Not Done 
Assay# 
*469 
472 
522 
Table 2.2.b.2 
Effect of glycine-HCI buffer on Ag-Mab bonds 
on Live Cells at 3TC 
Cell line Setl Set2 %Diss Set3 
(unc) 
SKC01 .719 .475 34.4 1.142 
BENN .227 .211 7 .506 
LS174T .299 .127 57.5 .399 
LS174T .391 .154 60.5 .263 
SKC01 .499 .350 29.9 .397 
SKC01 .334 .299 10.5 ND 
BENN .242 .141 41.7 ND 
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Set4 %Diss 
(con) 
.596 52.2 
.164 67.6 
.076 80.9 
.100 62.1 
.124 63.8 
ND ND 
ND ND 
A control group consisting of cells incubated with PBS followed by RAM-HRP 
was averaged and subtracted from all other groups. Most assays also included an 
additional negative control which used the non-CEA specific Ab Ag8. As with test 
groups this antibody was also treated with the glycine-HCl buffer. In all assays values 
for these groups were at the levels of general (RAM-HRP) control values and were not 
included in the calculations. 
Cell concentration : 5 x 1 OS cells ml-1 
Mab concentration : 5 p.g mi-1 except for assay #469(*) where the Mab concentration 
was doubled 
Setl : Tota111-285-14 Mab binding to cell line 
Set2 : Residual 11-285-14 Mab binding after Glycine-HCl treatment 
%Diss(unc): (% dissociation of unconjugated Mab) 
= 100- ((Set2 I Setl) * 100 %) 
Set3 : Tota111-285-14-HRP Mab binding to cells 
Set4 : Residual11-285-14-HRP Mab binding 
%Diss(con): (% dissociation of HRP conjugated Mab) 
= 100 - ((Set4 I Set3) * 100 %) 
ND :Not Done 
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A summary of the data given in Tables 2.2.b.1 and 2.2.b.2 appears in the following 
Table (2.2.b.3). 
Table 2.2.b.3 
Effect of the Glycine-HCI buffer on antigen-antibody 
bonds using live cells 
% reduction in absorbance readings 
Antibody LS174T SKCOl BENN 
11-285-14 RT 40.4 (3) 7.5 (4) 45.8 (2) 
3,.-C 59 (2) 24.9 (3) 24.4 (2) 
11-285-14 RT 48.1 (3) 60.5 (3) 70.4 (1) 
IHRP 3,.-C 71.5 (2) 58 (2) 67.6 (1) 
Percent (%) reduction in absorbance readings corresponds to % dissociation and 
numbers in parentheses determine the number of assays performed (numbers indicate 
mean values). 
There was inter-assay variability due to the nature of the assay, but low 
background and Ag8 control values as well as low variability within test groups minimize 
the possibility of loss of cells, or major artifacts contributing to the results. As was the 
case with the f"txed cell assays, the dissociating effect of the buffer, as reflected in a 
decrease in absorbance readings, varied from no dissociation to a maximum of 
approximately 60% dissociation in all cell lines tested and at both temperatures, in the 
case of the indirect assay using Mab and secondary Ab (RAM-HRP) (%Diss(unc), Tables 
2.2.b.1 and 2.2.b.2). When HRP conjugated Mabs were used (direct CELISA), there 
was a stronger dissociating effect (up to 80% dissociation). There did not seem to be any 
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significant difference in Mab-Ag bond dissociation for the two temperatures tested. The 
possibility of the increase in dissociation when HRP-conjugated antibodies were used 
being due to a buffer-mediated disruption of Ab-HRP bonds was then investigated 
(following section). 
m. 2.2.c Effect of the glycine-HCI buffer on Mab-IIRP bonds 
In order to examine a possible disruption of the Ab-HRP bond due to glycine-
HCl, direct EUSAs were performed employing both laboratory HRP-conjugated 
antibodies (11-285-14, Ag8) and the commercially available RAM-HRP. The 
concentration of antibodies used was again determined in preliminary titration assays. 
Assay results are provided again as absorbance readings in Tables 2.2.c.l and 2.2.c.2 
and summarized results are given in Table 2.2.c.3. 
All plates were coated with 100 p.l of 1 p.g mt1 antibody per well. % 
Dissociation was derived as before. 
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Table 2.2.c.1 
Effect of the glycine-HCl buffer on Ab-HRP bonds (RT) 
Assay# Antibody Pre-buffer Post-buffer %Diss 
treatment treatment 
474 11-285-HRP 1.989 1.692 15 
Ag8-HRP 1.218 .686 43.7 
RAM-HRP .468 .336 28.2 
476 (Sigma 11-285-HRP 2.612 2.209 15.4 
glycine) Ag8-HRP 1.903 1.299 31.7 
RAM-HRP 1.333 1.048 21.4 
476 (Aldrich 11-285-HRP 2.447 2.066 15.6 
glycine) Ag8-HRP 1.913 .985 48.5 
RAM-HRP 1.324 .986 25.5 
Table 2.2.c.2 
Effect of the glycine-HCl buffer on Ab-HRP bonds (3'rC) 
Assay# Antibody Pre-buffer Post-buffer % Diss 
treatment treatment 
474 11-285-HRP 1.686 .670 60.3 
Ag8-HRP 1.108 .183 83.5 
RAM-HRP .504 .214 57.5 
476 (Sigma 11-285-HRP 2.492 1.389 44.3 
glycine) Ag8-HRP 1.894 .511 73 
RAM-HRP 1.374 .660 52 
476 (Aldrich 11-285-HRP 2.477 1.039 58 
glycine) 
Ag8-HRP 1.881 .290 84.6 
RAM-HRP 1.474 .663 45 
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A summary of the above assays examining the effect of the buffer on antibodies 
conjugated to HRP (a combination of Tables 2.2.c.1 and 2.2.c.2) is presented in the 
following table (Table 2.2.c.3). 
Table 2.2.c.3 
Effect of Glycine-HCI on HRP conjugated antibodies 
Antibodies % reduction in absorbance readings 
RT 3T'C 
11-285-14-HRP 15.3 54.2 
Ag8-HRP 41.3 80.4 
RAM-HRP 25 51.5 
Numbers indicate the mean of three assays 
The two antibodies which were conjugated to HRP in our laboratory as well as 
the commercially available RAM-HRP were used to initially coat EUSA plates. In all 
three cases there was a reduction in absorbance readings after incubation with the 
Glycine-HCl buffer, possibly indicating a dissociating effect on the bonds between the 
antibodies and HRP. This dissociating effect was consistently more prominent at higher 
temperatures (37°C) for all Ab-HRP conjugates. Furthermore, there seemed to be 
differences in Ab-HRP bond stability among the conjugates with Ag8-HRP being the 
most unstable (highest level of dissociation). 
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m. 2.2.d ELISAs on Purified CEA 
In order to investigate the possibility of the cellular environment hindering the action of 
the buffer an EUSA assay was performed on plates coated with purified CEA. 
Table 2.2.d {ELISA #528) 
Effect of Glycine-HCI on purified CEA-Antibody bonds 
I Treatment I RT I 3'rC I 
11 .758 .594 
11 +Buffer Nil (-ve) Nil (-ve) 
11 + 11 .647 .452 
11 + Buffer + 11 .472 .246 
% Dissociation 100 100 
% Reassociation 73 54 
Plates coated with 100 J.tl of CEA at 2.5 1-'g ml1 and were subsequently incubated 
for two hours with anti-CEA Mab or non-specific antibody at 2 J.tg mi-1 (37°C). Second 
incubation with Mab was performed for 2 hours at 37°C. Values represent absorbance 
readings after subtraction of control values (controls: CEA + RAM-HRP and CEA + 
Ag8). % dissociation and reassociation derived as before. 
11 = 11-285-14 Mab; Buffer = Glycine-HCl buffer, pH 2.8. 
In this case we found that glycine-HCl completely dissociated antigen-antibody 
bonds (absorbance readings after buffer treatment were lower than control readings). 
There seemed to have been complete saturation of antigenic sites after the rrrst incubation 
with Mab, since the subsequent incubation did not result in increased readings. A 
moderate to high level of antibody reassociation with antigenic sites after buffer treatment 
was again observed suggesting minimal to moderate disruption of antigenic sites by this 
buffer. In this assay the same procedure was followed using the non-CEA specific Ag8 
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antibody as an additional specificity control. In this case all absorbance readings were 
at background levels, thus ensuring the specificity of binding for the anti-CEA Mab. 
Briefly, EUSA assays perfonned on both tiXed and live cells indicate that the 
average dissociating effect of this buffer on Ag-Ab bonds ranges from about 23% to 49% 
for ti.Xed cells and from 8% to 59% dissociation for live cells in the three cell lines 
tested. Generally, comparable levels of dissociation were achieved at both RT and 37°C. 
Dissociation levels were slightly higher (48-72%) where direct assays were employed 
(antibody directly linked to HRP), but subsequent testing showed that the additional 
dissociation could possibly be accounted for by the disruption of the enzyme-antibody 
linkage of the 11-285-14-HRP, Ag8-HRP and RAM-HRP conjugates. The possibility that 
the addition of glycine-HCl could result in reduced absorbance readings due to its 
stripping the antigen or antibody coat off the plate, was also examined using CEA or 11-
285-14 coated plates (data not shown). It was found that, in this case, the addition of 
glycine-HCl buffer did not lead to any decrease in absorbance readings relative to non-
buffer treated wells. 
A general summary of EUSA assay results depicting % reduction in 
immunostaining on both ti.Xed and live cells after Glycine-HCl buffer treatment is 
provided in Table 2.2.e. As before, dissociation of antigen-antibody bonds due to the 
effect of this buffer is considered to be directly related to reduction in absorbance 
readings. 
I Ab 
I 
11-285 
11-285 
11-285-
HRP 
m. 3. 
Table 2.2.e 
Summary of% dissociating effect of glycine-HCl buffer 
on rtxed and live cells (rounded assay averages) 
I Temp I LS174T I SKC01 I BENN I 
I 
RT 
I 
46 
I 
41 
I 
49 
I 3TC 41 43 23 
RT 40 8 46 
3TC 59 25 24 
RT 48 61 70 
3TC 72 58 68 
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CELLS I 
FIXED 
I 
LIVE 
Estimation of Antibody Internalization Employing an Indirect 
Radioimmunoassay 
Given the fact that, in our hands, the glycine-HCl buffer did not seem to have the 
capacity to fully dissociate Ag-Ab bonds, it became clear that the radioimmunoassay 
employed thus far would not provide accurate results. Consequently, a second type of 
RIA was employed in order to indirectly detect the amount of internalized antibody for 
similar incubation intervals as the ones tested above. Results of two such assays appear 
in figures 3.1 and 3.2, respectively. Controls consisted of cell samples incubated with 
the Ag8 antibody which is not specific for CEA. An extra control group (total bound 
radioactivity at 4°C) was employed in order to test for any possible effect of low 
temperature on antibody uptake, but was not used in deriving the amount of internalized 
antibody. In both the cases of test and control antibody, uptake (groups measuring total 
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radioactivity), seemed to plateau after the frrst 30-90 minutes of incubation, remaining 
relatively steady throughout the course of the experiment. Conversely, the group 
measuring surface activity only, showed a downward trend reflecting an increasing 
amount of antibody or Ag-Ab complexes being internalized. A comparison of 
internalization by test (11-285-14) and control (Ag8) immunoglobulins is depicted in 
figures 3.1.b and 3.2.b. 
Figure 3.1. Kinetics of total and surface uptake of 11-285-14 Mab (test) or Ag8 Ab 
(control), using the double labelling assay (experiment 1). 2.5 x lOS LS174T 
cells/sample were incubated with 2 p.g of 11-285-14 or Ag8 antibody at 37'C for 30 
minutes. 1 p.g 1~-labelled RAM was immediately added to all samples used in the 
assessment of total binding, whereas the same concentration of secondary antibody was 
added to the samples used in the assessment of surface binding at the beginning of the 
prespecified time intetvals. Figures 3.1 (a,b) and 3.2 (a,b) correspond to two separate 
assays. 
Figure 3.1.a. Total and surface binding of 11-285-14(solid lines) and Ag8 (dotted lines) 
antibodies, depicting the loss of 11-285-14 antibody from the cell surface as it becomes 
internalized by LS 17 4T cells. 
4C Ttotal = Total binding of test Ab (4°C) 
4C Ctotal = Total binding of control Ab (4°C) 
37C Ttotal = Total binding of test Ab (37°C) 
37C Ctotal = Total binding of control Ab (37°C) 
37C Tsurf = Surface binding of test Ab (37°C) 
37C Csurf = Surface binding of control Ab (37°C) 
Figure 3.1.b. Graphic representation of the kinetics of internalization of 11-285-14 Mab 
or Ag8 Ab by I..Sl74T cells (total activity-surface bound activity). 
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Figure 3.2. Kinetics of total and surface uptake of 11-285-14 Mab (test) or Ag8 Ab 
(control), using the double labelling assay (experiment 2). 2.5 x lOS LS174T 
cells/sample were incubated with 2 p.g of 11-285-14 or Ag8 antibody at 37>C for 30 
minutes. 1 p.g 125j:-1abelled RAM was immediately added to all samples used in the 
assessment of total binding, whereas the same concentration of secondary antibody was 
added to the samples used in the assessment of surface binding at the beginning of the 
prespecified time intetVals. 
Figure 3.2.a. Total and surface binding of 11-285-14(solid lines) and Ag8 (dotted lines) 
antibodies, depicting the loss of 11-285-14 antibody from the cell surface as it becomes 
internalized by LS174T cells. 
4C Ttotal = Total binding of test Ab (4°C) 
4C Ctotal = Total binding of control Ab (4°C) 
37C Ttotal = Total binding of test Ab (37°C) 
37C Ctotal = Total binding of control Ab (37°C) 
37C Tsurf = Surface binding of test Ab (37°C) 
37C Csurf = Surface binding of control Ab (37°C) 
Figure 3.2.b. Graphic representation of the kinetics of internalization of 11-285-14 Mab 
or Ag8 Abby LS174T cells (total activity-surface bound activity). 
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m. 4. Detection of Internalized anti-CEA antibody using Electron Microscopy 
Figures 4.1, 4.2, 4.3 (a and b) depict test and negative control samples of SKC01 
cells incubated with CEA-specific Mab-HRP conjugate (a) or control Ag8-HRP conjugate 
(b). Darker areas indicate accumulation of the CEA specific conjugate both around the 
cell surface and in lysosomal vacuoles in the interior of the cell. In contrast, no staining 
is evident either on the cell surface or in the cell interior in the case of negative controls 
(b). 
Figure 4: General legend. md results depicting internalization ofHRP labelled 11-285-
14 Mab (a), but not ofHRP labelled Ag8 Ab (b) by SKC01 human cancer cells (4 x Hf 
cells mi-1), following a two hour incubation period at 37°C. 
4.1.a,b Ab-HRP Mab concentration: 25 p.g mi-1 (2.5 p.g/well) 
4.2.a,b Ab-HRP Mab concentration: 50 p.g mi-1 (5 p.g/well) 
4.3.a,b Ab-HRP Mab concentration: 100 p.g ml1 (10 p.g/well) 
Figure 4.1.a 
Figure 4.1.b 
Figure 4.1 EM sections of SKC01 cells 
internalization of HRP conjugated 
concentration of 25 p,g ml-1 • 
4.1.a : 11-285-14-HRP anti-CEA Mab 
4.1.b : Ag8-HRP (non-CEA specific Ab) 
depicting uptake and 
antibodies at a 
l'igure 4.2.a 
l'igure 4.2.b 
Figure 4.~ EM sections of SKC01 cells 
internalization of HRP conjugated 
concentration of 50 p.g ml-1 • 
4.2.a : 11-285-14-HRP anti-CEA Mab 
4.2.b : Ag8-HRP (non-CEA specific Ab) 
depicting uptake and 
antibodies at a 
(--
) 
Figure 4.3.a 
Figure 4.3.b 
Figure 4.3 EM sections of SKC01 cells 
internalization of HRP conjugated 
concentration of 100 p.g ml-1 • 
4.3.a : 11-285-14-HRP anti-CEA Mab 
4.3.b : Ag8-HRP (non-CEA specific Ab) 
depicting uptake and 
antibodies at a 
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m. s. SDS/PAGE Analysis of Internalization 
We attempted to conirrm the progress of antibody internalization by examining 
both the membrane and cytosolic components of cells incubated with the anti-CEA Mab 
or control Ag8 for increasing time inteiVals (section 11.8). Approximately 5-6 repeats of 
the assay were performed for each cell line examined, but due to space considerations 
one representative Western blot per cell line is presented in this section. Figures 5a, 5b 
and 5c show the results of Western blots performed on membrane and cytosolic samples 
for three different CEA expressing cancer lines. In all cases, immunostaining for the 
primary anti-CEA antibody shows the presence of this Mabin both the membrane and 
cytosolic portions of the cells from a very early stage (after about 5 minutes of 
incubation). 
In Figure 5a anti-CEA bands are evident throughout the irrst 60 minutes of 
incubation (part A, lanes b,d,f,h,j,l) whereas non-specific control staining is only evident 
in the 60-minute cytosolic component (part A, lane k), and may indicate that beyond a 
60-min incubation inteiVal non-specific accumulation in the cytosol may occur. In part 
B of the same figure evidence for accumulation of non-specific antibody is again evident 
(lanes c,e,g,l). As shown by the controls in these gels (lanes a, h) intensity of staining 
is generally much higher. Even under these conditions however anti-CEA cytosolic 
samples corresponding to 90-minute and 120-minute incubations (lanes b, f) have the 
strongest intensity bands. In Figure 5b (SKC01 cells), there is strong evidence of 
increasing accumulation of anti-CEA Mabin the cytosol from the 5 min to the 60 min 
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incubation intervals (part A, lanes b, f, j). The highest anti-CEA intracellular 
accumulation furthermore, is noted at the longest incubation time of 180 min (part B, 
lane j). For this cell line only minimal accumulation of non-specific control antibody is 
evident in one case (part B, lane g). 
In the case of the human lung carcinoma line (BENN, figure 5c), similar levels 
of intracellular anti-CEA Mab are obtained throughout the incubation intervals examined 
(part A, lanes b, f, j; part B, lanes b, t), although part B seems weaker due to much 
fainter staining in the case of this gel. Also uptake of non-specific antibody is much 
higher in the case of this cell line (part A, lanes c, g, k) (see Discussion). 
An additional antigen specificity control is shown in figure 5d. In this case the 
cell line used shows very low levels of binding of 11-285-14, presumably due to its very 
low expression of CEA. There is only very weak evidence of anti-CEA antibody 
membrane binding (part A, lanes i, m), as is its intracellular accumulation (part A, lanes 
b, k; part B, lanes a, e). Conversely there is evidence of surface and cytosolic 
accumulation of non-specific antibody (part A, lanes g, j, 1, n). 
Figure 5. Detection of anti-CEA Mab in membrane and cytosolic portions of 
solubilized cancer cells using Western blots. 
1 x 101 cell samples from four human cancer cell lines were incubated with 200 p.g of 
11-28$-14 or Ag8 antibody from 5 minutes to 3 hr at half hour to one hour intervals at 
37°C. Cells were then solubilized and membrane and cytosolic samples were 
electrophoresed on SDS gels which were then Western blotted. ll-285-14 Mab at 50 p.g 
mi-1 was used as a positive control. Due to space considerations blots were combined 
in groups of two. Where appropriate, positive controls are shown for each blot in order 
to directly assess possible differences in background staining for each blot. For ease of 
reading lane assignment is provided in tabulated form. 
( cyt = cytosolic; mem = membrane). 
Note: The control Mab (11-285-14) is partially purified, hence more than a single band 
is evident on the SDS/PAGE gels. 
Figure S.a legend 
Description of Western blots of solubilized IS174T cells 
LANE ASSIGNMENT 
I I 11-285-14 I Ag8 I 
I TIME II I cyt I mem I cyt I mem I 
5 b d c e 
30 A f h g i 
60 j 1 k m 
90 b d c e 
120 B f i g J 
180 k m 1 n 
11-285-14 Controls: Lanes A(a), B(a), B(h) 
!93 
A 
m 1 k j ; h g f e d c b a 
B 
n m 1 k j ; h g f e d c b a 
Figure S.a 
Western blots derived from time course incubations of 
solubilized LS174T cells incubated with 200 ~g of anti-CEA 
(11-285-14) or non-CEA specific (Ag8) antibodies. 
TIME 
5 
30 
60 
90 
120 
180 
Figure S.b legend 
Description of Western blots of solubilized SKCOl cells 
LANE ASSIGNMENT 
11-285-14 Ag8 
cyt mem cyt 
b d c 
A f h g 
j 1 k 
b d c 
B f h g 
j NS k 
NS = No sample 
11-285-14 Controls: Lanes A(a), B(a) 
mem 
e 
i 
m 
e 
i 
NS 
A 
m 
B 
k 
k 
j i 
j i 
h g 
195 
h g f e d c b a 
f e d c b a 
Figure S.b 
Western blots derived from time course incubations of 
solubilized SKC01 cells incubated with 200 ~g of anti-CEA (11-
285-14) or non-CEA specific (Ag8) antibodies. 
I 
TIME 
5 
30 
60 
90 
120 
Figure S.c legend 
Description of Western blots of solubilized BENN cells 
LANE ASSIGNMENT 
11-285-14 Ag8 
I I cyt I mem I cyt I 
b d c 
A f h g 
j 1 k 
B b d c 
f h g 
11-285-14 Controls: Lanes A(a), B(a) 
mem 
I 
e 
i 
m 
e 
i 
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A 
m 1 k j i h 9 f e d c b a 
B 
a b c d e f 9 h i 
Figure S.c 
Western blots derived from time course incubations of 
solubilized BENN cells incubated with 200 ~g of anti-CEA (11 -
285-14) or non-CEA specific (AgB) antibodies. 
TIME 
5 
30 
.60 
90 
120 
180 
Figure S.d legend 
Description of Western blots of solubilized COL0320 cells 
LANE ASSIGNMENT 
11-285-14 Ag8 
cyt mem cyt 
b d c 
A f i g 
k m 1 
a c b 
B e i f 
k m 1 
11-285-14 Controls: Lanes A(a), A(h), B(h), B(g) 
mem 
e 
j 
n 
d 
j 
n 
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A 
n m 1 k j ; h g f e d c b a 
B 
n m 1 k j ; h g f e d c b a 
Figure S.d 
Western blots · derived from time course incubations of 
solubilized COL0320 cells incubated with 200 ~g of anti-CEA 
(11-285-14) or non-CEA specific (Ag8) antibodies. 
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m. 6. Comparison of SDS/PAGE and Flow Cytometric analysis in the 
depiction of anti-CEA Mab internalization 
In an effort to develop a more convenient assay for detecting antibody 
internalization, we attempted to make use of flow cytometry. The principle of this assay 
is that surface FITC-labelled antibody can be detected by anti-FITC antibodies which will 
"quench" surface fluorescence, while internalized FITC-labelled antibody will escape 
such detection and the subsequent quenching. In the case of an internalizing antibody 
therefore, initial (time 0) fluorescence should be minimal (with quenching effect being 
maximal), since the primary antibody would still be on the cell membrane and would not 
have been internalized yet. However, with increasing incubation intervals, fluorescence 
should increase progressively, as increasing amounts of internalizing antibody escape 
anti-FITC-mediated quenching. 
Table 6 provides a summary of the arithmetic estimation of the degree of anti-
CEA antibody internalization per time interval, for each of the three cell lines studied 
(values are means of results from six or seven repeat assays for each line). Internalization 
is expressed as a percentage of the positive control (% antibody internalization = test 
sample fluorescence reading I positive control fluorescence reading x 1 00). There was 
some degree of variability in tenns of antibody uptake (positive controls) for each cell 
line, which is also inevitably reflected in the test samples. This variability however, does 
not exceed differences in cell line characteristics nonnally observed with passaging of 
cell lines. 
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Table 6 
Estimation of anti-CEA Mab internalization by human 
· cancer cell lines using data from flow cytometric assays 
Cell Line Incubation Positive Test %Intern. 
time (min) control 
LS174T 0 27.5 (12) 10.7 (6.8) 38.2 (11.9) 
(7 assays) 
30 26.5 (11.4) 13.7 (8.5) 50.9 (15.3) 
90 25.5 (8.2) 14.5 (6) 58.6 (16.2) 
SKC01 0 69 (22.1) 11.1 (5.6) 15.4 (4.8) 
(6 assays) 30 59.4 (11.9) 18.1 (7) 30.5 (12.3) 
90 61 (7) 17.3 (6.2) 28 (7.9) 
COL0320 0 1.7 (0.9) 1.8 (0.9) NA 
(6 assays) 
30 1.5 (0.7) 2.3 (1.7) NA 
90 2.1 (1.2) 1.8 (0.9) NA 
Numbers correspond to % fluorescence emitted by the respective cell samples. Control 
ascites was used as a negative control. All values are means derived from the repeat 
assays indicated below the cell line. Numbers in parentheses indicate standard deviations 
for the respective groups. 
Positive control : fluorescence emitted by cell samples incubated with FITC-labelled 
anti-CEA Mab only. 
Test : fluorescence emitted by cell samples incubated with FITC-labelled anti-CEA Mab, 
followed by incubation with anti-FITC antibody. 
% Intern (% Internalization) : test x 100% 
control 
NA: Not Applicable (due to background fluorescence values for all samples of this cell 
line). 
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Studies on the progress of internalization using flow cytometry are depicted in 
Figures 6.l.a, 6.2.a and 6.3.a. The negative control employed in these assays consisted 
of a sample of the tumour cells studied, incubated with fluoresceinated control ascites, 
ie. antibodies which do not bind to CEA. This negative control is represented in the 
FACS image by the clear leftmost curve and is the point of reference for positive 
controls and test samples. The clear rightmost curve depicts positive controls, ie. cancer 
cell samples which have been incubated with FITC-conjugated anti-CEA antibody for 
different time intervals, but have not been subsequently treated with anti-FITC, so that 
no surface fluorescence quenching has occurred. These samples therefore represent total 
fluorescence of both surface and internalized antibody at each time interval (positive 
control). The middle (shaded) curve represents cancer cell samples incubated with FITC-
conjugated anti-CEA antibody for the same time intervals, but which have subsequently 
been treated with anti-FITC to quench surface antibody fluorescence. Thus, at each time 
interval the only fluorescence detectable from these cell samples should be fluorescence 
associated with internalized antibody. Actual FACS outputs corresponding to one assay 
for each cell line are shown in figures 6.l.a, 6.2.a and 6.3.a. As incubation times of 
LS174T (legend to Figure 6.1.a) and SKCOl (Figure 6.2.a and legend) cells with 
fluoresceinated anti-CEA antibody increased, there also occured an increasing right shift 
of the curve representing test samples. This shift represents increased depiction of 
fluorescence due to the fact that surface antibody is being progressively internalized and 
is no more subject to the anti-FITC quenching activity. However, as seen in figure 6.3.a, 
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when COL0320 cells (which express very low levels of CEA) are used, both positive 
controls and test samples exhibit a fluorescence level which is very close to that of the 
negative control, throughout the time intervals studied, reflecting the inability of the anti-
CEA antibody to adhere onto the cell surface. In order to ensure consistency with the 
previously performed cell solubilization assays (section m.5), such flow cytometric 
assays were coupled with Western blots, which were derived using membrane and 
cytosolic samples of solubilized cells from the same lines as before and were treated in 
parallel and under the same experimental protocol as the cells used for FACS analysis. 
Results of these SDS/PAGE assays are presented below their flow cytometric 
counterparts (Figures 6.1.b, 6.2.b, 6.3.b). 
In Figure 6.1. b we saw evidence (bands corresponding to the cytosolic portion 
of the sample) of anti-CEA antibody internalization by LS174T cells at all time intervals 
studied whereas for the most part no bands are visible on the lanes where cells were 
incubated with control ascites. Similar results were obtained for the SKC01 cell line 
(figure 6.2.b), whereas in the case of the COL0320 cells (very low CEA expressor; 
figure 6.3 .b), no bands were visible either for test or for negative control samples (with 
the exception of a very light band for the 30-minute cytosolic test sample), which was 
conimned by the FACS results. Lack of densitometric data prevent quantitative 
correlations of the results from the two sets of assays, however a large number of such 
assays with solubilized cells (Tsaltas et al., 1992) has provided evidence of increased 
antibody internalization through the time intervals studied for the same cell lines. 
Figure 6.1.a. Detection of anti-CEA antibody internalized by LS174T cells via FACS 
analysis (comparison with SDS/PAGE analysis). Samples of I.S174T cells (1 x 1()6 
cells/sample), were incubated with: 0.1 p.g ofFITC-labelled control ascites only (leftmost 
curve -negative control; this curve is overshadowed by the middle (test) curve; since it 
was not possible to provide clear coloured curves I.S174T results are better understood 
through the arithmetic data provided in this figure's legend or by comparing to figure 
6.2); 0.1 p.g ofFITC-labelled 11-285-14 Mab followed by a 30 minute incubation at OOC 
with anti-FITC (middle, shaded curve -test); or 0.1 p.g of FITC-labelled 11-285-14 
followed by a 30 minute incubation at ooc with PBS (positive control). To follow 
internalization, incubations with the anti-CBA-FITC-labelled Mab were performed for 
0 minutes (i), 30 minutes (ii), or 90 minutes (iii) at 3']0C, and the results were as 
follows: (Groups as per table 6, where summarized FACS results appear) 
&timation of anti-CEA Mab internalization by LS174T cells via FACS analysis 
Incubation time Positive control Test %Intern. 
0 39.71 18.09 45.5 
30 40.73 20.25 49.7 
90 34.67 23.67 68.3 
Figure 6.1.b. Detection of anti-CEA Mabin membrane and cytosolic portions of 
solubilized LS174T cells run in parallel with samples for FACS analysis. I.S174T 
samples of 1 x 10' cells each, were incubated with 200 p.g of 11-285-14 Mab, or control 
ascites for 0, 30 or 90 minutes at 37°C. Two blots were combined at a time to 
accomodate all samples of the cell line, with positive controls provided in each blot. For 
ease of reading, lane assignment is tabulated (test = incubated with 11-285-14; control 
= incubated with control ascites). 
Western blots of solubilized LS174T cells(Lane Assignment) 
Incubation Membrane portion Cytosolic portion 
Time 
Test Control Test Control 
0 c d e f 
30 g h j k 
90 1 m n 0 
11-285-14 positive controls : lanes a,b,i. 
2.os 
i ii iii 
Piqure 6.1.a 
a b c d e f g h i j k 1 m n o 
Figure 6.1.b 
Fiqure 6.1(a,b). Methodological comparison in the detection of 
internalized anti-CEA Mab by · LS174T cells, using flow 
cytometry ( 6. 1. a) , or Western blots of solubilized cells 
(6.l.b). (Legend provided on opposite page) 
Figure 6.2.a. Detection of anti-CEA antibody internalized by SKCOl cells via FACS 
analysis (comparison with SDS/PAGE analysis). Samples of SKC01 cells (1 x 1()6 
cells/sample), were incubated with: 0.1 p.g of FITC-labelled control ascites only 
(leftmost curve -negative control); 0.1 p.g of FITC-labelled 11-285-14 Mab followed by 
a 30 minute incubation at ooc with anti-FITC (middle, shaded curve -test); or 0.1 p.g of 
FITC-labelled 11-285-14 followed by a 30 minute incubation at OOC with PBS. To follow 
internalization, incubations with the anti-CEA-FITC-labelled Mab were perfonned for 
0 minutes (i), 30 minutes (ii), or 90 minutes (ill) at 37°C and the results were as shown 
in the following table (Groups as per table 6, where summarized FACS results appear) 
&timation of anti-CEA Mab internalization by SKCOl cells via FACS analysis 
Incubation time Positive control Test %Intern. 
0 95.48 17.03 17.8 
30 63.34 17 26.8 
90 59.07 20.76 35.1 
Figure 6.2.b. Detection of anti-CEA Mabin membrane and cytosolic portions of 
solubilized SKCOl cells run in parallel with samples for FACS analysis. SKC01 
samples of 1 x 10' cells each were incubated with 200 p.g of 11-285-14 Mab, or control 
ascites for 0, 30 or 90 minutes at 3~C. 11-285-14 Mab is used as a positive control at 
50 p.g mt-1• Two blots were combined at a time to accomodate all samples of the cell line 
with positive controls provided in each blot. For ease of reading, lane assignment is 
tabulated (test = incubated with 11-285-14; control = incubated with control ascites). 
Incubation 
Time 
0 
30 
90 
Western blots of solubilized SKCOl cells 
Lane Assignment 
Membrane portion Cytosolic portion 
Test Control Test Control 
c d e f 
g h j k 
1 m n 0 
11-285-14 positive controls : lanes a,b,i. 
. 
i07 
U3:161192D002,FL1-H,FL1-Height U3:161192D004,FL1-H,FL1-Height 
i ii iii 
Fiqure 6.2.a 
a b c d e f 9 h j k m n 0 
Figure 6.2.b 
Figure 6. 2 (a,b). Methodological comparison in the detection of 
internalized anti-CEA Mab by SKCOl cells, using flow cytometry 
(6.2.a), or Western blots of solubilized cells (6.2,b). 
(Legend provided on opposite page) 
Figure 6.3.a. Detection of anti-CEA antibody internalized by COL0320 cells via 
FACS analysis (comparison with SDS/PAGE analysis). Samples of COL0320 cells (1 
x 1Qli cells/sample), were incubated with: 0.1 p.g of FITC-labelled control ascites only 
(leftmost cutve -negative control); 0.1 p.g of FITC-labelled 11-285-14 Mab followed by 
a 30 minute incubation at ooc with anti-FITC (middle, shaded cutve -test); or 0.1 p.g of 
FITC-labelled 11-285-14 followed by a 30 minute incubation at OOC with PBS. To follow 
internalization, incubations with the anti-CBA-FITC-labelled Mab were performed for 
0 minutes (i), 30 minutes (ii), or 90 minutes (iii) at 3T'C and results were as shown in 
the following table (Groups as per table 6, where summarized FACS results appear) 
Estimation of anti-CEA Mab internalization by COL0320 cells via FACS analysis 
Incubation time Positive control Test %Intern. 
0 1.53 1.59 NA 
30 1.89 5.34 NA 
90 1.53 1.88 NA 
Figure 6.3.b. Detection of anti-CEA Mabin membrane and cytosolic portions of 
solubilized COL0320 cells run in parallel with samples for FACS analysis. COL0320 
samples of 
1 x 101 cells each were incubated with 200 p.g of 11-285-14 Mab, or control ascites for 
0, 30 or 90 minutes at 3T'C. 11-285-14 Mab is used as a positive control at 50 p.g mt1• 
Two blots were combined at a time to accomodate each cell line with positive controls 
provided in each blot. For ease of reading, lane assignment is tabulated (test =incubated 
with 11-285-14; control = incubated with control ascites). 
Incubation 
Time 
0 
30 
90 
Western blots of solubilized COL0320 cells 
Lane Assignment 
Membrane portion Cytosolic portion 
Test Control Test Control 
c d e f 
g i k 1 
m n 0 p 
11-285-14 positive controls : lanes a,b,j. 
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i ii iii 
Fiqure 6.3.a 
a b c d e f g i j k 1 m n 0 p 
Fiqure 6.3.b 
Figure 6. 3 (a, b). Methodological comparison in the detection of 
internalized anti-CEA Mab by COL0320 cells, using flow 
cytometry ( 6. 3. a), or Western blots of solubilized cells 
(6.3.b). (Legend provided on opposite page) 
m. 7. 
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Observation of the effect of hypertonic medium on anti-CEA Mab 
uptake and internalization, using flow cytometry. 
The involvement of clathrin in the uptake and internalization of the anti-CEA Mab 
was examined through cell incubation in hypertonic medium, a method which was 
recently shown to inhibit clathrin-mediated endocytosis by preventing clathrin and 
adaptors from interacting (Hansen et al., 1993). Antibody was again detected through the 
use of flow cytometry as described in the two previous sections. This assay involved the 
use of only one high CEA-expressor, the colorectal cancer cell line (SKC01), chosen 
mostly for the large number of CEA antigenic sites it expresses. The time course 
incubations at 37°C, which allowed for internalization of surface adherent anti-CEA 
antibody, again involved the three time intervals previously examined, namely 0, 30 and 
90 minutes. Assays were performed both after pre-incubating cells in hypertonic medium 
for 30 minutes, prior to the beginning of the experiment (Table 7 .a) and by incubation 
of test cell samples in hypertonic medium thereafter. Alternatively, as a further test, test 
cell samples were exposed to hypertonic medium through the course of the experiment 
only (no prior pre-incubation in hypertonic medium (Table 7.b)). 
From the two alternative treatments it became obvious that the decreased overall 
anti-CEA uptake by cells bathed in hypertonic medium, necessitated extensive (30 
minute) pre-incubation of the test samples in this medium. When the hypertonic medium 
was introduced following incubation of cells with the primary antibody (anti-CEA-FITC), 
uptake values were similar between the hypertonic-medium treated and regular-medium 
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treated groups. 
Overall, the use of hypertonic media seemed to have a sizeable and consistent 
effect in diminishing primary anti-CEA-FITC antibody uptake (see Table 7.a, samples 
(c) versus (e)) when pre-incubation of the cells in this medium took place however this 
medium did not seem to inhibit antibody internalization (as measured by this assay), to 
any appreciable degree (Table 7.a, (g) versus (h)). Lack of pre-incubation in hypertonic 
medium resulted in no change in anti-CEA-FITC uptake (Table 7.b, samples (c) versus 
(e)) and in no inhibition of its internalization (Table 7.b, samples (g) versus (h)). 
Interestingly, relative internalization in cells which were exposed to hypertonic medium 
during the course of the assay without being pre-incubated in this medium, seems to 
exceed internalization rates of cells which had been pre-incubated in such medium. 
However, more assays would have to be performed in order to ascertain that such a trend 
is not due to inter-assay variability. Representative FACS outputs from two such assays 
are presented in figures 7 .a and 7. b. 
Table 7.a 
Effect of hypertonic medium on Mab Internalization 
with 30 min. preincubation 
SAMPLES Average values 
(3 assays) 
O(min) 30(min) 
(a) mediumR 1.2 (0.6) 1.8 (0.7) 
(b) medium8 1.3 (0.8) 0.7 (0.2) 
(c) 11-285-FITCR 72.3 (21.1) 61.3 (17.7) 
(d) 11-285-FITC + 25.5 (20.5) 11 (6.3) 
anti-FITCR 
(e) 11-285-FITC8 38.9 (15.1) 30.4 (14.8) 
(f) 11-285-FITC + 3.8 (5.3) 4.7 (4.2) 
anti-FITC8 
(g) %Internal.R 33 (22.2) 17.3 (5.7) 
(h) %Internal.8 8.3 (9.9) 13.6 (6.8) 
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90(min) 
1.8 (0.3) 
1.0 (0.3) 
56.9 (23.9) 
20.7 (15) 
23.5 (6.5) 
6.1 (4.8) 
33.3 (12.1) 
26.6 (21) 
1 x 106 SKC01 cells were preincubated in hypertonic medium containing 0.45M sucrose 
for 30 min. at 37°C. All subsequent incubations were performed in respective (regular 
or hypertonic) media. 
The subscripts R, H signify regular and hypertonic medium respectively. 
Samples (a) to (h) are explained in the table. 
%Internal. =Internalized (non-anti-FITC quenched) primary antibody, as compared to 
its respective positive control i.e. sample (d) I sample (c) for regular medium and 
sample (f) I sample (e) for hypertonic medium (11-285-14-FITC, abbreviated in the table 
as 11-285-FITC). 
All % fluorescence values were read against a common negative control represented by 
sample (a). 
All data represent mean values of the respective groups from the combined (3) assays. 
Numbers in parentheses denote standard deviations. 
Table 7.b 
Effect of hypertonic medium on Mab Internalization 
without 30 min. preincubation 
SAMPLES Average values 
(3 assays) 
O(min) 30(min) 
(a) medium.R 1.1 (0.5) 1.0 (0.1) 
(b) medium a 0.2 (0.3) 0.3 (0.4) 
(c) 11-285-FITCR 58.0 (11.2) 50.9 (22.7) 
(d) 11-285-FITC + 6.5 (5.2) 6 (3) 
anti-FITCR 
(e) 11-285-FITCa 60.9 (24.4) 44.3 (25.7) 
(0 11-285-FITC + 12 (10.3) 14.8 (8) 
anti-FITCa 
(g) %1ntemal.R 10.8 (7.7) 11.7 (1.7) 
(h) %Internal. a 17.3 (11.4) 37.8 (27.7) 
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90(min) 
1.2 (0.4) 
0.3 (0.2) 
45.3 (19.7) 
11.1 (5.3) 
50 (23.8) 
20.1 (10.7) 
24.1 (4.6) 
41.3 (22.7) 
SKCOl cell samples were not subjected to pre-incubation in hypertonic medium (0.45M 
sucrose) this time, but all other incubations were performed on respective media as 
before. 
Again the subscripts a, H signify regular and hypertonic medium respectively. 
Samples (a) to (h) are explained in the table. 
%Internal. = Internalized (non-anti-FITC quenched) primary antibody, as compared to 
its respective positive control i.e. sample (d) I sample (c) for regular medium and 
sample (f) I sample (e) for hypertonic medium (11-285-14-FITC, abbreviated in the table 
as 11-285-FITC). 
All % fluorescence values were read against a common negative control represented by 
sample (a). 
All data represent mean values of the respective groups from the combined (3) assays. 
Numbers in parentheses denote standard deviations. 
Figures 7.a and 7.b combine FACS results of one run with 0, 30 and 90 minute anti-
CEA Mab incubation intervals at lanes i, ii and iii respectively. Table legends are 
provided in tabulated fonn opposite the figures for ease of reading. 
Legend for Figure 7 .a 
Effect of hypertonic medium on Mab Internalization 
with 30 min. preincubation 
SAMPLES Date of run: 20/ S/1994 
O(min) 30(min) 
(a) med.iumR 1.69 2.59 
(b) med.iumu 1.20 0.92 
(c) 11-285-FITC• 86.48 76.62 
(d) 11-285-FITC + 20.12 18.21 
anti-FITCR 
(e) 11-285-FITCu 51.20 45.18 
(f) 11-285-FITC + 9.87 9.40 
anti-FITCu 
(g) %Internal. It 23.26 23.77 
(b) %Internal.u 19.28 20.80 
90(min) 
1.32 
0.96 
50.24 
17.42 
28.31 
9.01 
34.67 
31.83 
1 x 106 SKC01 cells were preincubated in hypertonic medium containing 0.45M sucrose 
for 30 min. at 37°C. All subsequent incubations were perfonned in respective (regular 
or hypertonic) media. 
The subscripts R, H signify regular and hypertonic medium respectively. 
Samples (a) to (h) are explained in the table. 
%Internal. = Intema1ized (non-anti-FITC quenched) primary antibody, as compared to 
its respective positive control i.e. sample (d) I sample (c) for regular medium and 
sample (f) I sample (e) for hypertonic medium (11-285-14-FITC, abbreviated in the table 
as 11-~85-FITC). 
All % fluorescence values were read against a common negative control represented by 
sample (a). 
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288594ftl13~ 1-+f'FL1...,.aght 
(d) 
a.5'15141 ..... 1 ~1-+f'FL.l .... &ght 
(e) 
(f) 
i ii iii 
Figure 7.a 
FACS results of samples treated (both prior to beginning and throughout the assay) 
with hypertonic medium in order to examine the possibility of inhibition of antibody 
internalization via the clathrin-mediated pathway 
(i) Cells incubated with medium only at OOC. 
(ii) Cells incubated with 11-285-14 Mab for 30 min. at 3-r>C. 
(iii) Cells incubated with 11-285-14 Mab for 90 min. at 37°C. 
Legend for Figure 7 .b 
Effect of hypertonic medium on Mab Internalization 
without 30 min. preincubation · 
SAMPLES Date of run: 21 511994 
O(min) 30(min) 90(min) 
(a) mediuma 1.61 1.04 1.37 
(b) mediumu 0.50 0.73 0.45 
(c) 11-285-FITCa 50.49 74.57 61.87 
(d) 11-285-FITC + 7.38 9.34 13.37 
anti-FITCa 
(e) 11-285-FITCu 73.20 73.92 77.14 
(f) 11-285-FITC + 10.62 19.28 25.60 
anti-FITC8 
(g) . %Internal.a 14.62 12.52 21.61 
(h) %Internal.u 14.51 26.08 33.18 
SKC01 cell samples were not subjected to pre-incubation in hypertonic medium (0.45M 
sucrose) this time, but all other incubations were performed on respective media as 
before. 
Again the subscripts a, H signify regular and hypertonic medium respectively. 
Samples (a) to (h) are explained in the table. 
%Internal. = lntema1ized (non-anti-FITC quenched) primary antibody, as compared to 
its respective positive control i.e. sample (d) I sample (c) for regular medium and 
sample (f) I sample (e) for hypertonic medium (11-285-14-FITC, abbreviated in the table 
as 11-285-FITC). 
All % fluorescence values were read against a common negative control represented by 
sample (a) .. 
2.17 
(a) 
la82e'594EM2'-FL1 -H'-FL1 ~i ght 
(b) 
I ~815'1'1..1-+f'.FLl-fWiight 
(c) 
lt~94£81~1-H'FL1~Jgh~ . 
(d) 
3a~e11"•FL1-H'FL.1~igt>t 
(e) 
3•~1~1-+f'-FL1-..ivtlt 
i ii iii 
Figure 7.b 
FACS results of samples treated (during the assay only) with hypertonic medium in 
order to examine the possibility of inhibition of antibody internalization via the 
clathrin-mediated pathway 
(i) Cells incubated with medium only at OOC. 
(ii) Cells incubated with 11-285-14 Mab for 30 min. at 37°C. 
(iii) Cells incubated with 11-285-14 Mab for 90 min. at 37°C. 
IV. 1. 
CHAPTER IV 
DISCUSSION 
Immunoconjugate internalization: Mode and Significance 
The effective destruction of tumour cells by any of the major classes of cytotoxic 
immunoconjugates currently in experimental or clinical use, has been shown on a number 
of occasions to correlate with the ability of the targeting antibody to be internalized by 
the targeted cancer cell. 
Antibody internalizing ability has been found particularly essential in the case of 
immunotoxins (IT's), where internalization of the toxin is generally necessary for 
cytotoxic action. In fact, due to their extremely high cytotoxic potential, IT's have been 
some of the most widely studied "magic bullets". A general background on IT's has been 
given briefly in Chapter I, while a number of reviews on immunotoxins have appeared 
in the literature in the last 15 years (Vitetta et al., 1987; Olsnes et al., 1989; Lord et al., 
1985; Byers et al., 1992). The structure of toxins and method of IT preparation will not 
be repeated in this section, however the action of IT's on the protein synthesis machinery 
will be elaborated on briefly. 
Most bacterial toxins (such as diphtheria toxin and Pseudomonas aeruginosa 
exotoxin A) inactivate elongation factor 2, an enzyme required for the translocation of 
growing peptide chains from the A-site to the P-site of the ribosomes. Elongation factor 
2 modified by these toxins cannot properly interact with the ribosomes, resulting in 
blocking of protein synthesis (Olsnes et al., 1989). Most plant toxins inactivate the large 
ribosomal subunit, by modifying a loop in the 28S RNA of the subunit. Although toxins 
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are very effective cell killers, their cytotoxic efficacy depends directly on their binding, 
uptake and intracellular routing, in other words their ability to selectively internalize. For 
that reason immunotoxins have been the major class of immunoconjugates for which 
internalization potential has been studied in parallel with the development of new IT 
constructs. 
Some initial experimental evidence on this subject raised a number of questions, 
when it was found that IT killing of human melanoma cells (Casellas et al., 1982; Godal 
et al., 1986), was increased by ammonium chloride. This agent, which was thought to 
inhibit internalization, turned out to increase IT cytotoxicity on tumour cells that 
expressed high levels of the antigen being targeted (p97) (Casellas et al., 1982). The 
authors speculated that ammonium chloride (a lysosomotropic amine), inhibited the 
degradation of the IT by inactivating lysosomal enzymes through raising intralysosomal 
pH. The role of this agent and monensin (a carboxylic ionophore) was immediately 
investigated in an examination of the endocytosis of an antibody ricin-A conjugate 
(Carriere et al., 1985). In this study it was concluded that such agents markedly slowed 
down the speed of IT transportation through lysosomal compartments, thus increasing 
cytotoxic efficacy, probably both by lengthening the period the IT remains in a non-
lysosomal compartment, as well as by lowering intralysosomal pH. Notably, these agents 
did not interfere with the initial IT internalization process, which was thought to occur 
mostly through receptor-mediated endocytosis. 
Alternative experimental approaches however, such as subjecting cells to 
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hypotonic shock followed by incubation in potassium (K+)-free medium, showed at the 
time that human fibroblasts can arrest their coated pit formation and therefore arrest 
receptor-mediated endocytosis in the case of low density lipoprotein (Larkin et al., 1983). 
When Hep-2 cells were subjected to a similar treatment, it was shown that although 
cytotoxicity mediated by diphtheria toxin was blocked, the one mediated by ricin toxin 
was not (Moya et al., 1985), suggesting a non-receptor mediated internalization pathway 
for the unconjugated ricin toxin. However, a subsequent comparison of three anti-CEA 
ricin A ITs (Levin et al., 1987), suggested modulation of the antigen-antibody complex 
from the cell surface. 
While the debate on the endocytic pathway followed by toxins continued, the 
above study also suggested that cytotoxic efficacy of the ITs studied was not related to 
the affmity of the monoclonal antibody carriers to the CEA target antigen. This point 
however was also debated since it was later shown that the cytotoxic ability of an anti-
CEA IT containing ricin A (228-RTA), was potentiated by Mabs recognizing different 
epitopes, suggesting that enhanced antibody affmity leads to increased endocytosis of 
bound immunoconjugate and potentiates cytotoxicity (Byers et al., 1988). 
The one factor that seems to be more important than antibody affmity in terms 
of immunotoxin efficacy however, is the rate of IT internalization. Specifically, it was 
shown with human melanoma and small lung carcinoma cell lines using an anti- · 
ganglioside GD2 Mab linked to ricin-A toxin, that the rate of IT internalization correlated 
with cytotoxic activity against human tumour cells (Wargalla et al., 1989). Furthermore, 
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an analysis of the rate of endocytosis of another extremely potent ricin-A Mab against 
sarcomas and colon and ovarian cancer cells (Byers et al., 1991), showed that this 
particular IT internalized very slowly (possibly via smooth pits), and that in these cases 
cytotoxicity was not affected by potentiators such as ammonium chloride. 
In tum, the importance of internalization rate as the major variable influencing 
IT potency, has also been questioned. Specifically, it was determined using ITs 
constructed against different epitopes of murine B cells, that neither cross-linking nor rate 
of internalization could account for the degree of difference in potencies between various 
ITs (May et al., 1991). However, in the same study, the type of intracellular routing 
promoted by the choice of target antigen was found to have a profound effect on IT 
potency. When the respective effects of the intracellular compartments (namely 
endosomes versus lysosomes), were made relatively similar due to the pH-raising action 
of the lysosomotropic amine chloroquine, the less potent IT became 100 times more 
potent, whereas the other IT's potency was unaffected. This outcome was thought to 
reflect differential compartmentalization of the two ITs during intracellular routing. The 
role of another major compartment in intracellular routing, namely the Golgi region, has 
also been extensively studied mostly through the use ofbrefeldin A (BFA), which affects 
the Golgi network by causing a redistribution of its proteins into the ER (Wood et al., 
1991). Such disruption of the Golgi apparatus has been shown to inhibit the cytotoxicity 
of ricin, modeccin and PseudomolUJS toxin, (Yoshida et al., 1991), while more recently 
such Golgi-dependent inhibition of cytotoxic action was observed for cholera toxin 
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(Nambiar et al., 1993), although it differs considerably in structure and mode of action. 
Irrespective of what the point of greatest importance in the process of IT 
internalization is, one thing that seems to have been made rather clear is that IT's require 
that their specific endocytic mechanism be intact for maximizing, or for that matter, 
potentiating their cytotoxic action. To further illustrate the point, it has been shown that 
conjugation of an IT to a non-internalizing antibody completely abrogates any specific 
conjugate cytotoxicity (Cogliati et al., 1991). Such observations, along with the recent 
progress in the preparation of recombinant IT constructs whose internalizing profiles have 
yet to be elucidated (Brinkmann et al., 1993; Better et al., 1993; Friedman et al., 1993), 
make this a subject of urgent study. 
The mode of action of chemotherapeutic drugs has been, for the most part, less 
clearly defmed in tenns of membrane or intracellular targets, and studies correlating 
between immunoconjugate internalization and drug efficacy have been rather limited. 
Initial studies on Mab-methotrexate (Mab-MTX) conjugate uptake and internalization by 
melanoma and teratocarcinoma cell lines (Uadia et al., 1985; Shen et al., 1986), 
established some links between immunoconjugate efficacy and its degree of 
internalization and lysosomal degradation. A more detailed study on the nature of linkage 
and mode of action of methotrexate conjugated with Mabs against a mouse mammary 
tumour, or irrelevant antibody (Endo et al., 1988), suggested that amide-bond linked 
MTX is taken up by endocytosis, whereas a substantial portion of MTX linked by an 
ester or other less stable bonds is released extracellularly, and may then enter cells by 
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the MTX active transport system. In a recent effort to increase the levels of expression 
of the human folate receptor (hFR) using transfectants of human MCF-7 breast cancer 
cells (Chung et al., 1993), it was also shown that increased levels of hFR resulted in 
increased MTX uptake, internalization and cytotoxicity. Interestingly, some evidence 
derived from in vivo studies of the antitumour activity of a non-internalizing Mab-vinca 
alkaloid immunoconjugate (Starling et al., 1991), suggested that non-internalizing ICs 
may still have significant antitumour activity. Conversely, adriamycin hydrazone (ADM-
Hzn) immunoconjugates, were shown to be more cytotoxic against lymphoma tumour 
xenografts, when linked to internalizing rather than non-internalizing Mabs (Braslawsky 
et al., 1991). Furthermore, a recent in vitro study of the internalization of a doxorubicin 
anti-CEA Mab immunoconjugate, constructed using an aminodextran carrier (Shih et al., 
1994), showed that both the unconjugated Mab and the IC were internalized and 
distributed mostly in the cytoplasm ofLoVo cells, whereas unconjugated doxorubicin was 
quickly absorbed by the cells and concentrated in the nucleus of those cells. This 
immunoconjugate had previously shown a better therapeutic effect than either 
unconjugated doxorubicin or an irrelevant antibody conjugate (Shih et al., 1991). 
Unfortunately, due to the diverse mode of action of different chemotherapeutic drugs as 
compared to toxins and a paucity of information on IC internalizing potential and 
efficacy, it is impossible to clarify this relationship at the present stage. 
Internalization of radioimmunoconjugates has attracted interest (Mariani et al., 
1990; Scheinberg et al., 1991) as the potential of Auger emitters such as the commonly 
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used Iodine-125 (with an effective radius of only 20 to 30 A0 ) is greatly enhanced when 
the energy derived from the radionuclide is highly localised. This is a point of great 
interest since it has been shown that radiotherapy of small lesions necessitates nuclides 
with low energy radiation due to diffusion of long range radiation (Griffith et al., 1988). 
A number of studies on immunodiagnosis have also shown that retention time of 
radioactivity is a combination of labelling technique and the ability to internalize (Mariani 
et al., 1990). 
The problem inherent to most of these studies however, has been the lack of an 
adequate and consistent experimental model studying the process of internalization for 
each system under consideration. Methodologies which have been used to study antibody 
or immunoconjugate internalization, initially involved mostly indirect methodologies, 
such as attempting to detach radiolabelled cell-surface bound antibody via the use of low 
pH buffers (Matzku et al., 1986; Matzku et al., 1990; Starling et al., 1991; Tagliabue 
et al., 1991; Casalini et al., 1991) or using secondary radiolabelled antibody (Rosenthal 
et al., 1980) to detect and quantify any remaining surface primary antibody. Direct 
methods of visualization have primarily involved electron microscopy for the detection 
of internalized antibody conjugated to different extracellular markers such as horseradish 
peroxidase (HRP), cationized ferritin (CF) (Back et al., 1993) or colloidal gold (Weltzin 
et al., 1989). Fluorescence microscopy has been a preferred method for the direct 
detection of cell surface phenomena, such as the capping of antibodies tagged by 
fluorescein isothiocyanate (FITC) (Pulczynski et al., 1993). 
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Recently, direct or indirect methods have made use of flow cytometry, for faster 
quantitative analyses of internalized antibody (Pulczynski et al., 1993; Garrigues et al., 
1993; Hopper et al., 1990). Furthermore, the question of lysosomal degradation of 
internalized antibodies has been addressed by estimating the amount of remaining intact 
radiolabelled antibody which is precipitable with trichloroacetic acid (TCA) (Kyriakos 
et al., 1992). A method which allows visual detection of internalized antibody involves 
solubilization of cells previously incubated with antibody, followed by sodium dodecyl 
sulfate/ polyacrylamide gel electrophoresis (SDS/PAGE). This approach was developed 
as part of this project in order to verify quantitative internalization evidence derived from 
previously used assays (see section m.5 and Tsaltas et al., 1992), and has recently been 
used by another group for the detection of non-degraded internalized antibody (Garrigues 
et al., 1993). 
The present study attempts to establish a reliable and consistent approach to the 
study of internalization of a well characterised anti-CEA Mab by different human cancer 
lines, by providing a basis for comparison of results obtained by a number of direct and 
indirect techniques. 
IV. 2. 
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Direct radioimmunoassay for the detection of internalized antibody. 
This method was chosen due to its widespread use at the time the study was 
initiated, as well as its ability to generate quantitative results in a relatively 
uncomplicated manner. However, as described in the literature, this assay did incorporate 
a number of experimental shortcomings. For example, no time was allowed for the initial 
binding of antibody to antigen, hence the increasing binding values for all the time 
intervals studied. Additionally, since dead cells are permeable to Ig molecules, cell 
viability should have been determined as part of the assay procedure, as this would 
contribute to increased estimates for internalization. Nevertheless, we decided to initially 
perform the assay as described and our initial assays (presented in section ill. I), were 
generally indicative of moderate internalization of the particular antibody, at the 30% to 
40% level of total antibody uptake (although the fraction of antibody internalized varied 
according to incubation time). Also, there was consistently no evidence for any 
internalization at least during the trrst 30 minutes of incubation, despite the fact that 
general internalization prorlles for most antibodies that follow the endocytic pathway 
seemed to suggest that the process usually begins much earlier on (during the first 5 
minutes of antibody incubation), and that the 20 minute incubation interval with glycine-
HCl would have allowed some antibody to be internalized. 
Results were contradictory in terms of peak internalization and saturation of 
antibody uptake, since there was no consistent plateau observed on the respective binding 
curves. Furthermore, one of the assays (figure 1.1) showed a slight decrease in 
missing from the 
original book 
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IV. 3. Use of low pH glycine-HCI buffer in dissociating antigen-antibody 
bonds. 
The low pH (2.5 - 2.8) Glycine-HCl buffer has been used extensively in acid 
elution of antibodies from immunoadsorbents. More recently (during the last decade), 
assays employing the same buffer for the dissociation of bonds between antigen-antibody 
complexes have extended the use of this buffer and have established methodologies which 
are being used in studies involving internalization of antigen-antibody complexes (Matzku 
et al., 1986; Imamura et al., 1987; Matzku et al., 1990; Starling et al., 1991). 
The general outline of this method, as applied to internalization experiments, includes the 
following steps. 
1) Incubation of cells with antibodies specific to surface antigens for various time 
intervals, in order to allow for internalization of antibody or antigen-antibody complexes. 
2) Measurement of the total cell-associated antibody (comprising both surface-bound and 
internalized) on samples from each time interval. 
3) Application of the glycine-HCL buffer to the sample in order to dissociate surface 
bound Ag-Ab complexes. 
4) Estimation of the amount of antibody remaining in the target cell assuming that all 
surface bound complexes have been dissociated. 
5) Equating the amount of remaining radioactivity with the amount of internalized 
complexes. 
Recently, the question of incomplete Ag-Ab bond dissociation by this buffer has 
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also been addressed by another laboratory (Matzku et al., 1991), which had been 
instrumental in establishing this technique. However, no data have been provided to 
illustrate the nature and extent of this observation, and to our knowledge, there has been 
no attempt to date to analyze the degree of error that this experimental approach might 
introduce. This confidence in the effectiveness of the dissociating action of the glycine-
HCl buffer seemed peculiar in view of the repeated cautioning in the literature (Absolom 
et al., 1986; Helmerhorst et al., 1982; van Oss et al., 1981) suggesting the need for 
improvements in the methodology used to reverse attractive forces in antigen-antibody 
complexes. For example, a thorough analysis of the nature of such bonds (Absolom et 
al., 1986) strongly suggests that low pH conditions alone would generally prove 
ineffective in fully dissociating them. This review stresses the fact that antigen-antibody 
interactions are usually the combination of two types of attractive forces, namely van der 
Waals' and electrostatic (Coulombic) forces. Lowering the surface tension of the aqueous 
medium by adding organic solvents such as ethylene glycol or dimethyl sulfoxide, results 
in reversing the attractive van der Waals' force into a repulsive one, whereas extreme 
(either high or low) pH conditions are bound to reduce or even reverse the electrostatic 
attractive component. Therefore, although bond dissociation in other systems may be 
possible solely by pH adjustment, as is the case in the dissociation of DNA-anti-DNA 
complexes at high pH (de Groot et al., 1980), both pH adjusting and lowering of the 
surface tension of the surrounding aqueous medium are required in order to effectively 
reverse antigen-antibody binding (Helmerhorst et al., 1982; van Oss et al., 1981). 
Based on the above, a thorough examination of the role of this buffer on both 
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fixed and live cells expressing CEA was thought to be necessary. Both 
immunocytochemical assays and enzyme-linked immunosorbent assays (ELISAs) were 
employed to this end. In addition to the question of efficacy of the buffer in breaking 
antigen-antibody bonds, we also briefly investigated its possible role in the shedding of 
antigen-antibody complexes or in dissociating antibody-HRP bonds. Information on the 
latter would be useful in cases where such antibody conjugates are used in a direct assay. 
Initial immunoperoxidase results on ttxed cells provided no evidence of 
dissociation except in the case of the direct assay using HRP-conjugated antibodies. 
Similar EUSAs on ttxed cells did show evidence of partial dissociation at both room 
temperature and at 37°C, but in only one occasion was a high level of original binding 
shown to be lost (85 % dissociation). After averaging the dissociation values derived from 
a number of these assays (Tables 2.2.a.l and 2.2.a.2), it was shown that this buffer's 
dissociating effect did not exceed (on average) a 50% reduction in binding (Table 2.2.e), 
and that this effect was very similar for the three cell lines used. However, this 
dissociation effect did show some variability among the assays performed, while there 
was very little variability among wells belonging to the same group (usually 5 wells per 
group) in any particular assay. Although readings of individual plates were not generally 
presented in the results, for the sake of brevity and in order to avoid confusion, part of 
this variability seemed to be due to variation in the level of antibody uptake in each 
particular assay. This difference in uptake could be due to some variation in cell 
characteristics in terms of antigen expression after multiple passaging of cells. Such 
variations were commonly observed with most of the cell lines used in this project, as 
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documented in the FACS analysis of internalization (Table 6, standard deviations for 
means of antibody uptake values). In general, a higher overall uptake of antibody seemed 
to reduce the dissociating effect of the glycine-HCl buffer, a phenomenon which might 
be explained by an increased antibody avidity due to either level of antigen expression 
or conformational changes in the way this antigen was expressed. However, some 
exceptions did exist which would not support such a hypothesis (for example, in Table 
2.2.a.l, assay #386, low dissociating levels were observed despite rather high original 
antibody uptake by the two higher CEA expressor cell lines). Dissociation did not seem 
to be particularly favoured by one of the two temperatures during incubation with the 
glycine-HCl buffer. Furthermore, use of glycine obtained from different companies or 
slight increases in buffer incubation times, did not seem to have any effect either. 
Initial estimations of any distorting effect that the glycine-HCl buffer might have 
on antigenic sites (through evaluating the amount of antibody that can re-attach to those 
sites after treatment with this buffer), seemed to indicate that full reassociation could be 
achieved, suggesting intact antigen (%FB in tables 2.2.a.l and 2.2.a.2). However the 
implementation of a correction factor (as shown in tables 2.2.a.3 and 2.2.a.4), resulted 
in deriving a more accurate estimation of reassociation values shown in table 2.2.a.5. 
According to this derivation, reassociation of antibody to cells previously treated with the 
glycine-HCl buffer is quite low, indicating distortion of antigenic sites. 
Results tended to be more variable in the case of ELISAs employing live cells, 
probably due to the nature of the assay, but again dissociation levels rarely exceeded 
50%. However, when direct assays were performed using HRP-conjugated antibodies 
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there was a two to three fold increase in dissociation observed (tables 2.2.b.1 and 
2.2.b.2). This increase may have been attributed to antibody-HRP bond dissociation 
rather than CEA anti-CEA bond dissociation as shown in tables 2.2.c.1 and 2.2.c.2. In 
similar immunocytochemical assays (table 2.1) the low levels of dissociation observed 
only in the case where the HRP conjugate was used might be entirely attributable to 
dissociation of the enzyme. Results also indicated that the high dissociating effect on 
antibody-HRP bonds, seems to depend both on strength of bond (conjugation) and 
temperature conditions during incubation with the buffer (table 2.2.c). In general, our 
results indicate that use of the glycine-HCl buffer is particularly inappropriate in cases 
where such conjugates are used in direct assays, since dissociation levels do not only 
reflect dissociation between antigen-antibody complexes, but also the dissociation of 
enzyme from the antibody. 
In contrast to the above results, when purified antigen was used in similar assays 
there was complete dissociation of CEA anti-CEA bonds after a 20 minute incubation 
with this buffer (table 2.2.d). One possibility accounting for the difference between 
assays involving cells versus purified CEA, would be that cellular conformation might 
deny the buffer access to the desired epitope. This view is in contrast to a study 
involving different modes of binding and internalization of Mabs to human melanoma cell 
lines (Matzku et al., 1986). Although, according to this report, antigens expressed on 
the cell surface and complexed with antibody show no resistance to the dissociating effect 
of this buffer' the same investigator has more recently alluded to the fact that there may 
be incomplete desorption of high affmity antibodies when this buffer is used (Matzku et 
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al., 1990; Matzku et al., 1991). The systematic production of evidence shown in this 
thesis has certainly substantiated such fears. Furthermore, since it seems likely that 
degree of antibody desorption by this buffer is not uniform across a panel of antibodies, 
it is not feasible to introduce a uniform correction factor accounting for these differences. 
Realisation of this shortcoming has recently led this group to the evaluation of alternative 
ways of dissociating antigen-antibody complexes from cell surfaces (Matzku et al., 1991). 
Although there has been no such systematic study that we are aware of to date supporting 
the acknowledgment that this buffer may not be desorbing "very high" affmity antibodies 
(Matzku et al., 1990), alternative desorption procedures such as the one employing 
phospholipase C to detach CEA from its phosphotidylinositol bond (Matzku et al., 1991) 
have been suggested. Stripping of the antigen from the surface of the cell however, might 
be considered a rather drastic alternative, since it would make it impossible to further 
study the fate of the antigen (for example in cases where recycling potential is of 
interest). 
In conclusion, the consistency of our results across different assays involving high 
CEA-expressing cell lines, strongly indicates that routine use of glycine-HCl buffer for 
the purpose of dissociating cell-bound antigen-antibody complexes can introduce major 
inaccuracies in the analysis of antibody internalization experiments and its use in such 
experiments should be reconsidered. Alternatively, if this internalization assay is to be 
used in the future, the utmost care should be taken to ensure that the action of the buffer 
in question (or variants of it) is thoroughly investigated prior to use. 
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IV. 4. Use of an indirect radioimmunoassay in estimating antibody 
internalization 
The alternative indirect double radiolabelling assay, consistently showed relatively 
high retention of radioactivity correlating with an upward trend in antibody 
internalization. Both uptake and internalization seem to be specific to the anti-CEA 
antibody, since the nonspecific control antibody did not exhibit any significant uptake or 
residual activity. However, there were some notable differences between results derived 
from the direct versus the indirect RIA, the most obvious being the much lower activity 
registered in the case of the indirect assay, which at times reached 8-10 fold radioactivity 
decreases, as compared to respective groups in the direct assay. This was probably due 
to the fact that cell samples were pre-incubated with primary antibody as described in the 
literature (i.e. at 37°C and not at 0°C) for 30 minutes in order to establish initial binding. 
During this time it is certain that some internalization would have occurred, leading to 
decreased levels of surface-bound activity detectable by the secondary antibody. This pre-
incubation of cell samples at 37°C also led to another major difference between the two 
assays, namely that the groups used to test for differences in antibody uptake at 4°C 
versus 37°C did not show any appreciable differences in uptake when the indirect RIA 
was used, whereas a 50% decrease in uptake was noted at 4°C in the case of the direct 
(previous) RIA. Furthermore, there was no peak in internalization profile through the 
time intervals examined using the indirect RIA, but rather a steady upward trend 
suggesting continued internalization at almost the same rate up until the 150-minute 
interval. This rate of internalization was definitely much higher than the one noted with 
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the direct assay, however the most likely explanation for this is that cross-linking 
between primary and secondary antibodies may have strongly influence (increased) 
internalization activity. 
In general, although this method offered more consistent results that suggested 
vigorous and sustained internalization, it was subject to a number of theoretical 
shortcomings the most serious of which involved the augmenting effect that cross-linking 
caused by the secondary antibody would have on internalization. From a technical point 
of view the pre-incubation of samples with primary antibody should be performed at O"C, 
a larger number of samples per group should be included and cell viability should be 
determined for every step of the assay. Additionally, this assay followed a relatively 
complicated protocol, which made the study of short incubation time intervals quite 
difficult. Furthermore, both of the RIAs did not allow direct visualization of a possible 
internalization process. In view of all the above, it was decided that the 
tworadioimrnunoassays should be abandoned without introducing any of the necessary 
modifications and that a new approach should be developed, which would be free of 
theoretical and technical inadequacies. As a frrst step, we attempted to visualize the 
surface-bound and internalized antibody emplying a quantitative electron-microscopy 
approach. 
IV. 5. 
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Visualizing internalized antibody through Electron 
Microscopy. 
Labelling the test and control antibodies with HRP and incubating for a two hour 
time interval, resulted in cell sections which under EM analysis showed that our CEA-
specific Mab both accumulated on the cell surface of a high CEA expressor cancer line, 
and was internalized into lysosomal vacuoles (figures 4.1.a, 4.2.a, 4.3.a). In contrast 
no antibody uptake or internalization were evident with the HRP-labelled, non-CEA 
specific antibody at antibody concentrations of 25 and 50 p.g ml1 (figures 4.1.b, 4.2.b). 
Increasing the concentration to 100 p.g mi-1, led to much stronger staining but also a very 
low level of non-specific uptake as indicated by faint staining along the cell contour 
(figure 4.3.b) . This profile was evident on all samples examined (approximately 5 per 
group). Overall, this methodology provided very strong qualitative evidence for antibody 
internalization, although it did not allow for quantitation of surface-bound or internalized 
antibody. 
IV. 6. Detection of internalized antibody using SDS/PAGE. 
Strong evidence for internalization was also provided by Western blots of samples 
from membrane and cytosolic portions of cells incubated with test and control antibodies, 
which was developed in order to better defme changes in surface-bound and internalized 
antibody through time. Although this method had not been used in the literature for the 
study of internalization at the time we initiated this study, we found that it generally has 
the potential of assessing internalization in a more direct way. All three CEA expressor 
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lines tested showed definite evidence of CEA-specific Mab accumulation in the cytosolic 
portion of the cells, with mostly minor background accumulation of the control antibody. 
The high accumulation of non-specific antibody in the case of the BENN cell line may 
be due to a higher number of Fe receptors on the surface of BENN cells, although we 
have no direct evidence for this at present. Although, as stated before, all our test lines 
(LS174T, SKCOl and BENN) showed uptake and internalization of the anti-CEA Mab, 
it was interesting to note characteristics specific to each cell line. For example, strong 
evidence for time-dependent increasing intracellular accumulation of anti-CEA Mab 
which was CEA-specific (extremely low control antibody levels evident on blots) was 
obtained in the case of the SKCOlline, whereas this accumulation was relatively uniform 
in the case of LS174T and BENN cell lines. Factors such as levels of antigen re-
expression (turnover rate) and surface antigenic distribution particular to each cell line 
may be affecting the degree and rate of Mab internalization. Furthermore, some of the 
internalized antibody may be degraded intracellularly to a point where it cannot be 
detected by the secondary antibody employed in this assay. Although there is no evidence 
supporting the notion that differences in cell line characteristics (other than the type and 
level of receptors they express), may seriously affect intracellular routing and level of 
lysosomal degradation, this still remains a possibility. In the case of an additional 
specificity control provided by a very low CEA expressor line, we saw evidence of some 
non-specific antibody accumulation in our cell samples, whereas there was little evidence 
of CEA-specific antibody internalization other than in the cytosol after a 30 minute 
incubation (Figure 5d.A, lane g). We have no explanation for this at present and it is 
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possible that this band may be attributable to an artefact. Again, Fe receptor status of 
this, and the other lines, is not known at present. 
Although this assay provided clear and consistent results, it was also recognized 
that it was burdened with shortcomings, such as that it contained multiple steps, therefore 
increasing the probability of introducing errors at each step, that it was lengthy, and that 
it required large numbers of cells and amounts of antibody. The requirement for high cell 
numbers per sample, in addition to the practical difficulties in cell culture, also presented 
potential problems of cell aggregation and increased cell loss. Another problem was that, 
using this assay, we were not able to quantitatively defme internalization and that the 
level of possible contamination of cytosolic components by membrane components was 
again, not quantifiable. Furthermore, although this assay is ideal for estimating non-
degraded antibody, it may not detect all possible antibody fragments. Given that in most 
circumstances internalization is rapidly followed by sequestration of internalized material 
into lysosomal vacuoles and degradation, a more generalized approach would have to be 
followed for a more accurate estimation of internalized antibody levels. 
IV. 7. Detection of internalized antibody using flow cytometry. 
Internalization assays using flow cytometry developed in this laboratory {Hopper 
et al., 1990; Osborne, 1992) generated concise and reproducible internalization data. 
Characteristics particular to each line were again observed, as was the case with the 
SDS/PAGE analysis. For example the lines LS 17 4 T and SKCO 1, despite both being high 
CEA expressors, exhibited variable potential for anti-CEA internalization with SKC01 
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having the highest antibody uptake (consistently higher positive controls), and LS174T 
being the most avid "internalizer" (higher relative test curve shifts) (Table 6). In both 
lines there was strong evidence for very early internalization activity, as was noted with 
previous assays. Internalization seemed to plateau on average by the 30 minute interval 
incubation in the case of the SKC01 cell line (Table 6), whereas no decrease in 
internalization rate was observed in the case of the LS174T line. The COL0320 line 
provided evidence for the specificity of the process, since no anti-CEA antibody uptake 
was evident at any time (section m.6, Tsaltas et al., 1992; Osborne, 1992). 
In an effort to establish the reliability of internalization data produced using flow 
cytometry, SDS/PAGE assays similar to the ones presented in the previous section and 
flow cytometric analyses were compared. Indeed, when samples were run in parallel for 
FACS and SDS/PAGE analyses and treated in an identical manner, the same pattern 
emerged. Uptake and internalization (bands on membrane and cytosolic sample lanes) 
were clearly visible for all time intervals for both lines, with SKC01 sample bands being 
stronger (presumably higher overall antibody uptake). In certain cases some nonspecific 
uptake of control antibody was visible (LS174T membrane 30 min, SKC01 cytosol 0 
min), which we have no explanation for at present. No such non-specific uptake was 
noticed in the case of the COL0320 line. In general, results from flow cytometric 
analyses correlated well with those from Western blots. FACS results indicated highest 
antibody uptake in the case of the SKC01 cells, the cell line for which the strongest 
bands were also obtained for membrane samples. Similar results were obtained for 
internalized antibody ( cytosolic bands and absolute numbers for test samples during the 
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FACS analysis), although relative cutve shifts (percentage of antibody internalized) 
seemed to be highest for LS174T cells (although, due to moderate antibody uptake 
absolute amounts of internalized antibody for this cell line were relatively low in both 
procedures). Based on these obsetvations, it appears that internalization proriles can be 
affected by characteristics particular to the cell line. The cell line used as a specificity 
control (COL0320) showed no antibody uptake and consequently no internalization 
following either procedure. Interestingly, both assays showed evidence of very early 
internalization activity (0 minute samples). Presumably, procedures followed during both 
assays (i.e. length of initial washes following antibody application, or inability to 
completely remove primary antibody) allow for some internalization activity in the rrrst 
minutes of exposure to antibody. Although some additional intracellular antibody 
accumulation is discernible with both assays as incubation intetvals increase, it seems that 
in this model internalization activity is a very early phenomenon, with internalization 
rates remaining rather stationary thereafter. However, it is rather difficult to comment 
on the incremental nature (if any), of the progress of internalization based on the blots 
since there were no densitometric data available, although earlier results (previous 
section), provided some evidence of increasing internalized antibody with prolonged 
incubations. Slight procedural modifications of the Western blot assay (for example 
increased number of washes and resuspensions) which were necessary in order to make 
it possible to directly compare the two assays, may have also affected the degree of 
sensitivity of the Western blot assay. Based on those results it could be concluded that 
the assay for the detection of internalized antibody using flow cytometry compares well 
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with other reliable internalization assays and has the added advantages of being 
considerably faster, less cumbersome and requiring much lower amounts of the necessary 
cells and antibodies. A possible extension of this assay might involve the inclusion of 
control, glutaraldehyde-fixed cells for comparison with cell samples incubated at OOC. In 
this way the inhibition of endocytosis during washes or removal of supernatants would 
be verified. 
IV. 8. CEA-anti-CEA complexes and clathrin-mediated 
endocytosis. 
Endocytosis mediated by clathrin-coated vesicles is known to be perturbed by 
different mechanisms, such as cytosol acidification, potassium depletion and use of 
hypertonic media (Hansen et al., 1993) (discussed in section 1.6.5.c). Cytosol 
acidification interferes with budding of clathrin-coated vesicles from the plasma 
membrane, whereas potassium depletion and hypertonic media are believed to act by 
preventing clathrin and adaptors from interacting. Other methods of inhibiting 
endocytosis include pH -clamping of cells at neutrality with nigericin, swelling cells with 
hypotonic media and sticking cells to the surface of a culture dish with polylysine 
(Heuser, 1989). In an effort to examine whether internalization of monoclonal anti-CEA 
antibody proceeds via the clathrin-mediated pathway, cells were exposed to hypertonic 
medium containing a high concentration of sucrose. Results indicate that only prolonged 
incubation in hypertonic medium inhibits absolute amounts of antibody internalired due 
to a much reduced overall antibody uptake by cells treated in this manner (figure 7.a). 
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This inhibition does not take place when cells are exposed to hypertonic media 
throughout the assay but have not been pre-treated in such media (figure 7. b). These 
results suggest that disruption of clathrin-coated membrane domains partially abrogates 
internalization in our model, solely by reducing antibody uptake. The fact that uptake is 
only partially reduced (50% reduction in treated versus untreated samples), while 
internalization relative to uptake is either unchanged or increases, suggests that some 
CEA-anti-CEA complexes may also be internalized via an alternative pathway not 
involving clathrin. The profile of internalization in clathrin-inhibited samples, is quite 
similar to previous ones, inasmuch as the rate of internalization seems to be highest in 
the very initial stages of incubation with antibody (probably frrst few minutes). Since 
non-specific internalization through fluid-phase endocytosis is a much slower process than 
active endocytosis, it is very likely that this alternative endocytic pathway may involve 
a pathway similar to the recently demonstrated non-clathrin coated vesicle pathway (see 
section I. 6). 
IV. 9. Conclusions and future. 
Based on the above data, we conclude that the anti-CEA monoclonal antibody, 
11-285-14 does get specifically internalized by CEA expressing cancer cell lines. This 
information is essential to further construction of immunoconjugates, since the strong 
possibility that the cytotoxic moiety will be allowed to enter the cell may well influence 
the mode of drug conjugation so that it would become easier for the drug to detach from 
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its antibody carrier in order to exert its action. Furthermore, comparison of experimental 
results across the different assays used, suggests that the direct internalization assays 
involving the examination of solubilized membrane and cytosolic components of cells, 
as well as flow cytometry assays, provide a good indication of amount of antibody 
internalized. In comparison, the indirect internalization assays employed proved to be 
cumbersome and provided less conclusive results in our hands. 
The incorporation of results on the inaccuracy of the assay involving the low pH 
glycine-HCl buffer in the general body of knowledge on internalization seems to be 
particularly relevant, since this assay is still used to study internalization. It is interesting 
to note that even recently produced humanized Mabs, are still being characterized in 
terms of internalizing potential through the use of this assay (Caron et al., 1992). Since 
the production capacity of monoclonal antibodies is rapidly expanding with the use of 
different repertoires (Hoogenboom et al., 1992; Burton, 1993; Winter et al., 1991), their 
characterization in terms of endocytosis should be based on reliable and uniform 
procedures. 
Indeed, establishing a rapid and reliable internalization assay is central to the 
study of the dynamics of any antigen-antibody system, before it is attempted to evaluate 
the cytotoxic action of targeted immunoconjugates on cancer cells. Through use of 
SDS/PAGE on solubilized cells and flow cytometric assays, internalized antibody has 
been detected in all the CEA-positive cell lines examined. Furthermore, depiction of 
internalized antibody was possible without the use of radioactive probes, and was rapid 
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and consistent when flow cytometry was used. Given that flow cytometric techniques 
have been rapidly developing in recent years with the use of multiple cell markers 
(Stewart, 1992) for the detection of an ever increasing number of surface and 
intracellular proteins (Melamed et al., 1990), this approach seems to provide an excellent 
alternative to existing methods for the detection of internalized antibody. 
Eventually this method will be modified to accomodate detection of both drug and 
antibody, once satisfactory immunoconjugates have been produced in this laboratory. 
Initial attempts to detect doxorubicin separately via its natural fluorescence have not been 
successful due to an extensive overlap in the emission spectra of FITC and doxorubicin 
(Osborne, 1992) (emission peaks differing by no more than 20 nm). 
Another future project of great interest would involve the further examination of 
endocytic mechanisms of CEA-anti-CEA complexes. To date (to our knowledge), there 
has been no report on the mode of uptake and intracellular routing of this receptor 
molecule and its complexes. Preliminary work in this project has suggested that the 
endocytosis of this molecule proceeds via an active pathway possibly involving both 
clathrin-coated pits and non-clathrin-coated vesicles. The recent discovery of markers for 
non-clathrin-coated vesicles and related adaptors (Carter et al., 1993; Maholtra et al., 
1989; Orci et al., 1986; Serafmi et al., 1991), makes it possible to address the question 
of co-localization of these markers and markers of the CEA-anti-CEA complex. Given 
that CEA does not fall into the general category of transmembrane proteins that 
internalize following the recognition of signal peptides, the study of any further 
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similarities or differences in the mode of endocytosis of CEA versus such transmembrane 
proteins might shed some light both on the process of internalization and on particular 
characteristics of this elusive molecule. 
Another point of interest in terms of immunoconjugate internalization and 
processing, would involve the place and degree of their degradation (if any), and the 
effect of this degradation on their efficacy as cytotoxic agents. Such studies might involve 
the inhibition of various intralysosomal compartments (such as endosomes and lysosomes) 
through the use of agents that may disrupt intracellular trafficking, neutralize 
intralysosomal pH or inhibit lysosomal enzymes (such as lysosomotropic amines and 
carboxylic ionophores (Press et al., 1990)), coupled to estimation of levels of degraded 
antibody and degree of cytotoxic activity of respective immunoconjugates. 
It is entirely possible that the key to turning immunoconjugates into the 11 magic 
bullets 11 envisioned by Ehrlich, lies in deciphering the effect that a number of different 
factors have on the processing of these agents. We believe that their internalization and 
intracellular fate makes up an essential component of their potency and hope that work 
on this subject will be ongoing. 
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